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Abstract 
Currently, the field of mammalian membrane protein structural biology is in its 
infancy. Existing technologies and experiences have shown that it is possible to 
obtain the structures of mammalian membrane proteins if sufficient work and 
thought has been invested. However, there is still an urgent need to develop new 
methodologies and approaches to improve all aspects of this important area of 
biological research. Here, a series of novel technologies for the overproduction, 
purification and crystallisation of human membrane proteins are described which 
have been tested with a representative member from each of the G-protein 
coupled receptor (adenosine 2a receptor (A2aR)) and membrane enzyme (sterol 
isomerase (SI)) superfamilies. 
The methylotrophic yeast Pichia pastoris is an excellent host cell for the 
overproduction of recombinant proteins including membrane proteins of 
mammalian origin. However, the commercially available expression vectors are 
far from what is required to maximise the production levels as well as simplify 
the detergent extraction and purification of human membrane proteins. Here, a 
series of related expression constructs were made that had different 
combinations of tags at both ends of the recombinant protein. The final optimised 
expression vectors had a C3 protease-iLOV-biotin acceptor-His10 (CLBH) tag fused 
to the C-terminus of the recombinant protein. The -CLBH vectors gave high level 
production of both test proteins (one Nin – hSI; one Nout – hA2aR) that could be 
rapidly purified to homogeneity using a generic protocol. The position of the 
His10 tag did not affect the expression level of the recombinant protein. In 
contrast, fusion of the biotin acceptor domain to the C-terminus of the 
recombinant protein increased its expression by a factor of between 2-4. The 
biotin acceptor domain could also be fully biotinylated in vitro using 
recombinantly expressed biotin ligase allowing purification/immobilisation of the 
target protein with streptavidin beads. Removal of the expression/ purification 
tags from the recombinant proteins with C3 protease occurred more efficiently 
than when TEV protease was used.  
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An optimised protocol was developed that gave maximal production of our target 
proteins in fermenter culture at an induction temperature of 22°C. Care was 
taken to find a methanol feed rate that gave the highest levels of protein 
production without causing the accumulation of excess methanol in the culture 
(which is known to be toxic to the yeast). Using this protocol it was possible to 
make both hSI and hA2aR with a production level >10 mg of recombinant protein 
per litre of culture. 
As most MPs are colourless, target protein identification is usually performed by 
methods such as radioligand binding and/or Western blotting. However, these 
techniques can be time-consuming, use a lot of protein and do not give any 
information on the aggregation state of the protein in detergent solution. 
Previously, it has been shown that the processes of identifying and analysing 
membrane proteins in detergent solution can be accelerated by attaching green-
fluorescent protein to the C-terminus of the recombinant MP. Here, the potential 
of the recently described iLOV fluorescence tag for membrane protein 
applications was assessed. iLOV was shown to be an useful tool for optimising 
processes such as yeast clonal selection, protein production in fermenter culture, 
detergent and construct screening as well as tracking recombinant MPs through 
the purification process. Of note, the iLOV tag allowed a direct assessment of the 
stability and dispersity state of both target MPs in a range of detergents by 
fluorescence size exclusion chromatography (FSEC). Using this approach, it was 
shown that wild-type hA2aR solubilised using a combination of dodecyl-βD-
maltoside (DDM) and cholesteryl-hemisuccinate (CHS) aggregated during 
purification on a Ni2+ column. Furthermore, it was shown that the hA2aR agonist-
conformationally-fixed mutant Rag23 is stable in DDM without any CHS present. 
Moreover, Rag23 was found to be monodisperse in a series of short-chain 
detergents (decyl-βD-maltoside, nonyl-βD-maltoside (NM) and β-octylglucoside) 
suggesting that this mutant is well-suited to structural studies. SI was remarkably 
robust in short chain detergents demonstrating a reasonable level of stability in 
the short chain detergent NM. The FSEC experiments showed that wild-type SI has 
considerably higher intrinsic stability than native hA2aR suggesting that 
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membrane enzymes will prove to be more amenable to structural analysis than 
GPCRs.  
Rag23 and SI were both purified to homogeneity in a simple four-step procedure: 
i) Ni2+ purification, ii) cleavage with C3 protease, iii) reverse Ni2+ purification and 
iv) gel-filtration chromatography. A buffer/salt screen was devised that allowed 
those conditions where SI had maximal thermostability in detergent-solution to be 
identified. SI was found to have greatest stability in sodium phosphate buffer at 
acidic pH. Using this information, it was possible to purify monodisperse SI in DM 
suggesting that this protein may make an excellent candidate for structural 
studies too. 
Crystallisation trials with SI were performed using the commercially available 
sparse matrix screen MemSys/MemStart. In addition, a lipidic-sponge phase 
sparse-matrix crystallisation screen that was developed in collaboration with 
Prof. Richard Neutze (University of Chalmers, Sweden) was tested using SI. 
Cholesterol could be incorporated into all of the sponges that make up the screen 
upto a concentration of 10%. (This is important as the activity of many 
mammalian membrane proteins is cholesterol-dependent). To date, no diffracting 
crystals of SI have been obtained with either the conventional or lipidic-sponge 
phase crystallisation approaches. 
In short, a series of novel technologies/methodologies have been developed that 
will act as a platform for future efforts to solve the structures of a wide-range of 
human membrane proteins. 
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 1 Membrane protein structural biology 
1.1 Biological membranes 
Membranes are an essential component of all cells where they function as 
selectively-permeable barriers. They consist of a rich mixture of lipid molecules 
and proteins (Figure 1.1). In mammalian cells, the plasma membrane physically 
separates the intracellular components from the extracellular environment 
(Brown, 1998). Moreover, intracellular membranes are used to form distinct 
compartments within the cell that perform highly-specialised functions (e.g. 
mitochondria – oxidative phosphorylation; lysosome – protein degradation) 
(Brown, 1998). All biological membranes are primarily composed of a thin layer 
of amphipathic molecules called phospholipids (which have polar hydrophilic 
head groups and hydrophobic tails) (Singer and Nicolson, 1972). In an aqueous 
environment the phospholipids spontaneously form bilayers with the hydrophobic 
tails sandwiched between the two hydrophilic headgroups (Figure 1.1) (Singer 
and Nicolson, 1972; Rietveld and Simons, 1998). 
 
Figure 1.1 Schematic representation of a mammalian plasma membrane 
Higher-eukaryotic membranes are a rich mixture of lipid molecules and proteins. Both peripheral 
and integral membrane proteins are located at and in the phospholipid bilayer, respectively. 
Mammalian membranes are distinct from those found in bacteria, lower eukaryotes and plants in 
that they contain cholesterol (which gives the membrane increased rigidity).  
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Although mammalian cell membranes are primarily composed of phospholipids, 
they also contain sphingolipids, glycolipids and cholesterol (Figure 1.2) (Rietveld 
and Simons, 1998). In their simplest form, phospholipids consist of a glycerol 
backbone to which two fatty acids and a phosphate group are connected. 
Mammalian cells make a range of related phospholipids (phosphatidyl-choline, -
ethanolamine, -serine, -glycerol and -inositol) by attaching different headgroups 
to the core phosphate moiety (Figure 1.2). Many different fatty acids (including 
both saturated and unsaturated versions) can be added to the glycerol 
backbone. The biophysical properties of the fatty acid that are attached 
influence both the thickness and fluidity of the membrane (Becher and 
McIlhinney, 2005). Sphingolipids have a similar overall structure to phospholipids 
except that they have a sphingosine rather than a glycerol spine. Certain 
phospho- and sphingo-lipids located on the extracellular face of the plasma 
membrane have short carbohydrate chains attached to them and are called 
glycolipids (Figure 1.2). Cholesterol (Figure 1.2) is a major component of 
mammalian membranes and is exclusively found in higher eukaryotes. 
Cholesterol brings rigidity to membranes by restricting the movement of the 
fatty acids in neighbouring phospholipids through its bulky four-ring structure 
(Brown and London, 1998; Chini and Parenti, 2009).  
Membranes are dynamic, and can be described as a “fluid mosaic” as they 
behave like a two-dimensional liquid in which all the lipid and protein molecules 
diffuse to a greater or lesser extent (Singer and Nicolson, 1972). There are 
regions in mammalian membranes that have high local concentrations of 
cholesterol and sphingolipids called lipid rafts (Brown and London, 1998; Brown, 
1998). Rafts are more ordered and tightly packed than the surrounding bilayer 
and float freely in the membrane. Rafts function as specialised membrane 
microdomains that enable certain signalling and trafficking events at the cell’s 
surface to be compartmentalised (Rietveld and Simons, 1998; Simons and 
Ikonen, 2000; Becher and McIlhinney, 2005; Epand, 2006). 
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Figure 1.2 Chemical structures of selected lipids found in mammalian membranes 
Higher-eukaryotic membranes contain four different kinds of lipid namely phospholipids (for 
example - phosphatidylcholine), sphingolipids (sphingomyelin), glycolipids (glucocereboside) and 
cholesterol.  
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1.2 Membrane proteins 
Proteins found on/in membranes can be classed either as peripheral or integral 
membrane proteins according to the way that they attach to the membrane 
(Singer and Nicolson, 1972) (Figure 1.1). Peripheral membrane proteins (MPs) are 
located at the surface of membranes where they are anchored to them either 
directly by interacting with the lipid bilayer or indirectly via contact with an 
integral membrane protein. Peripheral MPs can usually be released from the 
membrane by washing with buffer of high ionic strength. In contrast, integral 
MPs (as their name suggests) span the entire membrane, and consist of two 
hydrophilic regions (that are exposed on either side of the membrane) separated 
by a hydrophobic region (that is buried within the membrane core). These 
proteins can only be released from the lipid bilayer by treating the membrane 
with detergent. As integral MPs need to be coated with detergent at all times in 
aqueous solution, they are considerably harder to work compared to either 
soluble of peripheral MPs. As even mild detergents are denaturants when 
integral MPs are removed from the membrane for structural studies it is not 
uncommon for the protein to lose its functional activity (Seddon et al., 2004). 
1.3 Membrane proteins and secondary structure 
Following translation, proteins fold first into a series of defined small secondary 
structures from which a 3-dimensional shape is eventually formed. There are 
two main types of secondary structure found in all proteins called α-helix and β-
sheet, both of which are formed by hydrogen bonding between the carbonyl and 
amine groups of the protein backbone (Figure 1.3) (Kennedy, 1978). α-helices 
are more common than β-sheet, and have a right-handed coiled conformation. In 
an α-helix, every backbone N-H group donates a hydrogen bond to the backbone 
C=O group of the amino acid four residues previous (Kabsch and Sander, 1983). 
There are ca. 3.6 amino acids per turn of helix (Pauling and Corey, 1951a; 
Pauling et al., 1951). The other main type of secondary structure is β-sheet, and 
it consists of neighbouring β-strands (stretches of polypeptide where the 
backbone has an almost fully-extended conformation) that are hydrogen bonded 
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to each other (Figure 1.3) (Kabsch and Sander, 1983). Where the β-strands all 
have a similar orientation the β-sheet that is formed is denoted parallel. Where 
the β-strands have alternating orientations, the β-sheet is described as being 
anti-parallel (Pauling and Corey, 1951b).  
The most common secondary structure found in integral MPs is the α-helix with a 
minimum of 17-20 residues required to span the bilayer (Kennedy, 1978; Nyholm 
et al., 2007; McLuskey et al., 2010). α-helices are energetically stable in the 
membrane as the amine and carbonyl groups of the peptide bonds are involved 
in hydrogen-bonding within the helix. The majority of the amino acids that occur 
within membrane-spanning helices tend to be hydrophobic in nature (Nyholm et 
al., 2007). The presence of proline and/or glycine residues in a helix can cause it 
to kink (as was observed in the structure of rhodopsin) (Palczewski et al., 2000). 
The number and orientation of the helices traversing the membrane, in 
combination with the variation of the connecting loop regions, creates a diverse 
range of membrane proteins including transporters, ion channels and receptors. 
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(A) 
 
(B) 
 
 
 
Figure 1.3 Representation of the two main types of protein secondary structure 
(A) is an α-helix in which every backbone N-H group donates a hydrogen bond to the backbone 
C=O group of the amino acid four residues previous. There are ca. 3.6 amino acids per turn of 
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helix. (B) shows an anti-parallel β-sheet with hydrogen bond “bridges” between neighbouring β- 
strands. Hydrogen bonds are shown as black broken lines. 
Alternatively, the plasma membrane can be traversed by a large β-sheet that has 
been twisted and coiled to form a closed structure called a β-barrel (Schulz, 
2000). β-strands in β-barrels are arranged in an anti-parallel fashion with the 
first strand hydrogen bonded to the last (Kennedy, 1978; Cowan et al., 1992; 
Buchanan, 1999). Unlike transmembrane α-helices that are largely composed of 
aliphatic amino acids, the β-sheets that make up β-barrels do not have obvious 
long hydrophobic regions which makes their identification from primary 
sequence analysis alone difficult (Schulz, 2000). Furthermore, whereas α-helical 
containing integral MPs have a ubiquitous distribution, proteins that have a β-
barrel structure are only found in the outer membranes of gram-negative 
bacteria as well as mitochondria and chloroplasts (Schulz, 2000). 
 
1.4 History of membrane protein structural biology 
The PDB currently contains nearly 60,000 entries of which 700 are structures of 
integral membrane proteins. Of these, however, only 200-250 are regarded as 
unique structures (White, 2009; McLuskey et al., 2010). The number of integral 
membrane protein structures solved to date does not reflect either their 
importance in biology or indeed their natural abundance (with 30% of the genes 
in a typical genome encoding MPs) (Arora and Tamm, 2001). The slow rate at 
which MPs have had their structures determined reflects the many challenges 
that have to be overcome before crystals that diffract to high resolution are 
obtained. These include the difficulties of making membrane proteins in a 
heterologous system on a milligram scale, preventing the protein from 
aggregating once it has been removed from its membrane environment as well as 
trying to find the optimal detergent for crystallisation. Furthermore, mammalian 
MPs have proved to be even more difficult to work with than bacterial MPs as 
they are harder to make in large amounts as well as being less stable in 
detergent solution. This is reflected in the PDB where there are <20 unique 
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mammalian membrane protein structures (White, 2009; McLuskey et al., 2010). 
Having said this, membrane protein crystallisation is no longer considered as 
difficult, and with considerable advances in technology, ca. 30-40 new integral 
MP structures are being deposited each year in the PDB (Figure 1.4) (White, 
2009). Here, a brief overview of the history of membrane protein structural 
biology is presented.  
 
Figure 1.4 Progress in determining membrane protein structures 
(A) The number of new structures reported each year since 1985. (B) A plot of the cumulative 
number of membrane protein structures solved (y-axis) versus the number of years since the first 
integral MP structure was solved (x-axis). The number of new membrane protein structures is 
increasing exponentially on a yearly basis. Figure adapted from (White, 2009). 
In 1975, bacteriorhodopsin became the first membrane protein to have its 
structure elucidated. Using low-resolution (7 Å) electron microscopy data 
Richard Henderson and Nigel Unwin were able to unequivocally show that 
bacteriorhodopsin consisted of seven transmembrane α-helices (Henderson and 
Unwin, 1975). However, at this resolution, it was not possible to visualise the 
molecular details of bacteriorhodopsin’s structure. It was another ten years 
before the first membrane protein structure at atomic resolution was obtained 
when Johann Deisenhoffer and Hartmut Michel solved the structure of the 
reaction centre (RC) from the purple photosynthetic bacteria 
 
Membrane protein structural biology  9 
Rhodopseudomonas viridis to a resolution of 3 Å (Figure 1.5) (Deisenhofer et al., 
1984; Deisenhofer et al., 1985). This landmark achievement was recognised 
when Michel, Deisenhoffer and Huber were awarded the Nobel Science prize for 
Chemistry in 1988. The RC is a protein-pigment complex of ca. 145 kDa 
consisting of three different sub-units (H, L, and M). The L and M subunits form 
the core of the RC and have five transmembrane α helices each (Michel, 1982). 
The H sub-unit has just one transmembrane helix which interacts with both L 
and M, and its globular domain is located in the bacteria’s cytoplasm. The RC 
was solved in complex with a cytochrome that interacted with the periplasmic 
side of the core formed from the L and M sub-units (Deisenhofer and Michel, 
1989). The protein acts as a scaffold holding the pigments at the correct 
geometry to allow efficient charge separation and electron transfer. 
 
Figure 1.5 The first high-resolution structure of a membrane protein 
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The photosynthetic reaction centre from the purple bacteria Rhodopseudomonas viridis (accession 
code 1PRC) was the first membrane protein to have its structure solved to atomic resolution by X-
ray crystallography (Deisenhofer et al., 1984; Deisenhofer et al., 1985). The heavy chain is 
coloured black, medium chains are red, light chains are yellow and the globular domain is coloured 
green. 
Since this RC structure, several other photosynthetic integral MP complexes from 
purple bacteria have had their structures determined including the RC from Rb. 
sphaeroides (Yeates et al., 1987; Stowell et al., 1997), light harvesting 
complexes from Rps. acidophila (McDermott et al., 1995; McLuskey et al., 2001) 
and Rs. molischianum (Koepke et al., 1996), as well as the “core” complex from 
Rps. palustris (Roszak et al., 2003). In addition, structures of photosystem (PS) II 
(Zouni et al., 2001; Kamiya and Shen, 2003; Ferreira et al., 2004) and PSI 
(Krauss et al., 1996; Schubert et al., 1997) from cyanobacteria, as well as PSI 
(Ben-Shem et al., 2003; Amunts et al., 2007) and light-harvesting complex II 
(LHCII) (Liu et al., 2004; Standfuss et al., 2005) from plants (all integral 
membrane proteins) have been determined to atomic resolution. The structures 
of these photosynthetic complexes have given detailed insights into the 
molecular mechanisms of light capture, charge separation and water-splitting 
which occur in nature.  
Arguably, the most important process that occurs within cells is the production 
of adenosine triphosphate (ATP) by oxidative phosphorylation. This process 
occurs in and across the inner mitochondrial membrane (IMM) (where both the 
electron carriers and ATP synthase are located). Electrons are transferred from 
either NADH or FADH2 to molecular oxygen which is reduced to water. Electron 
transport through complexes I (NADH dehydrogenase), III (Cytochrome bc1 
complex) and IV (Cytochrome oxidase) results in H+ pumping across the IMM. The 
proton-gradient which results is used to drive the formation of adenosine-
triphosphate (ATP) from inorganic phosphate and adenosine diphosphate (ADP) 
via the integral membrane protein ATP synthase. The structures of all four 
electron transfer complexes (I-IV) (Iwata et al., 1995; Tsukihara et al., 1996; 
Iwata, 1998; Iwata et al., 1998; Yankovskaya et al., 2003; Hunte et al., 2010) 
and ATP synthase (Abrahams et al., 1994; Stock et al., 1999) (Figure 1.6) have 
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all been solved to atomic resolution. The structure of ATP synthase was solved 
by John Walker and co-workers, for which he was awarded the Nobel Prize for 
Chemistry in 1997. ATP synthase has three distinct domains:  the transmembrane 
rotor domain, a globular catalytic domain and a rod subunit (comprising of two 
anti-parallel alpha helices) that connects the transmembrane and catalytic 
regions (Stock et al., 1999). Proton translocation through the rotor domain 
causes the catalytic region to turn, which drives the formation of ATP. 
 
Figure 1.6 The 3-dimensional structure of F1-ATP synthase 
ATP synthase (accession code 2XOK) is composed of a number of subunits forming the proton 
translocating transmembrane domain (coloured black) and the catalytic portion which is comprised 
of α (red), β (green), γ (blue) and ε (yellow/orange) subunits (Stock et al., 1999). 
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β-barrel containing proteins are found in the outer membranes of gram-negative 
bacteria, mitochondria and chloroplasts where they have functions as diverse as 
ion transport, passive nutrient uptake, membrane anchors, membrane-bound 
enzymes as well as defense against attack proteins (Buchanan, 1999; Schulz, 
2000). Membrane protein β-barrels contain between 8 and 22 strands, and the 
overall pore size depends on the number of β-strands that make up the barrel 
(Buchanan, 1999; Schulz, 2000). The first membrane protein with a β-barrel 
motif to have its structure solved was porin from Rb. capsulatus (Figure 1.7) 
(Weiss and Schulz, 1992). Porin is a 16-stranded β-barrel that associates to form 
homo-trimers, and carries out passive diffusion of small (ca. 600 Da) molecules. 
OmpA and OmpX both contain eight stranded barrels (Figure 1.7) (Pautsch and 
Schulz, 1998; Vogt and Schulz, 1999). These proteins are not thought to have any 
channel activity but rather function as transmembrane anchors. The structures 
of other bacterial β-barrel containing MPs are discussed in (Buchanan, 1999; 
Schulz, 2000). Recently, structures of the voltage-dependent anion channel 
(VDAC) (the major pathway for entry and exit of metabolites across the outer 
mitochondrial membrane) from human (Bayrhuber et al., 2008) and mouse 
(Ujwal et al., 2008) have been solved to atomic resolution. The VDACs contain a 
19-stranded β-barrel.  
Although membrane proteins that contain β-barrel structures are relatively rare, 
there are a large variety of protein families that have transmembrane α-helical 
domains. These include transporters, water and ion channels, enzymes as well as 
G-protein coupled receptors.  
The major facilitator superfamily (MFS) is the largest family of active 
transporters, comprising one quarter of all transport proteins (Saier et al., 
1999). These proteins overcome the thermodynamically unfavourable process of 
transporting a substrate across the membrane against a concentration gradient 
by either utilising the free energy stored in an electrochemical ion (e.g. Na+, H+) 
gradient or coupling the primary transport event to the movement of a second 
substrate down a concentration gradient. There are three main types of MFS 
protein : i) uniporters - that translocate a single substrate across the membrane, 
 
Membrane protein structural biology  13 
ii) symporters – that transport two or more substrates across the membrane in 
the same direction (e.g. the lactose/H+ symporter LacY), and iii) antiporters – 
that transfer two or more substrates across the membrane in opposing directions 
(e.g. the inorganic phosphate/glycerol-3-phosphate antiporter GlpT)) (Law et 
al., 2008). 
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(A) 
 
(B) 
 
(C) 
 
Figure 1.7 Examples of membrane proteins with a β-barrel type structure 
(A) porin (2OMF), (B) OmpA (1BXW), and (C) OmpX (1QJ8). ( Weiss and Schulz, 1992; Pautsch 
and Schulz, 1998; Vogt and Schulz, 1999)  
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The first member of the MFS family to have its structure solved was LacY from E. 
coli (to a resolution of 3.5 Å) (Figure 1.8(A)) (Abramson et al., 2003 a,b). Since 
then, numerous bacterial MFS transporters have had their structures solved 
including GlpT (Huang et al., 2003), the multidrug transporters EmrD (Yin et al., 
2006) and EmrE (Chen et al., 2007), the Na+/H+ antiporter NhaA (Figure 1.8 (B)) 
(Hunte et al., 2005), the sodium-dependent glutamate transporter GltPh 
(Yernool et al., 2004), the leucine transporter LeuT (Yamashita et al., 2005) and 
the zinc transporter YiiP (Lu and Fu, 2007). As yet, no mammalian MFS 
transporter has had its structure solved. 
 (A) 
 
(B) 
 
Figure 1.8 Structures of bacterial members of the MFS family 
(A) the lactose/H+ symporter, LacY (1PV7) has a large internal hydrophilic cavity which opens to 
the cytoplasm (Abramson et al., 2003 a,b) and (B) the Na+/H+ antiporter, NhaA (1BL8) has a water 
pore on the outer side (Hunte et al., 2005). 
ATP-binding cassette (ABC) transporters use the energy released on ATP 
hydrolysis to transport specific substrates across the membrane. All ABC 
transporters have a four-domain structure in common consisting of two 
nucleotide binding domains (NBD), that hydrolyse ATP and drive the transport 
reaction, and two transmembrane domains (TMD) that form the translocation 
pathway (Higgins, 1992; Rees et al., 2009). The first ABC transporter to have its 
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structure determined was the vitamin B12 importer from E. coli (BtuCD) to a 
resolution of 3.2 Å (Figure 1.9) (Locher et al., 2002). Since then, a further five 
bacterial (including the multidrug resistance protein Sav1866) (Dawson and 
Locher, 2006; Hollenstein et al., 2007 ; Oldham et al., 2007; Pinkett et al., 
2007; Ward et al., 2007) and one mammalian (P-glycoprotein) (Aller et al., 2009) 
ABC transporters have had their structures solved. 
 
Figure 1.9 The bacterial ABC transporter that transfers vitamin B12 across the inner 
cytoplasmic membrane 
The α helices (coloured blue through green) create the transmembrane region of BtuC domains 
while the BtuD regions (coloured yellow through red) are involved in ATP-binding. In combination 
these four domains complete the BtuCD structure (accession code 1L7V) (Locher et al., 2002). 
Aquaporins are water-specific membrane channels that allow water to move 
freely and bi-directionally across the membrane (Meinild et al., 1998). 
Structures for bacterial (GlpF, AqzP) (Fu et al., 2000; Savage et al., 2003), plant 
(Tornroth-Horsefield et al., 2006) and mammalian (AQP1, 4 and 5) (Murata et 
al., 2000; Horsefield et al., 2008; Ho et al., 2009) aquaporins are known (Figure 
1.10). 
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Ion channels allow the selective passage of particular ions (e.g Na+, K+, Cl-) 
across membranes in response to signals such as ligand-binding (e.g. glutamate, 
GABA) or changes in transmembrane voltage. All ion channels have a similar 
architecture with multiple sub-units arranged around a central pore (where the 
ion conduction pathway is located). The first ion channel to have its structure 
determined was the K+ channel from the bacteria S. lividans (KcsA) (Doyle et al., 
1998). Since this ground-breaking achievement, a plethora of other bacterial ion 
channels have had their structures solved including the Ca2+-gated K+ channel 
from M. thermoautotrophicum (MthK) (Jiang et al., 2002a), the Kv from A. 
pernix (KvAP) (Jiang et al., 2002b), the inward-rectifying K+ channel from 
Burkholeria pseudomallei (KirBac1.1) (Kuo et al., 2003), the non-selective cation 
channel (Shi et al., 2006), the large and small mechanosensitive channels from 
M. tuberculosis (MscL) (Chang et al., 1998) and E. coli (MscS) (Bass et al., 2002), 
respectively as well as the ClC Cl- channels from S. enterica and E. coli (Dutzler 
et al., 2002; Dutzler et al., 2003). Several ion channels of mammalian origin 
have also been determined including rat Kv1.2 (a member of the K+ Shaker 
channel family) (Long et al., 2005), chicken Kir2.2 (Tao et al., 2009), the human 
high-conductance voltage and Ca2+-activated (BK) channel (Yuan et al., 2010), 
the chicken acid sensing ion channel (Jasti et al., 2007), the zebrafish ATP-gated 
P2X(4) ion channel (Kawate et al., 2009) and the rat AMPA-sensitive ionotropic 
glutamate receptor (GluA2) (Sobolevsky et al., 2009). The abundance of ion 
channel structures in the PDB suggests that they are considerably more tractable 
to work with than most other membrane protein superfamilies.  
The major mammalian G-protein coupled receptor superfamily has proved 
remarkably resistant to crystallisation. However, several GPCR structures have 
recently been solved and deposited in the PDB. These include bovine rhodopsin 
(Palczewski et al., 2000), the human β2-adrenergic receptor (Cherezov et al., 
2007; Rasmussen et al., 2007), turkey β1 adrenergic receptor (Warne et al., 
2008) as well as the human adenosine 2a receptor (Jaakola et al., 2008). These 
are discussed in more detail in Section 2. 
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In short, there are now a substantial (several hundred), and increasing, number 
of bacterial membrane proteins in the PDB with rather few (several tens) of 
mammalian origin. This reflects the extra difficulties in obtaining high quality, 
diffracting crystals of membrane proteins from mammalian cells as compared to 
those from bacteria.  
(A) 
 
(B) 
 
(C) 
 
(D) 
 
Figure 1.10 Structures of selected water and ion channels showing the ways that the 
aqueous pore can be organised  
The human water channels (A) aquaporin 1, AQP1 (accession code 1FQY) and (B) aquaporin 5, 
AQP5 (3D9S) (Murata et al., 2000; Ho et al., 2009). (C) The potassium channel from Streptomyces 
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lividans, KcsA (1BL8) (Doyle et al., 1998). (D) The E. coli mechanosensitive channel of small 
conductance, MscS (2OAU) (Bass et al., 2002). 
1.5 The problems associated with solving the structures 
of mammalian membrane proteins 
Before the structure of any mammalian membrane protein can be solved, 
several major obstacles need to be overcome. Firstly, milligram quantities of the 
protein of interest are required for either crystallographic or nuclear magnetic 
resonance experiments (Sarramegna et al., 2003). In certain instances, 
mammalian membrane proteins exist in native tissues at sufficiently high levels 
to allow their purification to homogeneity e.g. rhodopsin. However, this is not 
the case for the vast majority of mammalian membrane proteins which need to 
be overexpressed in an appropriate host cell system before they can be purified 
(Seddon et al., 2004). Secondly, the mammalian MP needs to be isolated from its 
native membrane environment by detergent solubilisation. The choice of 
detergent is critical as mammalian MPs are very unstable and are readily 
denatured by detergent (Lacapere et al., 2007). Thirdly, the protein has to be 
purified to homogeneity prior to structural analysis in a monodisperse state 
keeping its activity intact. However, given their poor stability, many mammalian 
membrane proteins tend to aggregate during the purification process (Gutmann 
et al., 2007). Finally, mammalian membrane proteins (like all membrane 
proteins) have relatively small exposed polar surface areas making them 
considerably harder to crystallise than soluble proteins.  
 
1.6 Engineering membrane proteins for crystallisation  
Given that membrane proteins are so difficult to crystallise, mammalian ones in 
particular, it is imperative that the protein to be used in the crystallisation trials 
is largely rigid, thermostable, homogenous and has sufficient polar surface 
exposed to allow the formation of crystal contacts. As most wild-type 
mammalian membrane proteins do not fulfil all of these criteria, it is often 
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necessary to engineer the target protein to increase the probability of it 
crystallising. There are a variety of techniques that can be employed to increase 
the stability and rigidity of target proteins as well as their homogeneity. These 
include using deglycosylated mutants (Fraser, 2006), removing disordered 
regions from the protein (Cherezov et al., 2007), introducing single point 
mutations to increase its stability (Standfuss et al., 2007) as well as adding 
binding partners to “lock” the target protein into a particular conformation 
(often increasing the available polar surface area for lattice contacts) 
(Palczewski et al., 2000; Rasmussen et al., 2007). With all of these strategies, 
however, it is possible to engineer mutants that have non-physiological 
properties. Therefore, care must be taken when trying to create modified 
proteins better suited to crystallisation trials so that they retain their biological 
activity also. 
 
1.6.1 Removing regions predicted to be disordered 
It is not uncommon for proteins involved in signalling (eg p53, GPCRs) to have 
large regions that are intrinsically disordered. Well-ordered crystals cannot be 
obtained for proteins that have extensive flexible regions (Warne et al., 2009). 
Utilising disorder predictor programs such as RONN (University of Oxford) likely 
site(s) of disorder within the target protein can be identified and removed by 
mutagenesis (Yang et al., 2005). For example, the C-terminal tails of most 
GPCRs are highly disordered and are routinely removed by researchers trying to 
make a crystallisable construct (Warne et al., 2003; Fraser, 2006; Rasmussen et 
al., 2007; Rosenbaum et al., 2007; Magnani et al., 2008). Not unexpectedly, 
removal of disordered regions from a target protein can improve its expression 
by reducing the number of protease sensitive sites within it (Warne et al., 2003).  
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1.6.2 Increasing the thermostability and therefore the 
crystallisability of membrane proteins     
Most mammalian membrane proteins that function at the cell surface are 
glycosylated. Although not necessarily an impediment to crystallisation, it is 
often desirable to remove the glycosylation site(s) from the target protein by 
mutagenesis to ensure that the final purified sample has negligible 
heterogeneity. Although many glycosylation-deficient mutants retain wild-type 
properties (Fraser, 2006), this is not always the case (Tate, 2001).  
The contribution that individual amino acids make to the thermostability of a 
membrane protein can be readily determined by combining alanine-scanning 
mutagenesis with an appropriate activity assay following partial heat-
denaturation of the Ala mutants (for example DAG kinase (Gorzelle et al., 1999), 
the β1-adrenergic (Serrano-Vega et al., 2008) and adenosine 2a receptors 
(Magnani et al., 2008)). Once the amino acids that are critical for stability have 
been identified, it is possible to combine several mutations to make a 
temperature- and detergent-resistant mutant suitable for crystallisation 
(Standfuss et al., 2007). Proteins can also be selectively engineered to have 
increased stability, through the introduction of cysteine residues that form 
disulphide bonds fixing the protein’s conformation (Blois and Bowie, 2009).  
An alternative way that the thermostability of a membrane protein can be 
increased is through the addition of a specific ligand (eg inhibitor, agonist, 
antagonist). Indeed, the recent structures of the β1-, β2-adrenergic and 
adenosine 2a receptors were all solved in the presence of a high-affinity (pico- 
to nano-molar) inverse agonist (Cherezov et al., 2007; Rasmussen et al., 2007; 
Rosenbaum et al., 2007; Hanson et al., 2008; Jaakola et al., 2008). One of the 
reasons that rhodopsin has proved considerably more tractable to crystallisation 
than ligand-activated GPCRs is that in the ground state its ligand, 11-cis-retinol, 
is covalently bound to it making rhodopsin substantially more thermostable 
compared to other GPCRs (Standfuss et al., 2007). 
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To increase the probability of getting a membrane protein to crystallise 
strategies for increasing their polar surface area have been developed. For 
example, cytochrome oxidase (Hunte and Michel, 2002) and the β2 adrenoceptor 
(Rasmussen et al., 2007) have been successfully crystallised in complex with an 
antibody binding fragment (FAb) (Figure 1.11 (coloured red)). The rationale 
behind this approach is that when the FAb binds to the target protein it creates a 
complex with a large polar surface area that can readily form lattice contacts 
(Hunte and Michel, 2002). Although this approach has been successfully used to 
obtain crystal structures of selected membrane proteins it is not widely 
practiced as generating FAb is both expensive and time-consuming.  
A related approach has recently been developed by Stevens and co-workers (The 
Scripps Research Institute, California) where, to improve the crystallisability of 
GPCRs, they largely replaced the receptor’s third intracellular loop (IL3) with 
T4-lysozyme. This GPCR-fusion protein has a large hydrophilic domain useful for 
forming crystal contacts. This approach has been used to solve the structures of 
the β2-adrenoceptor (Figure 1.11 (coloured blue)) (Cherezov et al., 2007) and 
the adenosine 2a receptor (Jaakola et al., 2008) to atomic resolution. 
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Figure 1.11 Overlay of the two structures of the ligand-activated GPCR, β2-adrenergic 
receptor, that have been solved using strategies to increase their polar surface area 
Displayed in red is a complex of the human β2-adrenergic receptor in complex with a Fab that binds 
to IL3 (accession code 2R4R); while blue shows a chimera consisting of the human β2-adrenergic 
receptor with T4-lysozyme instead of IL3 (accession code 2RH1). 
1.7 Heterologous production of mammalian membrane 
proteins 
Mammalian membrane protein expression can be performed in a variety of host 
cells [reviewed in (Sarramegna et al., 2003)] including bacteria (Weiss and 
Grisshammer, 2002), yeast (Reilander and Weiss, 1998; Jahic et al., 2006), 
insect (Cherezov et al., 2007; Rasmussen et al., 2007) and mammalian cells 
(Mize et al., 2008). For any given protein, the choice of system will depend on a 
number of factors including the availability of specialised expression vectors and 
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strains, budget as well as any post-translational modifications required for 
maintaining the protein’s functionality (Sarramegna et al., 2003).  
Although bacterial expression systems are routinely used to make soluble 
mammalian proteins their use with membrane proteins from higher-eukaryotes is 
rather more restricted. This is not surprising given that bacteria cannot perform 
many of the post-translational modifications that occur in mammalian cells (e.g. 
glycosylation, palmitylation) that are often required for full activity of the 
membrane protein. Furthermore, as the lipid composition of bacterial 
membranes is very different from that in higher eukaryotic cells it is not possible 
to functionally produce those mammalian membrane proteins that have specific 
lipid requirements in bacteria. This said, however, E. coli has been used to make 
both integral (including GPCRS) (Tucker and Grisshammer, 1996; Weiss and 
Grisshammer, 2002) and peripheral mammalian membrane proteins (e.g. 11β-
hydroxylase) (Zollner et al., 2008) in milligram amounts. The main advantages of 
making mammalian membrane proteins in bacteria are the short (ca. 20 min) 
doubling-time of the host cell and the use of cheap media (Sarramegna et al., 
2003).  
Yeasts (in particular Saccharomyces cerevisiae and Pichia pastoris) are 
commonly used to make mammalian membrane proteins as they combine a short 
generation time (ca. 2 h) on cheap growth media with their ability to perform 
many of the post-translational modifications that occur in higher eukaryotes 
(Reilander and Weiss, 1998). The methylotrophic yeast P. pastoris has been 
shown to be particularly useful for making a wide-range of human membrane 
proteins including GPCRs, ion channels, transporters and pumps (Weiss et al., 
1995; Weiss et al., 1998; Grunewald et al., 2004; Andre et al., 2006; Fraser, 
2006; Shukla et al., 2007; Horsefield et al., 2008 ; Aller et al., 2009 ; Ho et al., 
2009; Tao et al., 2009). The main advantages of using P. pastoris are that it has 
a very strong, methanol-inducible promoter (Alcohol Oxidase 1 (AOX1)) which 
drives the production of high levels of recombinant protein (Hartner and Glieder, 
2006; Jahic et al., 2006) as well as its ability to grow to high cell densities in 
fermenter culture (>109 cells/ml) (Fantoni et al., 2007). One drawback of using 
yeast, however, is that its membranes contain ergosterol (the principal fungal 
 
Membrane protein structural biology  25 
sterol) instead of the mammalian one, cholesterol. This lack of cholesterol is 
thought to have prevented the functional expression of certain human 
membrane proteins in yeast including the serotonin transporter (Tate, 2001) and 
the µ-opioid receptor (Lagane et al., 2000). 
Insect cells that have been infected with recombinant baculovirus are useful for 
expressing a number of mammalian membrane proteins. Indeed, all of the 
ligand-activated GPCRs that have been crystallised to date have been made in 
insect cells (Cherezov et al., 2007; Rasmussen et al., 2007; Jaakola et al., 2008; 
Warne et al., 2008). Other advantages of this system are that they perform a 
simple form of glycosylation as well as growing to cell densities of 107-108 
cells/ml in spinner flasks (Sarramegna et al., 2003). Although the media for 
growing insect cells costs substantially more than that for either bacteria or 
yeast, it is also significantly less expensive than that for mammalian cells. 
In many respects, mammalian cells are the ideal host system for making 
mammalian membrane proteins as the lipid composition of the membrane is 
exactly what the recombinant proteins require as well as the cells having all of 
the machinery to perform post-translational modifications to the target protein. 
However, mammalian cells have several drawbacks including a long generation 
time (>24h), they grow to low cell density in bioreactors (106-107 cells/ml) and 
the media can be prohibitively expensive (Sarramegna et al., 2003; Tate et al., 
2003). 
As there is a wide-range of expression systems available, each with their own 
advantages and disadvantages, the particular host cell chosen for heterologous 
expression will largely be determined by the particular mammalian membrane 
protein being over-expressed. Whichever system is chosen, it must deliver high 
yields of functional protein (Tate et al., 2003).  
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1.8 Detergent solubilisation 
Prior to their purification, membrane proteins are extracted from the lipid 
bilayer by adding an amphipathic substance usually detergent. Although 
detergents come in many shapes and forms they all have a hydrophilic head-
group connected to a hydrophobic domain. The nature of the headgroup defines 
the class of detergent: anionic detergents have a negatively charged headgroup 
whereas cationic detergents are positively charged. Detergents with headgroups 
that have both positive and negative charges are termed zwitterionic whereas 
those detergents without a charged headgroup are classified as non-ionic 
(Seddon et al., 2004).  
The choice of detergent used for solubilisation is critical and the chosen one 
must retain the protein’s stability and functionality in solution. Although strong 
ionic detergents (e.g. LDAO) are excellent at solubilising membranes they can 
also remove essential lipids from a protein’s surface rendering it useless for 
structural studies (Johansson et al., 2009). Therefore, mild non-ionic detergents 
(e.g. DDM) are commonly used for solubilisation as they often yield stable, 
active protein in aqueous solution (Misquitta and Caffrey, 2003). 
The concentration at which discrete detergent monomers spontaneously forms 
micelles is known as the critical micelle concentration (CMC). Membranes can be 
readily solubilised by adding detergents at a concentration significantly (10 – 20 
times) greater than their CMC. The detergent molecules replace the lipids 
surrounding the MP resulting in the formation of discrete MP-containing micelles 
(Figure 1.12). Following solubilisation, the target protein can be purified using 
conventional chromatographic techniques for crystallisation trials (Weiss and 
Grisshammer, 2002; Krueger-Koplin et al., 2004). To prevent membrane proteins 
precipitating out of solution, however, all purification buffers must contain 
detergent with a concentration greater than the CMC. 
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Figure 1.12 Schematic diagram showing solubilisation of an integral membrane protein with 
detergent 
Following the addition of detergent at levels 10-20 fold greater than its critical micelle concentration 
(CMC), the lipids surrounding the membrane protein are stripped away and replaced by detergent. 
This results in the formation of discrete protein-detergent micelle complexes. If the solubilisation 
detergent is harsh all of the native lipids may be stripped away. When milder detergents are used, 
those lipids that bind tightly to the surface of the protein are often retained. If a second detergent or 
lipid is included within the solubilisation mixture mixed micelles will result. 
When working with membrane proteins the particular detergent used in the 
crystallisation trials is often a critical determinant of whether or not any crystals 
are obtained. Large detergent micelles (e.g. DDM) can mask the hydrophilic 
(non-transmembrane) regions of membrane proteins, preventing the formation 
of protein-protein interactions necessary for crystal formation (Kobilka, 2007). In 
contrast, as short chain detergents have small micelles they are better suited to 
membrane protein crystallisation. However, this factor has to be weighed 
against the effect of the detergents’ tail length on its ability to stabilise the 
target membrane protein (Prive, 2007). In general, detergents with long (C=12) 
alkyl chains tend to be stabilising whereas those with short (C=8) tails are not. 
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Therefore, for the vast majority of mammalian membrane proteins the 
detergents best suited for crystallisation can not be used because they are too 
destabilising (Gutmann et al., 2007; Prive, 2007). One way in which this problem 
can be overcome is by engineering thermostable mutants of the target protein 
that retain their structure in short chain detergents. For example, considerable 
effort was invested by Tate and co-workers to make a thermostable mutant of 
the turkey β1-adrenergic receptor which was stable in a wider range of 
detergents than the wild type protein (Serrano-Vega et al., 2008; Warne et al., 
2008) (Figure 1.13). Using their most thermostable mutant, it was possible to 
grow diffracting crystals of the β1AR in the detergent octyl-thioglucoside from 
which a structure to atomic resolution has been obtained (Warne et al., 2008).  
While modifications of protein sequence can aid protein stability in detergent 
solution, it is becoming increasingly apparent that the activities of many 
mammalian membrane proteins are influenced by specific lipids, in particular by 
cholesterol (Epand, 2006). By including specific lipids in the solubilisation 
mixture as well as the purification buffers it is possible to increase the stability 
of the target protein in solution (Lacapere et al., 2007). For example, the 
cholesterol derivative cholesterol hemisuccinate (CHS) is essential to obtain 
radioligand binding by the human adenosine 2a receptor in detergent solution 
(Weiss and Grisshammer, 2002; Fraser, 2006). 
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Figure 1.13 Stability of (a) wild-type and (b) a thermostable mutant of the turkey β1 
adrenoceptor in various detergents 
In contrast to that observed for the wild-type receptor, the thermostable mutant was able to bind 
radioligand even when it had been solubilised using the harsh detergents octyl-glucoside (OG), 
nonyl-glucoside (NG) and LDAO. Diffracting crystals of the thermostable mutant were obtained 
using the short-chain detergent octyl-thioglucoside. (Figure taken from (Serrano-Vega et al., 
2008)). 
 
1.9 Membrane protein purification 
Following solubilisation, the protein of interest must be purified to homogeneity 
prior to structural experiments. Two of the most common approaches to 
purifying soluble proteins are ion-exchange and gel-filtration chromatography. In 
ion-exchange chromatography, proteins are firstly bound to a charged resin and 
then selectively eluted by gradually increasing the ionic strength of the buffer 
(Seddon et al., 2004). With gel-filtration, proteins are separated according to 
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their molecular weight by passage through a size exclusion chromatography 
column where large proteins pass through the column quickly and smaller 
proteins travel more slowly through the bead resin. These purification 
techniques can also be used with membrane proteins but the presence of 
detergent limits their effectiveness.  
More recently, recombinant membrane proteins have been made as fusions with 
affinity tags located at either their N- or C- termini. All affinity tags bind to 
specific chromatographic resin, allowing the protein to be purified rapidly and 
efficiently (Lundstrom, 2005). For example, a deca-histidine tag (His10) binds to 
immobilized metal (usually Ni2+ but also Co2+ or Zn2+) affinity chromatography 
(IMAC) resin. Non-specific proteins can be removed from the column by washing 
it with a buffer of high ionic strength containing a small (30 mM) concentration 
of imidazole. The recombinant protein can be eluted using a high (300 mM) 
concentration of imidazole (which competes with the His tag for binding to the 
metal ion). Affinity chromatography is the best approach for purifying membrane 
proteins as long as the detergent micelle does not interfere with binding of the 
tag to the resin.  
 
1.10 Membrane protein crystallisation  
1.10.1 Aggregation 
For crystallisation to occur, the protein must be monodisperse in solution 
(Krueger-Koplin et al., 2004). However, due to their hydrophobic nature 
membrane proteins have a propensity to aggregate in detergent solution 
rendering efforts to crystallise them meaningless (Sanders and Oxenoid, 2000; 
Gutmann et al., 2007). Factors that affect membrane protein aggregation 
include the protein to detergent ratio, glycerol and salt content of the buffer as 
well as the type of detergent used. However, caution must be exercised when 
changing any of these parameters as they have to be compatible with 
crystallisation trials.  
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1.10.2 Crystal growth by vapour-diffusion 
Protein crystallisation typically requires a highly concentrated (>10 mg/ml) pure 
protein sample which on the addition of a precipitant (and possibly small 
amphiphile molecules) starts to form crystals (Garavito et al., 1996). The 
precipitant drives the formation of nucleation sites which, as the protein 
concentration within the drop increases due to water loss, forms the site of 
crystal growth (Caffrey, 2003). The formation of well-ordered crystals requires 
slow, regulated crystal growth which is highly influenced by the protein’s 
concentration and solubility. As the range of possible precipitants is large, the 
process of identifying which will be best for crystal growth can be particularly 
time consuming. However, the development and use of sparse matrix screens for 
initial crystallisation trials has greatly helped to overcome this rate-limiting 
step. Crystal hits are then optimised through a series of small variations to the 
original crystallisation condition with a view to facilitating slow, ordered crystal 
growth resulting in good quality diffracting crystals (Caffrey, 2003; Kobilka and 
Schertler, 2008). Depending on the orientation of the individual proteins and the 
position of their lattice contacts, crystals of varied shape and symmetry can be 
formed (Nollert, 2005). However, in the case of membrane proteins the process 
of obtaining crystals is complicated by the presence of detergent(s) (Arora and 
Tamm, 2001), which often mask the extra-membrane/hydrophilic regions of the 
protein, preventing the formation of crystal contacts (Mohanty et al., 2003). 
 
1.10.3 Lipidic Cubic Phase 
As well as trying to grow crystals of membrane proteins in detergent solution, 
the protein of interest can also be crystallised in a lipid environment called a 
lipidic cubic phase (Nollert, 2005). A lipidic cubic phase is a structured 3-
dimensional matrix of lipid bilayers linked through a network of interconnected 
aqueous pores (Landau and Rosenbusch, 1996; Cherezov et al., 2006). This 
matrix has been used successfully in conjunction with standard crystallization 
techniques to solve the structure of a range of proteins including a purple 
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bacterial photosynthetic RC (Katona et al., 2003) as well as the β2-adrenergic 
(Cherezov et al., 2007) and adenosine 2a receptors (Jaakola et al., 2008). The 
principle advantage of the cubic phase is that it allows the formation of protein 
crystals in a native-like membrane environment (Landau and Rosenbusch, 1996) 
that tend to be of a superior quality than those grown from detergent solution 
(Wadsten et al., 2006). This is due to the increase in stability of the membrane 
protein when it is reconstituted into a bilayer environment (Johansson et al., 
2009). However, cubic phase can only be used for crystallising membrane 
proteins with small extra-membrane domains as the aqueous channels are not 
big enough to accommodate proteins with large hydrophilic regions (Cherezov et 
al., 2006; Wohri et al., 2008). 
 
1.10.4 Lipidic Sponge Phase 
Recently, it has been shown that the cubic phase can be swollen by treatment 
with solvents such as PEGs (Bender et al., 2008). This ‘swollen’ lipidic phase is 
known as the sponge phase and has aqueous channels ca. 3x larger than the 
cubic phase. This means that the sponge phase has the potential for crystallising 
membrane proteins with large extra-membrane domains (Cherezov et al., 2006; 
Wadsten et al., 2006). Several proteins have already had their structures solved 
in the sponge phase (Wohri et al., 2009), and it is an emerging technique which 
should prove useful for obtaining diffracting crystals of (mammalian) membrane 
proteins. 
 
1.11 Project context 
Currently, the field of mammalian membrane protein structural biology is in its 
infancy. Existing technologies and experiences have shown that it is possible to 
obtain the structures of mammalian membrane proteins if sufficient work and 
thought has been invested. However, there is still an urgent need to develop 
new methodologies and approaches to improve all aspects (expression, 
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purification and crystallisation) of mammalian membrane protein structural 
biology. 
 
1.12 Aim 
The main aim of my Ph.D. was to develop new technologies for the 
overproduction, purification and crystallisation of human membrane proteins, 
and then test them with a representative member from each of the GPCR 
(adenosine 2a receptor) and membrane enzyme (sterol isomerase) superfamilies.  
 
1.13 Objectives 
i) to create a series of P. pastoris expression vectors that give high 
production levels of recombinant protein which can be readily purified to 
homogeneity by affinity chromatography  
ii) to develop an optimised methodology that gives maximal production of 
recombinant membrane proteins in fermenter cultures of P. pastoris  
iii) to develop a protocol for monitoring the aggregation status of 
recombinant membrane proteins immediately following detergent solubilisation 
and over the course of the purification process 
iv) to develop a method for determining the stability of purified membrane 
proteins in a range of buffers and salts  
v) to create a lipidic-sponge phase screen and compare its usefulness in 
obtaining mammalian membrane protein crystals compared to conventional 
crystallisation experiments in detergent solution 
 
 
 2  G-protein coupled receptors and 
cholesterol biosynthesis 
 
2.1 Human membrane proteins 
In Chapter 1, the problems associated with solving the structures of mammalian 
(including human) membrane proteins were detailed at length. However, as 
there are many different families of human membrane protein it is pertinent to 
ask whether or not they are all equally difficult to work with or are some 
proteins more amenable to study than others. All membrane proteins can be 
classified into two main groups ― those that have conformational flexibility (e.g. 
receptors, transporters) and those that are essentially rigid (e.g. enzymes, ion 
channels). This chapter focuses on the human adenosine 2a receptor (a GPCR) 
and sterol isomerase (an enzyme involved in the late stages of cholesterol 
biosynthesis) as representative members of the conformationally-dynamic and 
rigid-body membrane protein superfamilies, respectively. 
 
2.2 Membrane proteins with conformational flexibility 
Receptors, which function in information transfer, and transporters, that 
translocate specific substances across lipid bilayers, have considerable 
conformational flexibility consistent with their function. However, the inherent 
flexibility that allows these proteins to exist in multiple conformational states is 
not readily compatible with growing protein crystals. It is not surprising then 
that there are so few structures of mammalian receptors and transporters 
compared to, for example, ion channels (which have rigid structures). 
Furthermore, the ligand-activated GPCRs that have had their structures solved 
had all been locked into particular conformations using either ligands 
(Palczewski et al., 2000; Jaakola et al., 2008) or by site-directed mutagenesis 
(Warne et al., 2008). The available structures of mammalian membrane proteins 
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in the PDB suggests that those proteins with high mobility are harder to work 
with than those that are rigid. I chose to work on the human adenosine 2a 
receptor, a GPCR, as a model human membrane protein with high 
conformational flexibility.  
 
2.3 G-protein coupled receptors 
G-protein coupled receptors (GPCRs) are a large protein super-family that 
function in the plasma membrane of mammalian cells (Kobilka, 2007). They are 
highly conserved throughout evolution with approximately 1% of the human 
genome encoding them (Sarramegna et al., 2003). GPCRs can be classified into 5 
distinct groups (Type 1 to 5) by sequence homology (Deupi and Kobilka, 2007) of 
which type-1 GPCRs (also known as rhodopsin-like receptors) are the largest and 
best studied group (Cherezov et al., 2007; Deupi and Kobilka, 2007; Fredholm et 
al., 2007a). Although GPCRs show poor homology between families (Klabunde 
and Hessler, 2002), they all have a common 7-transmembrane alpha-helical 
structure with an extracellular amino terminus and an intracellular carboxyl 
terminus (Figure 2.1) The hydrophobic transmembrane domains are connected 
by 3 intra- (IL1-3) and 3 extra-cellular (EL1-3) loops. The size of the loops and 
terminal tails can vary dramatically between receptors (Klabunde and Hessler, 
2002). GPCRs perceive specific chemical messages in the extracellular 
environment and then convert this information to a signal within the cell 
(Lefkowitz, 1998; Bockaert and Pin, 1999; Kobilka, 2007).  GPCRs are so-called 
because they activate specific heterotrimeric GTP-binding proteins (G-proteins) 
via their intracellular loops and C-terminal tail following agonist-binding (Ladds 
et al., 2003).  
GPCRs can be activated by a wide-range of ligands including single photons of 
light, ions, nucleosides, hormones and large polypeptides (Kobilka, 2007). This 
enables GPCRs to control a wide range of physiological activities within the body 
including the perception of light and smell, heart rate as well as mood 
regulation. The ligand binding site can be located anywhere on the extracellular 
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side of the GPCR including the N-terminal region, extracellular loops and/or 
within the transmembrane segments. This said, the type and size of ligand does 
not necessarily determine where it binds to the receptor (Deupi and Kobilka, 
2007; Kobilka, 2007). 
 
Figure 2.1 Schematic representation of a G-protein coupled receptor 
(A) The basic topology of a GPCR consists of 7-transmembrane regions connected by 3 intra- (IL1-
3) and 3 extra-cellular (EL1-3) loops. Ligands bind either at the extracellular surface or within the 
protein’s TM domain whereas receptors couple to heterotrimeric G-proteins mainly via their third 
intracellular loop and C-terminal tail. (B) All GPCRs interact with a G-protein Gα subunit which in 
the inactive (GDP) state is tightly associated with the Gβγ complex. 
Receptors were originally classified according to the endogenous ligand found to 
act upon it (Figure 2.2) (Cherezov et al., 2007). However, it was quickly 
discovered that certain endogenous ligands caused a range of physiological 
effects in different tissues by binding to more than one receptor (Palmer et al., 
1995). Upon further investigation, it was found that receptors that bound the 
same ligand had quite distinct protein sequences. For example, the three β-
adrenergic receptors have only 50% amino acid sequence identity in their 
transmembrane regions (Warne et al., 2008). Therefore, there was a need to 
sub-classify close family relatives. Receptor sub-types usually have different 
tissue distributions as well as distinct pharmacological properties (both ligand 
binding and efficacy of G-protein activation), and in many cases bind different 
G-proteins (Bockaert and Pin, 1999).  
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Due to their abundance and cellular location, GPCRs are the major site of action 
for therapeutic drugs (Kobilka, 2007). However, other than their basic 7-
transmembrane topology little is known about the intricacies of their structure 
or mechanism of action.  
 
Figure 2.2 Schematic diagram illustrating GPCR sub-classification 
Many endogenous ligands bind to several highly-related receptors in the body. Receptor sub-types 
mainly differ from each other in the length of their N- and C-termini as well as their extra- and intra-
cellular loop regions.  
2.3.1 GPCRs - signalling mechanisms 
Following ligand-binding GPCRs selectively activate signalling cascades within 
the cell via the activation of specific G-proteins (Bockaert and Pin, 1999; 
Kobilka, 2007). When a ligand binds to the receptor (Lundström, 2005) a 
conformational change occurs within the intracellular region of the protein that 
allows specific G-proteins to bind and become activated (Bockaert and Pin, 
1999; Kobilka, 2007). In their inactive state, G-proteins exist as heterotrimers 
consisting of alpha (α), beta (β) and gamma (γ) subunits that form a high affinity 
complex (Lambright et al., 1996). Activated GPCRs can initiate the exchange of 
the Gα subunits bound GDP for GTP, by acting as guanine-nucleotide exchange 
factors (GEFs) (Ritter and Hall, 2009). This then leads to the dissociation of Gα-
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GTP from the Gβγ subunits (Ladds et al., 2003), which can alter the activity of 
downstream effecter proteins (such as adenylyl cyclase). By either inhibiting or 
stimulating the production of second messengers (such as cyclic AMP) an 
intracellular signal is generated (Flower, 1999). 
The DRY motif is found at the boundary between the second transmembrane 
helix and the second intracellular loop of type I GPCRs (Rovati et al., 2007). This 
motif is essential for G-protein coupling to the ligand-bound receptor and plays 
an important role in GPCR activation. Other than forming stabilizing interactions 
within the receptor constraining the inactive form, the role of the DRY motif in 
effecting G-protein coupling is not yet understood (Yao et al. 2006).  
2.3.1.1 G-proteins 
When G-proteins were originally discovered there was thought to be just one of 
each kind of sub-unit. Since then, however, 20 α, 6 β and 11 or 12 γ subunits 
have been identified in humans (Hamm, 1998; Neves et al., 2002) which give rise 
to a large number of distinct G-protein hetero-trimers each of which generate a 
specific range of intracellular signals (Figure 2.3) (Ladds et al., 2003). The α 
subunits can be classified into 4 distinct groups by sequence homology – Gs, Gi, 
Gq/11, G12/13 (Neves et al., 2002). The first group, Gs, is the best studied and 
upon GDP-GTP exchange activates adenylyl cyclase increasing the intracellular 
levels of cyclic AMP (cAMP). Gi acts in direct opposition to Gs inhibiting adenylyl 
cyclase thereby decreasing cAMP levels (Hamm, 1998). Members of the Gq/11 sub-
family activate phospolipase C which hydrolyses phosphatidylinositol 
biphosphate to give the second messengers inositol triphosphate (IP3) and 
diacylglycerol (DAG) (Neves et al., 2002). G12 acts on guanine nucleotide 
exchange factors (GEFs) to activate GTPase-activating proteins.  
In addition, the Gβγ subunits regulate the activity of other proteins/signalling 
events in the cell. For example, Gβγ can activate inward rectifying K+ channels 
(Logothetis et al., 1987; Dascal, 1997) as well as modulate the voltage-
dependence of specific calcium channels (Herlitze et al., 1996; Ikeda, 1996; De 
Waard et al., 1997). Furthermore, Gβγ can regulate Ras which, in turn, controls 
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the activity of certain mitogen-activated protein kinases (MAPK) (Schmitt and 
Stork, 2002) (including the extracellular signal-regulated kinases (ERKs) (Koch et 
al., 1994; Obara et al., 2008)), as well as the c-Jun NH2-terminal kinases (JNKs) 
(Coso et al., 1997).  
 
Figure 2.3 Overview of intracellular signals generated by G-proteins following GPCR 
activation 
Agonist binding at the GPCR leads to the selective activation of associated G-proteins by 
catalysing the exchange of GDP for GTP at the Gα sub-unit. This causes the Gα and Gβγ sub-units 
to dissociate. Gα-GTP alters the activity of downstream signalling enzymes such as adenylyl 
cyclase and phospholipase C which, in turn, alters the levels of second messenger molecules 
cAMP and IP3/DAG, respectively. The Gβγ subunits modulate other signalling pathways. For 
example, Gβγ has been found to activate mitogen activated protein kinases (MAPKs) via Ras. 
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The duration of signals propogated by the Gα and Gβγ sub-units is determined by 
the GTPase activity of the Gα subunit (Cabrera-Vera et al., 2003). Following 
hydrolysis of the bound GTP to GDP, the Gα and Gβγ sub-units re-associate, 
returning the G-protein to its resting state (Lambright et al., 1996). 
Although the third intracellular loop of GPCRs is known to be a critical 
determinant of which G-protein complex is activated by each receptor (Kobilka 
and Schertler, 2008) certain GPCRs have been shown to couple to more than one 
type of G-protein depending on the particular ligand bound to the receptor as 
well as the pool of G-proteins available within each cell (Ladds et al., 2003).  
2.3.1.2 GPCR desensitisation 
To prevent chronic over-stimulation of cells GPCR signalling needs to be 
switched off (Figure 2.4) (Ferguson, 2001; Ma and Pei, 2007). This is 
accomplished by phosphorylation of specific residues in the cytoplasmic regions 
of agonist-bound GPCRs by G-protein coupled receptor kinases (GRKs) (Tobin et 
al., 2008). In certain cases, phosphorylation is enough to prevent G-protein 
binding (Maudsley et al., 2005). However, in most cases, GPCR phosphorylation 
is followed by recruitment of an arrestin protein to the receptor’s C-terminal 
tail that physically blocks G-protein activation (Gurevich and Gurevich, 2006; Ma 
and Pei, 2007). There are four arrestin proteins (Ferguson, 2001; Rajagopal et 
al., 2010) that associate with phosphorylated GPCRs (Brzostowski and Kimmel, 
2001; Gurevich and Gurevich, 2006; Ma and Pei, 2007). By blocking G-protein 
activation, arrestins “switch off” the intracellular signalling cascade (Bockaert 
et al., 2004). The arrestins also target the GPCR for internalisation where they 
are either dephosphorylated and recycled to the plasma membrane or targeted 
to the lysosome for degradation (Hall and Lefkowitz, 2002; Bockaert et al., 
2004; Gurevich and Gurevich, 2006; Kelly et al., 2008). Receptor desensitisation 
is an important aspect of GPCR biology not just in switching off the current 
signalling event but also priming the receptor for receiving a new signal 
(Lefkowitz, 1998). 
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Figure 2.4 GPCR desensitisation via the combined action of G-protein receptor kinases 
(GRKs) and arrestins 
Following agonist binding, GPCRs are able to selectively activate specific G-proteins starting a 
signalling cascade within the cell. To switch off signalling by the receptor, G-protein receptor 
kinases (GRKs) phosphorylate specific residues in the cytoplasmic tail of the agonist-bound 
receptor. This drives the recruitment of arrestin proteins to the receptor and ultimately results in 
receptor internalization where it is either dephosphorylated and recycled to the cell surface or 
targeted to the lysosome for degradation. Prior to internalisation, arrestins can stimulate G-protein 
independent signalling. In certain cases, phosphorylation of the agonist-bound GPCR by the GRK 
is sufficient to prevent G-protein binding, switching off the signal. This figure is adapted from ((Ma 
and Pei, 2007)).  
2.3.1.3 G-protein independent signalling 
Recently, it has been shown that GPCRs can also signal in a G-protein 
independent fashion (Bockaert and Pin, 1999; Kobilka, 2007) by binding 
regulatory proteins called GPCR interacting proteins (GIPs) (Bockaert et al., 
2004; Gsandtner et al., 2005; Ritter and Hall, 2009). Due to the large number of 
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proteins that act as GIPs their modes of action can vary considerably. Known 
effects include altering the pharmacological properties, function and trafficking 
of GPCRs (Brzostowski and Kimmel 2001; Ritter and Hall 2009).  
Two of the best characterised GIPs are β-arrestin 1 and 2 which, following 
recruitment to a GPCR, act as multi-functional adaptor proteins, scaffolding a 
diverse group of signaling proteins at the receptor, thereby modulating the 
downstream activity of a number of signaling networks (reviewed in (DeWire et 
al., 2007)). For example, β-arrestin 1 recruits an activated non-receptor tyrosine 
kinase (SRC), to selected receptors causing the downstream activation of 
extracellular-signal related kinase (ERK) (Luttrell and Gesty-Palmer, 1999; 
Luttrell et al., 2001). β-arrestins are also known to cause transactivation of the 
epidermal growth factor receptor (EGFR) in a SRC-dependent manner, as well as 
being involved in the regulation of receptor trafficking and the activity of small 
GTPases (Rajagopal et al., 2010).   
Other GIPs include (i), the Janus family of kinases (JAKs) and members of the 
signal transducers and activators of transcription (STATs) (Marrero et al., 1998), 
(ii) PDZ domain containing proteins such as the Na+ H+ exchange regulatory 
factor (which controls the activity of the Na+-H+ exchanger type 3 (NHE3)) (Hall 
et al., 1998 a,b), and (iii) phosphoinositide-3-kinase (PI3K) sub-unit p85 that 
influences the activity of the Akt signaling pathway (Bousquet et al., 2006). 
These examples give just a flavour of the ways that GIPs extend the capacity of 
GPCRs to regulate cellular processes. In summary, by binding GIPs, GPCRs are 
able to generate an enormous diversity of intracellular signals in distinct cellular 
compartments in response to a relatively small number of endogenous ligands. 
2.3.1.4 GPCR oligomerisation 
Another important aspect of GPCR signalling is that of receptor oligomerisation. 
In recent years, considerable evidence has been obtained showing that many 
proteins exist as dimers, and sometimes even as higher order oligomers in both 
homo- and hetero-oligomeric complexes (Javitch, 2004). It has even been 
suggested that all GPCRs exist in some form of multimeric complex (Breitwieser, 
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2004; Fredholm et al., 2007a). Dimerisation was first established for members of 
the type III class of GPCRs (including the metabotropic glutamate receptor 5 
(Romano et al., 1996; Romano et al., 2001) and γ-aminobutyric acid (GABA) 
receptors (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; Kuner 
et al., 1999; Ng et al., 1999)). Since then, it has become increasing apparent 
that GPCRs from all families interact with different partner GPCRs on the 
surface of cells in a variety of complexes. There is considerable evidence that 
GPCR dimerisation occurs at the level of protein synthesis in the endoplasmic 
reticulum or during maturation in the Golgi and it is thought that many, if not 
most GPCRs, are trafficked to the plasma membrane as part of a dimeric 
complex (Bulenger et al., 2005; Milligan, 2007). 
The biological significance of heterodimerisation is not well understood, or 
exploited, but is predicted to have a major impact on drug discovery in the 
coming years (George et al., 2002). This said, certain ligands have been shown 
to have direct and selective effects on the conformation of the individual 
receptors that make up hetero-dimers. For example, in the case of the GABA(B) 
receptor, binding of the neurotransmitter in the N-terminal region of the 
GABA(B)R1 sub-unit results in activation of a G-protein by the GABA(B)R2 
protomer (Jones et al., 1998; Breitwieser, 2004; Milligan, 2009). This implies 
communication between two receptor units with distinct conformational changes 
in both proteins following ligand binding.  
Although there are now numerous reports of GPCR oligomerisation in the 
literature, not all of the suggested dimers are likely to occur in native tissues. 
There are two main reasons for this: i) in transient transfection experiments 
possible GPCR dimers/oligomers that are detected may just be an artifact of 
receptor overexpression in a non-native background, and ii) even when a number 
of clear differences in the function and pharmacology of co-expressed pairs of 
GPCRs have been observed care has to be taken to discriminate between those 
effects that are due to direct protein-protein interactions and those that are 
produced indirectly via downstream signaling and feedback control (Milligan, 
2007). A physiologically-relevant and therapeutically interesting example of 
receptor hetero-oligomerisation is that between the adenosine 2a receptor 
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(A2aR) and the dopamine D2 receptor (D2R). These GPCRs have been shown to 
exist as heteromeric complexes in both transfected and striatal tissue (Ferre et 
al., 2001; Fuxe et al., 2007). Furthermore, in brain A2aR antagonists have a 
strong inhibitory effect on the activity of the D2R reducing tremor and rigidity in 
patients with Parkinson’s disease (Ferre et al., 2001; Fuxe et al., 2007).  
2.3.2 GPCRs: conformational complexity 
In the past, GPCRs have been described as “bimodal switches” in which they 
exist in either an active or inactive conformation (Kobilka and Deupi, 2007) 
(Figure 2.5 (A)). However, this “lock and key” model did not account for the 
association of G-protein with the receptor and so the simple ternary complex 
model as a description of GPCR biology was devised (Figure 2.5 (B)). This model 
was later modified to take account of the high and low affinity states of both 
receptor and receptor-G protein complexes for ligand (Figure 2.5 (C)). Many 
receptors have been shown to have constitutive activity (Klinger et al., 2002) 
allowing them to signal in the absence of an agonist (Vauquelin and Van Liefde, 
2005). This finding gave rise to the extended ternary complex model (Figure 2.5 
(D)). Common to all of these models is the assumption that the receptor has a 
unique conformation depending on which partner(s) (eg agonist, G-protein) are 
associated with it. Although these models may appear complicated the reality is 
considerably more convoluted with the fact that most GPCRs bind partial 
(inverse) agonists that stabilise the receptor in a series of conformational 
intermediates each with their own signalling properties (Ladds et al., 2003; 
Kobilka and Deupi, 2007). Although both ligands and G-proteins are known to 
preferentially interact with discrete GPCR states, fluctuations between 
conformations can occur spontaneously (Vauquelin and Van Liefde, 2005). 
The vast range of conformations that GPCRs are known to exist in has proven to 
be a substantial barrier in efforts to crystallise GPCRs. Well-ordered crystals 
(required for structure determination) can only be formed from a 
conformationally homogeneous sample. Therefore, strategies for stabilising 
specific receptor conformations have to be used with all GPCRs before crystals 
that diffract to high resolution can be obtained. 
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Figure 2.5 Various models describing the possible conformational states of GPCRs 
(A) The two-state model in which ligand (L) binding to the receptor (R) results in the formation of a 
LR complex generating an active receptor conformation (R*) that signals to downstream effectors. 
(B) The simple ternary complex model (where G is for G-protein). (C) The full ternary complex 
model which accounts for the high and low affinity states of both R and RG for L. (D) The discovery 
of constitutively active GPCR mutants resulted in the development of an extended ternary complex 
model in which the receptor can adopt an active conformation (Ra) in the absence of L or G 
binding. Ri denotes the inactive conformation of the receptor. (Red indicates a fully active complex, 
orange is constitutive activity, yellow is inactive receptor.) This figure was modified from (Rajagopal 
et al., 2010). 
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2.3.3 Current structural knowledge of GPCRs  
To date, only four G-protein coupled receptors have had their structures solved 
to atomic resolution (figure 2.6) (Palczewski et al., 2000; Cherezov et al., 2007; 
Rasmussen et al., 2007; Jaakola et al., 2008; Warne et al., 2008) which, 
considering their biological importance, gives some indication of how difficult it 
is to obtain a GPCR structure.  
 
Figure 2.6 GPCR structures in the PDB 
Available structures include (A) rhodopsin (1F88), (B) turkey β1-adrenergic receptor (2VT4), (C) 
human β2- adrenergic receptor with IL3 replaced with T4 lysozyme (2RH1), (D) human β2-
adrenergic receptor in complex with a Fab (2R4R), and (E) the human adenosine 2a receptor with 
T4 lysozyme (3EML), (Palczewski et al., 2000; Cherezov et al., 2007; Rasmussen et al., 2007; 
Jaakola et al., 2008; Warne et al., 2008). 
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The first mammalian GPCR to have its structure solved to high resolution was 
bovine rhodopsin (Palczewski et al., 2000). This is not surprising as rhodopsin has 
several properties that make it easier to work with compared to other GPCRs. 
Firstly, as rhodopsin has a high natural abundance it did not have to be 
overexpressed in a heterologous host before structural studies could begin. 
Secondly, rhodopsin covalently binds 11-cis-retinal (which acts as an inverse 
agonist) stabilising the receptor in its inactive conformation (Palczewski et al., 
2000). Finally, the bound retinal chromphore gives rhodopsin a red colour which 
makes it easy to identify those fractions containing receptor throughout the 
purification process (Teller et al., 2001). 
Rhodopsin functions in the perception of light (Palczewski et al., 2000; Teller et 
al., 2001). On absorbing a photon of light energy the bound retinal changes from 
an all-cis to an all-trans conformation that activates rhodopsin which, in turn, 
activates the G-protein transducin (Sheikh et al., 1996). Thus far, 15 discrete 
rhodopsin structures have been solved and deposited in the PDB, each giving 
different insights into rhodopsin’s mechanism of activation.  
The first rhodopsin structure confirmed the 7TM alpha helical topology that had 
been predicted for all GPCRs. However, an additional irregular α-helix (helix 8) 
that is situated along the surface of the cytoplasmic membrane was also 
observed (Figure 2.6 (A)) (Palczewski et al., 2000). The 7 TM helices vary in 
length according to the angle that they cross the membrane. Proline residues in 
TM I, IV, VI and VII creates kinks in the α-helices. The receptor is held together 
by hydrogen bonds between helices, a disulphide bond (between extracellular 
loop 2 and TM3) as well as a salt bridge (between the E/DRY motif (Glu134, 
Arg135 and Tyr136) in TM3 and Glu247 & Thr251 (both TM5)).  
Further structural studies have identified several water molecules that occur 
within the transmembrane region of rhodopsin which are essential for the 
formation of the hydrogen-bond network between helices (Okada et al., 2002; Li 
et al., 2004). To understand the changes in protein conformation that 
accompany rhodopsin’s photochemical reactions structures of various 
intermediate photostates (including inactive (or “dark” state) rhodopsin through 
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bathorhodopsin, lumirhodopsin, metarhodopsin I and deprotonated 
metarhodopsin II (the active “light” state) have been determined (Choi et al., 
2002; Nakamichi and Okada, 2006 a,b; Salom et al., 2006). 
Although heterologous expression of rhodopsin has proved difficult, by 
introducing a stabilising disulphide bond and removing its only glycosylation site 
it has been possible to obtain milligram quantities of recombinant rhodopsin 
from which diffracting crystals and a high-resolution structure have been 
obtained (Standfuss et al., 2007). This was a landmark achievement as it was the 
first time that any GPCR had been produced in a heterologous host and then 
crystallised. 
More recently, a crystal structure has been obtained for ligand-free opsin that 
shows the structural changes that occur within the E/DRY motif and TM5-7 when 
the receptor is in its active conformation (Park et al., 2008). Furthermore opsin 
has recently been crystallised in complex with a peptide from the alpha subunit 
of the G-protein transducin (Scheerer et al., 2008). This structure has given the 
first insights into the conformational changes that occur on G-protein binding 
and activation by a GPCR.  
As rhodopsin is an atypical GPCR, it was not clear how relevant the structures of 
rhodopsin would be to the wider GPCR family. Within the past few years, 
however, structures of the human β2 adrenergic receptor (Figure 2.6 (C, D)), the 
turkey β1 adrenergic receptor (Figure 2.6 (B)) and the human adenosine 2a 
receptor (Figure 2.6 (E)) have all been deposited in the PDB. For all of these 
proteins, diffracting crystals were only obtained using modified receptor 
constructs in which the highly mobile third intracellular loop (known to be 
involved in G-protein coupling) had been replaced with T4 lysozyme (Cherezov 
et al., 2007; Jaakola et al., 2008), shortened (Warne et al., 2008) or bound by a 
Fab fragment   (Rasmussen et al., 2007). Furthermore, diffracting crystals were 
only obtained using purified receptor that was deglycosylated, had a truncated 
C-terminal tail and had either an antagonist or inverse agonist bound (which 
locked the receptor into an “inactive” state).  
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The β2-adrenoreceptor (β2AR) is probably the best characterised ligand-
activated GPCR primarily as it was the first non-rhodopsin GPCR to be cloned 
(Dixon et al., 1986) but also because it is an important therapeutic drug target 
in the treatment of cardiovascular and pulmonary disease (Kolb et al., 2009; 
Overington et al., 2006; Takeda et al., 2002). Structures of carazolol-bound 
β2AR have been solved in two different ways (Cherezov et al., 2007; Rasmussen 
et al., 2007). In the first method, the β2AR was co-crystallised with a specific 
antibody fragment (Fab) bound to the flexible third intracellular loop. Using this 
approach a structure at a resolution of 3.7 Å was obtained though the electron 
density around the ligand binding site was poorly resolved (Rasmussen et al., 
2007). In the second method IL3 was replaced with T4 lysozyme. Crystals of this 
receptor construct were grown in a lipidic-cubic phase that diffracted to a 
resolution of 2.4 Å (Cherezov et al., 2007). Reassuringly, the two methods gave 
structures where the arrangement of the TM helices and the specific interactions 
between carazolol and the receptor were essentially the same (Cherezov et al., 
2007; Rasmussen et al., 2007; Rosenbaum et al., 2007). Furthermore, the 
arrangement of transmembrane helices in the β2AR was found to be largely 
similar to that in rhodopsin. However, an additional short helix in EL2 occurs in 
the β2AR which differs from that in rhodopsin where there is a flexible loop. The 
helix in EL2 is thought to prevent the movement (and closing) of the ligand-
binding pocket in the β2AR (which is permanently capped in rhodopsin) 
(Standfuss et al., 2007).  
Although carazolol and retinal occupy similar spaces in the β2AR and rhodopsin, 
the β-ionone ring of retinal extends deeper into the ligand binding pocket than 
carazolol contacting the highly conserved Trp265 in helix VI of rhodopsin 
(Cherezov et al., 2007). Changes in the side-chain of Trp 265 are thought to 
occur upon activation of rhodopsin (as well as other type I GPCRs). The 
interactions between retinal (a full inverse agonist) and Trp 265 are thought to 
contribute to rhodopsin’s lack of basal activity. In contrast, the β2AR structure 
shows that carazolol does not interact with this “toggle switch”, likely 
explaining why it is a partial and not a full inverse agonist (Cherezov et al., 
2007).  
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A high resolution structure of the turkey β1-adrenergic receptor was obtained 
from diffraction quality crystals of a detergent-resistant thermostable mutant 
(that had been created following extensive mutagenesis of the receptor) (Warne 
et al., 2008; Warne et al., 2009). By identifying mutations that conferred 
thermostability on the receptor, as well as locking the protein in an inactive 
conformation, it was possible to obtain pure, monodisperse protein in short 
chain detergents (Serrano-Vega et al., 2008) which gave crystals that diffracted 
to 2.7 Å (Warne et al., 2008). 
When the structures of the β1- and β2-ARs are compared, there are no 
significant differences in the positions of the TM helices. Furthermore, the short 
α-helix in EL2 identified in the β2AR structures is present in β1AR also. This 
structural feature may allow GPCRs to bind diffusable ligands rapidly and 
reversibly (Warne et al., 2008). The β1- structure varies from the β2-AR, 
however, in that it has an additional helix located within IL2. A hydrogen bond 
between Tyr149 in the IL2 helix and Asp138 in TM3 may potentially play a role in 
receptor G-protein specificity but further studies are required to clarify this 
suggestion (Warne et al., 2008). 
The most recent GPCR to have its structure determined was the human 
adenosine 2a receptor which was solved using the T4-lysozyme insertion 
approach (Jaakola et al., 2008). The receptor was co-crystallised with the 
antagonist ZM241385 and a structure to 2.6 Å resolution obtained. Although the 
hA2aR has the same helical scaffold as both the β1- and β2-ARs, the way in 
which the antagonist ZM241385 binds to the receptor (perpendicular to the lipid 
membrane interacting with EL2 and EL3) is completely different (Jaakola et al., 
2008). This suggests that further GPCR structures may reveal a diverse range of 
ligand binding pockets (Jaakola and Ijzerman, 2010). In contrast to the helix that 
occurs in the EL2 of the β-ARs, the hA2aR has three disulphide bridges (which 
are essential for high-affinity antagonist binding) instead (Jaakola and Ijzerman, 
2010).  
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While these structures have greatly enhanced our knowledge of GPCR biology at 
the molecular level, only through obtaining further structures of different GPCRs 
in a range of conformational states will it be possible to fully understand the 
molecular details of GPCR activation. 
2.3.4 Structure-based drug design against GPCRs  
Given that GPCRs are one of the largest protein superfamilies, function at the 
cell surface and regulate a vast array of physiological processes, it is not 
surprising that a large number of existing therapeutic molecules act against 
them. However, many drugs have side-effects arising from non-specific 
interactions of the therapeutic with other cellular proteins. It is hoped that by 
solving the structures of ligand-activated GPCRs to atomic resolution it will be 
possible to design drugs that act specifically against particular receptors, 
reducing the problem of unwanted side-effects. 
2.3.5 Human adenosine receptors 
Adenosine is an important chemical involved in the inflammatory response with 
its extracellular accumulation being the first major signal in response to 
ischaemia and inflammation (Ohta and Sitkovsky, 2001; Murphree et al., 2002; 
Sands and Palmer, 2005). The levels of adenosine that accumulate can vary 
dramatically dependent on the level of stress and the tissue affected (Jacobson 
and Gao, 2006). Adenosine is formed from AMP by the action of the AMP 
selective 5’ nucleotidase, and its rate of formation is directly proportional to the 
amount of available AMP (Fredholm et al., 2007b). 
In humans, there are four adenosine receptor subtypes - A1, A2a, A2b and A3. 
Although all of them are activated by adenosine (Gsandtner and Freissmuth, 
2006), there is only ~50% sequence homology between the receptor subtypes 
(Figure 2.7) (Moreau and Huber, 1999). Upon adenosine binding, these receptors 
activate different G-proteins and signalling pathways within the cell (Palmer et 
al., 1995; Gsandtner et al., 2005).  For example,  the A2a receptor activates Gαs 
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Figure 2.7 Sequence alignment of the four human adenosine receptor subtypes 
When the amino acid sequences of the adenosine receptor subtypes were compared it was found 
that they had ca.  37% sequence identity. The alignment also shows that the adenosine 2a 
receptor subtype is unique in that it has an extremely long C-terminal tail - over 90 residues longer 
than any of the other adenosine receptor subtypes. Residues highlighted in red have 100% 
consensus while those boxed in blue have amino acid substitutions maintaining type. The green 
arrows indicate potential transmembrane domains. 
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whereas A1 activates Gαi. This means that according to the type of adenosine 
receptor possessed by a cell, the presence of extracellular adenosine may either 
increase or decrease its cAMP level stimulating different intracellular signalling 
pathways (Olah, 1997). As well as their distinct signalling properties, the tissue 
distribution of the different adenosine receptor subtypes varies (Moreau and 
Huber, 1999) - A1 and A2a are present in both the cardiovascular and central 
nervous systems, A2b is ubiquitously expressed throughout the body while A3 
receptors are highly enriched in the brain. 
2.3.6 The human adenosine 2a receptor 
The human adenosine 2a receptor (hA2aR) is expressed in high levels in lymphoid 
tissues such as spleen, leukocytes and blood platelets (Sands et al., 2004) as 
well as vascular endothelial cells and striatal neuronal cells (Ferre et al., 2001; 
Gsandtner and Freissmuth, 2006). hA2aR signaling has been extensively studied 
(Gomez and Sitkovsky, 2003; Sands et al., 2004; Sands and Palmer, 2005) and it 
has been shown to be a key therapeutic target in the treatment of many 
inflammatory diseases (Jacobson and Gao 2006). Agonist molecules that interact 
with the A2aR down-regulate inflammation by inhibiting pro-inflammatory 
responses within the cell (Sands and Palmer, 2005), and are useful for treating 
diseases such as atherosclerosis, sepsis and tumour progression. More recently, 
hA2aR antagonists have become of interest to researchers developing new 
treatments for Parkinson’s disease as the hA2aR dimerises with dopamine D2 
receptors (Ciruela et al., 2004) increasing the affinity of the D2 receptor for 
agonists in the presence of an A2aR antagonist (Ferre et al., 2001).  
The hA2aR has a unique C-terminal tail 122 amino acids in length (Figure 2.8). 
This is considerably longer than what is typical for a family I GPCR whose C-tails 
are usually in the region of 10-40 amino acids long. The hA2aR C-tail shows no 
sequence similarity with any other GPCR yet it is highly conserved between 
species, and is thought to play an important role in either trafficking or G-
protein independent signaling but is not involved in G-protein coupling (Olah,  
1997; Moreau and Huber, 1999). This region is predicted to be highly disordered, 
and likely explains why it is able to interact with a diverse range of adaptor 
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proteins (Fredholm et al., 2007b). For example, the C-tail of the hA2aR has been 
shown to interact with α-actinin (which mediates receptor internalization) 
(Burgueno et al., 2003), Usp4 (which is important for maintaining the cell 
surface position of the hA2aR) (Milojevic et al., 2006) and ARNO (which activates 
MAP kinase) (Gsandtner et al., 2005). 
 
Figure 2.8 Schematic diagram of the human adenosine 2a receptor 
Of note are the regions of the hA2aR predicted to be transmembrane as well as the receptor’s 
large intracellular C-terminal tail. Colours are dependent on individual amino acid. 
 
2.4 Rigid-bodied membrane proteins 
In contrast to those membrane proteins with high conformational flexibility, 
rigid bodied membrane proteins are considered relatively easy to work as they 
have defined structures with very little, if any, regions that are natively 
disordered. Furthermore, these MPs tend to exist in a limited number of 
conformational states only. For example, ion channels tend to exist in either an 
open or closed state. For these reasons a relatively large number of mammalian 
rigid-bodied MPs have had their 3-dimensional structures solved including water 
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channels (Murata et al., 2000; Horsefield et al., 2008; Ho et al., 2009), ion 
channels (Long et al., 2005; Tao et al., 2009), transporters (Aller et al., 2009) 
and enzymes (Binda et al., 2002; Hernandez-Guzman et al., 2003; Ago et al., 
2007; Martinez Molina et al., 2007). 
As yet, only three mammalian integral membrane enzymes have had their 
structures solved (Binda et al., 2002; Hernandez-Guzman et al., 2003; Ago et 
al., 2007; Martinez Molina et al., 2007). This is rather surprising considering 
enzymes have highly-ordered structures with fixed active sites where specific 
substrates bind in a particular orientation in proximity to those amino acid 
residues that participate in the catalytic reaction (Nelsetuen, 1995; Welch, 
1995; Binda et al., 2002). In my Ph.D., I worked on the cholesterol biosynthetic 
enzyme sterol isomerase as an example of a human rigid-bodied MP.  
 
2.5 Cholesterol 
Cholesterol is the principal mammalian sterol. It is an amphipathic molecule 
consisting of a hydrophilic hydroxyl group, a rigid four-ring structure and a 
hydrocarbon tail (Figure 2.9). Cholesterol is an essential component of 
mammalian cell membranes where it regulates the membrane’s structure, 
permeability and fluidity. The hydroxyl group of cholesterol interacts with the 
polar head groups of both phospho- and sphingo-lipids while the hydrocarbon 
part restricts the movement of the fatty acid chains of neighbouring lipid 
molecules (Rietveld and Simons, 1998). Cholesterol rich regions of membranes 
are known as lipid rafts. These have been shown to play important roles in 
regulating a diverse range of cellular processes including polarised trafficking 
events, endo- and exo-cytosis as well as signal transduction (Lucero and Robbins, 
2004; Ramstedt and Slotte, 2006). Cholesterol is essential for the full activity of 
many different mammalian membrane proteins including GPCRs (Gimpl et al., 
1995; Klein et al., 1995; Albert et al., 1996; Gimpl et al., 1997; Pang et al., 
1999; Lagane et al., 2000; Gimpl and Fahrenholz, 2002), transporters (Shouffani 
and Kanner, 1990; Rothnie et al., 2001; Tate, 2001; Magnani et al., 2004), 
 
G-protein coupled receptors and cholesterol biosynthesis 56 
pumps (Ding et al., 1994; Cornelius, 2001) and ion channels (Fernandez-Ballester 
et al., 1994). Cholesterol can modulate the activity of membrane proteins in two 
different ways: firstly, cholesterol contributes to the stability and functionality 
of membrane proteins by exerting lateral pressure on their transmembrane 
domains (Gimpl et al., 1997); secondly, specific interactions between the 
protein and cholesterol can be essential for the protein’s activity (Gimpl et al., 
1997; Tate, 2001; Hanson et al., 2008). In addition to its role in the membrane, 
cholesterol is also the biosynthetic precursor of a wide-range of biologically 
active molecules including bile acids (Song et al., 2007; Ferdinandusse et al., 
2009), steroid hormones (eg cortisol, aldosterone, progesterone, estrogen and 
testosterone) (He et al., 2010) as well as several fat-soluble vitamins (eg Vitamin 
D) (Holick, 1995). In short, cholesterol is a pivotal molecule at the centre of 
mammalian cell biology. 
 
Figure 2.9 Chemical structure of cholesterol  
Cholesterol has three distinct regions comprising of (A) a hydroxyl head group, (B) a rigid ring 
structure and (C) a hydrocarbon tail. 
2.5.1 Cholesterol homeostasis 
The amount of cholesterol in our bodies is more or less the same from day to 
day, and in a typical male adult is ca. 35g. However, cholesterol is made and 
turned over on a daily basis. Although each day we make ca. 1000 mg of 
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cholesterol and take-in an additional 200-500 mg from our diet, we lose an 
equivalent amount of cholesterol via excretion in bodily fluids (Charlton-Menys 
and Durrington, 2008). Cholesterol is continuously moved between different 
parts of the body and, due to its hydrophobic nature, is transported in the blood 
within lipoproteins (Moebius et al., 2000; Ikonen, 2006; Daniels et al., 2009). For 
example, very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) 
transport cholesterol from the liver to peripheral tissues (Simons and Ikonen, 
2000). In contrast, high-density lipoproteins (HDL) carry cholesterol back from 
the extremities of the body to the liver where it is either broken down or 
converted into bile salts (Schmitz and Grandl, 2009). The cholesterol content of 
cells is dynamic, and the steady-state levels of cholesterol in individual cells are 
determined by the relative rates of cholesterol synthesis, uptake and export 
(Daniels et al., 2009). Moreover, within each cell a cholesterol gradient exists 
with the highest and lowest levels occurring in the plasma membrane and 
endoplasmic reticulum, respectively (Schmitz and Grandl, 2009). When excess 
amounts of cholesterol accumulate in the body, disease always results. For 
example, elevated blood LDL-cholesterol levels are a major risk factor for 
atherosclerosis (and from this other cardiovascular diseases such as heart attacks 
and stroke) (Ikonen, 2006; Daniels et al., 2009).  
2.5.2 Cholesterol biosynthesis 
In humans, cholesterol is primarily made in the liver and cells of the central 
nervous system (Charlton-Menys and Durrington, 2008). An overview of 
cholesterol synthesis is presented in Figure 2.10. Cholesterol synthesis starts 
with the reaction of acetyl CoA with acetoacetyl-CoA to form 3-hydroxy-3-
methylglutaryl CoA (HMG-CoA). Reduction of this molecule to mevalonate is the 
committed step in cholesterol biosynthesis. This reaction is catalysed by the 
enzyme HMG-CoA reductase which is inhibited by the statin family of drugs 
(which are commonly used to lower blood cholesterol levels) (Charlton-Menys 
and Durrington, 2008). Following this, a series of molecular reactions occurs that 
results in the formation of squalene which is then cyclicised to form lanosterol 
(Do et al., 2009). Lanosterol is converted to zymosterol through another series 
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of chemical modifications. Finally, cholesterol is made from zymosterol via three 
intermediates - cholesta-7,24-dienol, cholesta-5,7,24-trienol and 7-
dehydrocholesterol – requiring the activity of a C8-C7 sterol isomerase, a C5 
desaturase, a C24- and a C7-sterol reductase, respectively (Figure 2.10)  
(Moebius et al., 2000).  
2.5.3 C8-C7 sterol isomerase 
Sterol isomerase (SI) catalyses the movement of the double bond in the second 
sterol ring from the C8 to the C7 position (Figure 2.10) (Moebius et al., 1998). SI 
does not require any redox co-factors or metal ions to perform the isomerisation 
reaction, and it is unique amongst the cholesterol biosynthetic enzymes in that 
it is able to catalyse the reverse reaction also (Bae et al., 2001). SI is located in 
the membrane of the endoplasmic reticulum (Simons and Ikonen, 2000), and is 
predicted to have four transmembrane domains (Figure 2.11). SI was originally 
identified as an emopamil-binding protein (EBP) (Silve et al., 1996), and was 
thought to have an effect on ischemia, immunosuppression and neuroprotection 
(Moebius et al., 2000). Since then, it has been shown that emopamil does not 
exert its effects through sterol isomerase activity as originally thought. 
 
 
G-protein coupled receptors and cholesterol biosynthesis 59 
 
Figure 2.10 Overview of cholesterol biosynthesis 
Cholesterol is formed from acetyl CoA and acetoacetyl CoA through a series of molecular 
reactions. Of note, C8-C7 sterol isomerase catalyses the conversion of zymosterol to cholesta-
7,24-dienol.  
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Figure 2.11 Schematic representation of sterol isomerase 
Sterol isomerase is predicted to have four transmembrane domains (amino acids coloured 
individually). 
2.5.3.1 Monogenic disease of sterol isomerase 
At present, seven inherited disruptions of cholesterol biosynthesis have been 
described, five of which are post-squalene (Moebius et al., 2000). Conradi-
Hünermann-Happle (CHH) syndrome is caused by stable loss-of-function 
mutations within the gene encoding sterol isomerase (Has et al., 2000). Due to 
its X-linked dominant inheritance pattern (Moebius et al., 2000), CHH is also 
called chondrodysplasia punctata type II (CPDX2) (Becker et al., 2001). The 
disease occurs almost exclusively in females but there has been a recent report 
of CDPX2 in a male patient (Aughton et al., 2003). The key clinical features of 
CDPX2 are due to the skeletal dysplasia causing assymeteric limb shortening, 
short stature and scoliosis however it also affects the skin (linear ichthyosis), 
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eyes (cataracts) and hair (alopecia) (Figure 2.12). This severe phenotype is 
discernable from birth, and is caused by an inability to make cholesterol during 
fetal development. Several loss-of-function mutations (E80K, R110Q, R147G, 
R147H) in SI have been identified in CDPX2 patients (Braverman et al., 1999; 
Derry et al., 1999; Has et al., 2000; Becker et al., 2001). Currently, there is no 
treatment for this debilitating disease.  
 
Figure 2.12 The physical abnormalities of a person with CDPX2 
(a) Asymmetric facial appearance, showing coarse, sparse hair, undirected growth of eyebrows 
with sparse lateral growth, a flat nasal bridge, bilateral epicanthus, and strabismus. (b) Cicatricial 
alopecia and sparse irregular hair growth and premature graying. Figure courtesy of (Whittock et 
al., 2003). 
2.6 Conclusion 
By working with the adenosine 2a receptor (a flexible membrane protein) and 
sterol isomerase (a rigid-bodied membrane protein) together, I wanted to 
determine whether or not it is equally easy (or difficult) to produce highly- 
dynamic and rigid human membrane proteins in milligram quantities, purify 
them to homogeneity without aggregation and grow diffracting crystals. 
Moreover, over the course of my Ph.D., I wanted to develop new 
technologies/methodologies that would make it easier to work with my two 
target proteins (and could be readily adapted for use with other mammalian 
membrane proteins). 
 3 Materials and Methods 
 
3.1 Strains 
Escherichia coli strain DH5α (Invitrogen) was routinely used for transforming and 
propagating both the cloning and recombinant expression plasmids. 
Occasionally, the Dam- E. coli strain SCS110 (Stratagene) was used when 
unmethylated plasmid DNA was required for digestion with a methylation-
sensitive restriction enzyme (such as XbaI). All protein production in E. coli used 
the BL21 (DE3) strain (Novagen). Recombinant MP expression was performed in 
the Pichia pastoris strain X33 (Invitrogen).  
3.2 Media 
E. coli was grown either on LB (1% tryptone, 0.5% yeast extract and 1% NaCl) or 
LS-LB (1% tryptone, 0.5% yeast extract and 0.5% NaCl) media according to the 
antibiotic being used for selection. Bacteria containing ampicillin-resistant 
plasmids were grown on LB, zeocin resistant ones on LS-LB.  
P. pastoris strains were routinely cultured using YPD (1% yeast extract, 2% 
peptone and 2% glucose) medium. For small-scale expression experiments, the 
yeast transformants were grown on BMGY (1% yeast extract, 2% peptone, 100 mM 
potassium phosphate pH 6, 1.34% yeast nitrogen base, 4 x 10-5% biotin and 1% 
glycerol) and then induced using BMMY (same as BMGY except that it contains 
0.5% methanol instead of 1% glycerol). 
3.3 Expression plasmid construction 
The original human adenosine 2a receptor cDNA was obtained from Dr. Timothy 
Palmer (University of Glasgow). Previously, the N-linked glycosylation site at 
Asn154 had been removed by mutating this residue to Gln (Fraser, 2006). This 
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deglycosylated version of the receptor cDNA was denoted dG hA2aR. cDNA of 
thermostabilized mutants of hA2aR which were conformationally-fixed to 
preferentially bind either antagonist or agonist, (known as Rant21 and Rag23, 
respectively) were provided by Dr. Chris Tate (MRC-LMB, Cambridge). 
Human sterol isomerase cDNA was purchased from OriGene (US). 
hSI and the hA2aR were expressed using modified versions of the basic Pichia 
pastoris expression vectors pPICZA and pPICZαA (both Invitrogen), respectively.  
3.3.1 PCR amplification and sub-cloning strategies 
Oligonucleotide primers used in all PCR reactions had at least 21 bases 
complimentary to the template DNA, and had a GC content of ca. 40%. Primers 
were synthesised by either Sigma-Genosys (UK) or Eurofins MWG Operon 
(Germany). Primers were resuspended in H2O to a concentration of 50 pmol/µl, 
and stored at -20°C.  
All PCR reactions were performed using KOD HotStart DNA Polymerase (Merck 
Biosciences) using the appropriate template and primer combinations. Typically, 
PCR reactions consisted of an initial 2 min Polymerase activation step at 98°C. 
This was followed by between 25-35 cycles each consisting of a DNA 
denaturation step (98°C for 20s), primer annealing (55°C for 10s) and DNA 
extension (70°C for 20s per kb of DNA being amplified). After the last cycling 
step, the PCR reaction was concluded with a further 10 min at 70°C to ensure all 
de novo DNA synthesis had occurred. 
PCR products were run on 1% (w/v) agarose gels alongside a 1kb DNA ladder 
(Promega). DNA was visualised using SYBR Safe DNA gel stain (Invitrogen). DNA 
fragments were extracted from the agarose gel using QIAquick Gel Extraction kit 
(QIAGEN). A-tails were added to all extracted PCR products using Taq 
polymerase (New England Biolabs) with dATP as substrate prior to ligation into 
the cloning vector pGEM-T Easy (Promega). The ligation mixture was 
transformed into DH5α cells by heat shock (42°C for 1 min; 2 min on ice; 1h 
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shaking at 37°C in LB), plated-out on LB agar plates containing 100 µg/ml 
ampicillin (Invitrogen) and 100 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (Roche Applied Science), and incubated overnight at 
37°C. Colonies containing recombinant vector where white whereas those that 
contained vector only were blue. 
Several putative white colonies for each pGEM construct were grown up in 5 ml 
of LB containing 100 µg/ml ampicillin overnight at 37°C. Plasmid DNA was 
isolated from cell cultures using the QIAprep spin miniprep kit (QIAGEN). The 
identity of recombinants was confirmed first by restriction digestion and then by 
sequencing (which was carried out at the DNA Sequencing and Services facility, 
University of Dundee). 
At a later stage, DNA fragments were sub-cloned from the pGEM-T Easy vectors 
into the P. pastoris expression plasmids. Ligation reactions were performed 
using T4 DNA ligase (New England Biolabs). Following transformation into DH5α, 
the cells were plated-out onto low-salt LB plates containing the antibiotic zeocin 
(25 µg/ml). pPICZ(α)A plasmid DNA was isolated and charaterised as described 
for pGEM-T Easy except that the colonies were grown up in LS-LB/Zeocin. 
Glycerol stocks were prepared for all E. coli transformants containing the 
desired plasmids (both cloning and expression), which were stored at -80°C. 
3.3.2 Making a truncated version of dG hA2aR 
Truncated dG hA2aR was amplified using the primers GCGCCTGAATTCATGCCCAT 
CATGGGCTCCTCG and ATCTTAGCGGCCGCACTGGTGCCAGCTGCCTTGAAAGG that 
contained the restriction sites EcoRI and NotI, respectively (restriction sites are 
coloured red). The reverse primer truncated the C-terminal tail of the hA2aR at 
Ser 320. The PCR was carried out as described in Section 3.3.1 using a full-length 
dG hA2aR cDNA as template (Fraser, 2006). The PCR fragment was sub-cloned 
into pGEM-T Easy as described in Section 3.3.1.  
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3.3.3 Construction of the AαHT – TB expression plasmid 
A His10-tag followed by a TEV protease recognition site was incorporated into a 
pPICZαA vector that already contained dG hA2aR  immediately upstream of the 
EcoRI cloning site using the forward primer GAGGCTGAAGCTCATCATCATC 
ATCATCATCATCATCATCATGAAAATCTGTATTTCCAGAGTGAATTCATGCCCATCATGG
GC and reverse primer GCCCATGATGGGCATGAATTCACTCTGGAAATACAGATTTTC 
ATGATGATGATGATGATGATGATGATGATGAGCTTCAGCCTC (where the hA2aR 
sequence is in green, the EcoRI site is in red, the TEV site is in purple, the His10 
tag is in blue and the pPICZaA sequence is in black). 
Furthermore, the biotin acceptor domain from P. shermanii was amplified by 
PCR using the PinpointTM Xa-1 vector (Promega) as template using the primers 
GCGGCCGCTGAAAATCTGTATTTCCAGAGTGCCGGTAAGGCCGGAGAGGGCGAG and 
TCTAGATCACCCGATCTTGATGGACCCTGACCGCCCTGCACGGC which contained 
NotI and XbaI restriction sites, respectively. [Restriction sites are in red, the TEV 
site is in purple and the biotin acceptor site is in aqua]. The PCR fragment was 
sub-cloned into pGEM-T Easy (Section 3.3.1) before it was transferred to the 
AαHT- dG hA2aR expression vector introducing the TEV-biotin acceptor domain 
between the NotI and XbaI restriction sites.  
3.3.4 Creating HT – trunc dG hA2aR – TB  
The truncated dG hA2aR cDNA described in 3.3.2 was sub-cloned into the AαHT – 
TB expression vector detailed in 3.3.3 between the EcoRI and NotI restriction 
sites.  
3.3.5 Creating HT – trunc dG hA2aR – TLB 
The HT – trunc dG hA2aR – TB vector was modified by Dr. Niall Fraser introducing 
SpeI and NdeI restrictions immediately downstream of the TEV protease site and 
upstream of the biotin acceptor site, respectively. 
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The iLOV domain was amplified by PCR with the primers GCTTAGACTAGTATAGA 
GAAGAATTTCGTCATCACTG (forward) and ACGATCCATATGTACATGATCACTTCCAT 
CGAGCTG (reverse) using a cDNA template gifted to me by Dr. John Christie 
(University of Glasgow). [Restriction sites are coloured red and ilOV sequence is 
in pink]. The forward and reverse primers contained SpeI and NdeI restriction 
sites, respectively.  The iLOV PCR product was first sub-cloned into pGEM-T Easy 
(Section 3.3.1) and then transferred to the modified HT- trunc dG hA2aR – TB 
expression vector by restriction digestion with SpeI and NdeI.   
3.3.6 Creation of GU hA2aR, Rant21 and Rag23 cDNAs 
The trunc dG hA2aR cDNA was modified to i) remove a part of IL3 predicted to 
be disordered, and ii) shorten the truncation so that it was the same as the 
Rant21/Rag23 constructs. This was accomplished by PCR in several stages using 
the HT- trunc dG hA2aR -TLB construct as template. PCR reaction 1 was 
performed using the 5AOX1 primer that binds to the pPICZαA vector, 
GACTGGTTCCAATTGACAAGC (forward) with the reverse IL3 deletion primer, 
AGCATGGACCTCCTTCAGCTGTCGTCGCGCCGCCAG). [C-terminal to the IL3 
deletion is in orange; N-terminal is blue]. PCR reaction 2 was performed using 
the forward IL3 deletion primer CGACAGCTGAAGGAGGTCCATGCTGCCAAGTCACT 
G and reverse reduced C-terminal truncation primer ACGATTTTCAGCGGCCGC 
TGCCTTGAAAGGTTCTTGCTGCCT). These two PCR products were combined in a 
third PCR reaction using the forward 5AOX1 and reverse truncation primers to 
create the Glasgow University (GU) version of the hA2aR.  
A Rant21 PCR product was generated in exactly the same way as for the GU 
construct. Rag23, however, required an additional modification to remove its 
glycosylation site so it was made by combining three PCR products (instead of 
two for GU & Rant21). Firstly, the glycosylation site was removed by performing 
a PCR reaction using the 5AOX forward primer with a reverse primer that 
overlapped the glycosylation site GGAGTGCGCCTTGCCCTCCTTTGGCTGACCGCA 
[underline denotes the Asn154Gln change]. PCR reaction 2 was performed using 
the glycosylation site forward primer GGCAAGGCGCACTCCCAGGGCTGCGGGGAG 
GGC with the reverse IL3 deletion primer AGCATGGACCTCCTTCGCCTGTCGTCGC 
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GCCGCCAG. [C-terminal to the IL3 deletion is in orange; N-terminal is blue]. PCR 
reaction 3 was performed using the forward IL3 deletion primer 
CGACAGGCGAAGGAGGTCCATGCTGCCAAGTCACTG and the reverse reduced C-
terminal truncation primer. These three PCR products were combined in a fourth 
PCR reaction using the forward 5AOX1 and reverse truncation primers to create 
the deglycosylated IL3 deleted version of Rag23. 
The GU, Rant21 and Rag23 PCR products were first sub-cloned into pGEM-T Easy 
(Section 3.3.1) and then transferred into the modified HT- TLB expression vector 
by restriction digestion with EcoRI and NotI.   
 
3.3.7 Creating the -CLBH expression plasmids  
The CLBH tag was generated by PCR with the primers GCGGCCGCTGTCCTATTCC 
AGGGCCCAACTAGTATAGAGAAGAAT (forward) and TTCTAGATCAGTGATGGTGATG 
GTGATGGTGATGGTGATGCCCGATCTTGATGAGACCCTGACC (reverse). [Key: the C3 
protease site is denoted by purple, the His10 tag in blue].  The -CLBH PCR 
product was first sub-cloned into pGEM-T Easy (Section 3.3.1) and then 
transferred into the basic pPICZA and pPICZαA vectors by restriction digestion 
with NotI and XbaI.   
GU-, Rant21- and Rag23-CLBH were created by sub-cloning the three hA2aR 
cDNAs from the HT-TLB vectors into the Aα-CLBH vector by restriction digestion 
with EcoRI and NotI. 
Sterol isomerase was amplified from the cDNA obtained from Origene using the 
primers GAATTCATGACTACCAACGCGGGCCCCTTG (forward) and GCGGCCGCAGTT 
CTTCTTGCTCTTGGCTTTTG (reverse). The hSI PCR product was first sub-cloned 
into pGEM-T Easy (Section 3.2.1) and then transferred into the A-CLBH vector by 
restriction digestion with EcoRI and NotI. 
 
 
Materials and Methods   68 
3.4 Transformation of recombinant expression plasmids 
into P. pastoris 
E. coli that had been previously transformed with the P. pastoris expression 
vectors were grown up overnight from glycerol stocks in 100 ml of LS-LB/Zeocin 
at 37°C with constant shaking. The cells were pelleted by centrifugation and 
plasmid DNA isolated using the QIAGEN plasmid Maxi kit. The DNA was then 
concentrated by precipitating it using ethanol. 10-50 µg of plasmid DNA in a final 
volume of 20 µl was linearised overnight by digesting with PmeI (New England 
Biolabs). Linearised plasmid was mixed with 80 µl of competent X33 cells (that 
had been made as described in the Pichia Easy Select manual (Invitrogen)). After 
incubating on ice for 5 min, the yeast were transformed by electroporation (2kV, 
5 ms). The yeast were allowed to recover for 2h at 30°C in 1 M sorbitol before 
they were plated out on YPDS plates containing different concentrations of 
Zeocin (from 0.2 to 2.0 mg/ml). Following a 72 h incubation at 30°C, numerous 
colonies appeared on the plates. These were re-streaked on fresh YPD plates 
containing 0.5 mg/ml Zeocin. 
3.5 Recombinant MP production in P. pastoris 
3.5.1 1 ml cultures in 48-well plates 
Clonal selection of yeast that had been transformed with iLOV-containing 
expression plasmids was performed by measuring whole cell fluorescence from 
yeast cells that had been grown and induced on a 1 ml scale in a 48-well sterile 
plate (Section 5.3). Per clonal selection, the expression level was determined for 
12 different colonies. For each of the transformants, two 1 ml cultures were 
established in BMGY. The plate was then shaken for 24 h at 30°C. The cells were 
pelleted by centrifugation (1500 g, 5 min), and then resuspended in BMMY. The 
plate was returned to the shaking incubator for a further 24 h at 22°C. After 
this, cells were harvested by centrifugation and washed twice with distilled 
water before being resuspended in 1 ml of distilled water. 20 µl of the cells from 
every culture were transferred to a 96-well black plastic plate (Corning) and 
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made upto to a final volume of 200 µl with distilled water for determining whole 
cell fluorescence levels. Glycerol stocks were prepared for the transformant 
found to have the highest expression level of the target protein by mixing equal 
volumes of an overnight culture grown in YPD with sterile 50 % (v/v) glycerol in a 
sterile cryovial. The cultures were snap-frozen using liquid nitrogen and stored 
at –80°C.  
3.5.2 Small-scale (10 ml) expression cultures 
Clonal selection of yeast transformed with αHT – trunc dG hA2aR – TB and αHT – 
full-length dG hA2aR –TB was performed by single-point radioligand binding 
analysis on membranes isolated from cells grown and induced on a 10 ml scale 
(Section 4.3.2). Individual transformants were grown up in 10 ml of BMGY in 
sterile 50 ml falcon tubes at 30°C for 24h. The cells were spun down (1500 g, 5 
min) and re-suspended in 10 ml of BMMY, and grown for a further 24 h at 22°C. 
Cells were harvested by centrifugation (4000g, 5min, 4°C), and membranes made 
as described in Section 3.6.2. 
3.5.3 Medium-scale (100 ml) expression cultures 
Yeast transformed with αHT- dG hA2aR – TB and αHT- trunc dG hA2aR – TB were 
grown at 30°C in 500 ml shake-flasks containing 100 ml of BMGY until the 
cultures had an OD600 of between 2-6. At this point, receptor production was 
induced by adding 0.5% methanol, reducing the temperature to 22°C and adding 
10 mM theophylline. 0.5% methanol was also added 12 and 24 h post-induction. 
Cells were harvested by centrifugation (5000g, 20 min, 4°C) after 36 h. 
Membranes were made as described in Section 3.6.2 which were later used in 
radioligand binding assays for assessing the pharmacological properties of the 
expressed receptors (Section 4.4). 
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3.5.4 Recombinant MP production in fermenter culture 
All fermentations were carried out using an Applikon® 7L fermentor vessel and 
ADI 1025 bioreactor system. Dissolved oxygen (dO2) was maintained above 25% 
through feedback of agitation (minimum 1000 r.p.m.) and compressed air (0.8 
litre min-1). Oxygen (1 bar pressure) was automatically drawn in as necessary to 
help maintain the dO2 setpoint during growth at high-cell densities. The pH was 
maintained at around 5 through addition of 23% NH4OH. Antifoam A (Fluka) was 
added drop-wise as required to reduce foaming during culture growth.  
4 litres of basal salts media containing 4% glycerol (Table 3.1) was autoclaved 
within the glass fermentation vessel. To this, 15 ml of PTM1 trace salts was 
added (Table 3.1). The media was inoculated with 200 ml of yeast that had been 
grown up overnight in YPD so that the initial fermenter culture had an OD600 of 
0.5-1.0. Cultures were grown on basal salts media for 18 h at 30°C until all of 
the original glycerol had been consumed. Following this, the culture was feed 
50% glycerol (v/v) for 11 h at a rate of 1.09 ml/min. The yeast were then starved 
for 1 h to ensure that any residual glycerol had been consumed before the 
culture was adapted for growth on methanol (4 h at 0.07 ml/min followed 12 h 
at 0.09 ml/min methanol). Target MP production was induced by reducing the 
culture temperature to 22°C. [When hA2aR was being made in fermenter 
culture, 50 mM theophylline powder was added at this stage].  Methanol feeding 
continued for a further 12 h at 0.13 ml/min followed by 36 h at 0.33 ml/min. 
Samples were taken at regular timepoint intervals to assess culture growth by 
measuring OD600 and/or wet cell weight. Recombinant MP production levels were 
determined either by single-point radioligand binding analysis or measuring iLOV 
fluorescence. After 80 – 96 h cultivation, the fermentations were stopped and 
the cells harvested by centrifugation (5000g, 20min, 4°C). The pellets were 
stored at -20°C, and used as they were required.  
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 Components Amount per litre 
Basal salts medium Phosphoric Acid (85%) 
Calcium Sulphate 
Potassium Sulphate 
Magnesium Sulphate – 7H20 
Potassium Hydroxide 
Glycerol 
Water 
(26.7 ml) 
0.93 g 
18.2 g 
14.9 g 
4.13g 
40.0 g 
to 1 litre 
Sterilised by autoclaving 
 
PTM1 trace salts Cupric Sulphate – 5H2O 
Sodium Iodide 
Magnesium Sulphate – H2O 
Sodium Molybdate – 2H2O 
Boric Acid 
Cobalt Chloride 
Zinc Chloride 
Ferrous Sulphate – 7H2O 
Biotin 
Sulphuric Acid 
Water 
6.0 g 
0.08 g 
3.0 g 
0.2 g 
0.02 g 
0.5 g 
20.0 g 
65.0 g 
0.2 g 
5.0 ml 
to a final volume of 1 
litre 
Sterilised by filtration 
 
Table 3.1 Recipes for fermentation media and trace feed solution 
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4 litres of basal salts media was prepared and autoclaved immediately prior to commencing a 
fermentation. PTM1 trace salts were made and stored in 50 ml aliquots at 4°C, and used as it was 
required.  
 
3.6 Cell lysis and membrane preparation 
3.6.1 Chemical cell lysis 
After the iLOV fluorescence intensity had been measured in intact cells, the 
cells from the 1 ml yeast cultures in the 48 well plates were re-pelleted by 
centrifugation (1500g, 5 min) and the water discarded.  The cells were lysed 
using 100 µl of Yeast Buster™ Protein Extraction Reagent (Merck) and 10 µl 
Benzonase nuclease (Merck). To ensure complete rupturing the cells were placed 
in a shaking incubator at 30oC for 30 min. Following this, 1 ml of distilled water 
was added to each well before the plate was centrifuged (1500g, 5 min) to 
pellet cell debris. The supernatants containing the cell contents were removed 
and their protein concentration determined by BCA assay (Pierce) using BSA as 
standard.  
3.6.2 Small-scale membrane preparation 
10 ml cell pellets (Section 3.5.2) were resuspended in Breaking Buffer (4 mg/ml 
BSA, 5 mM EDTA, 150 mM NaCl in 50 mM Tris HCl pH 7.4). An equal volume of 
glass beads was added and the cells were broken by vortexing (5 x 1 min). The 
beads were separated by filtration through a chromatography column and the 
flow-through containing membranes was subjected to centrifugation. A low 
speed spin (10,000g, 10 min) was used to pellet cell debris and unbroken cells. 
The supernatant was retained and centrifuged at high speed (150,000g, 30 min) 
to pellet membranes. Membrane pellets were resuspended in 1 ml of 150 mM 
NaCl in 50 mM Tris HCl pH 7.4, and the protein concentration determined by BCA 
assay (Pierce) using bovine serum albumin (BSA) as standard.  
 
Materials and Methods   73 
3.6.3 Large-scale membrane preparation 
Cell pellets from fermentation cultures were thawed overnight at 4°C and 
resuspended in Breaking Buffer (5 mM EDTA, 150 mM NaCl in 50 mM Tris HCl pH 
7.4). Homogenised cells were passed through a Constant Systems cell disrupter 
three times at a pressure of 30 kPsi. Following this, 10% glycerol (v/v) and 
protease inhibitors (phenylmethanesulfonylfluoride (PMSF) and benzamidine) 
were added to the ruptured cells. Membranes were then isolated by 
centrifugation as described in Section 3.5.2. Membrane pellets were 
resuspended in a Membrane Resuspension Buffer consisting of 10% glycerol and 
150 mM NaCl in either 50 mM Tris HCl, HEPES or sodium phosphate buffer at a pH 
of 7.4). The protein concentration of the membranes was determined by BCA 
assay (Pierce) using BSA as standard. Membranes were diluted with the 
appropriate Membrane Resuspension Buffer so that they had a final 
concentration of 20 mg/ml. These were stored at -20°C in 50 ml aliquots. 
 
3.7 Measuring iLOV fluorescence 
3.7.1 iLOV excitation and emission spectra 
Excitation and emission spectra for pure iLOV (a gift from Dr. John Christie, 
University of Glasgow) were recorded and compared against those obtained for 
flavin mononucleotide (FMN) and P. pastoris X33 membranes. Measurements 
were made in quartz cuvettes (pathlength 1 cm) using a Perkin-Elmer L550B 
spectrophotometer. Fluorescence was measured at right angles to the excitation 
beam. Excitation spectra were recorded from 300 – 460 nm measuring 
fluorescence emission at 485 nm. Emission spectra were recorded between 470 
and 600 nm, exciting the samples at 450 nm.  
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3.7.2 Measuring iLOV fluorescence in 96 well plates 
The iLOV fluorescence of individual samples (e.g. whole cells or FSEC elution 
fractions) was determined using a FLUOstar OPTIMA plate-reader. 200 µl of each 
sample was added to a single well in a black Corning 96-well plate. Samples 
were excited at 450 nm and iLOV fluorescence emission measured at 520 nm. 
Results were analysed using the OPTIMA data analysis software. Fluorescence 
readings from intact yeast cells were used in combination with protein 
concentration measurements to determine expression levels in clonal selection 
experiments. 
 
3.8 Radioligand binding analysis 
All radioligand binding assays on ‘wild-type’ hA2aR were carried out using the 
potent, selective A2a antagonist [3H] ZM241385 (American Radiolabelled 
Chemicals). Assays on Rag23 were performed using the agonist [3H] NECA 
(Amersham Biosciences). The same Binding Buffer (5 mM EDTA in 50 mM Tris HCl 
pH 7.4) was used with both radioligands. All measurements were made in 
quadruplicate.  
3.8.1 [3H] ZM241385 binding 
Saturation and single-point binding assays on membrane-bound hA2aR contained 
between 1-10 µg protein in a final volume of 500µl. 0.1U of adenosine 
deaminase (Roche Applied Science) was also added to each cocktail in order to 
degrade any adenosine released from the membranes. Saturation binding was 
performed by incubating [3H] ZM241385 (final concentration 0.02 – 12 nM) with 
receptor for 1 h at 30°C. Non-specific binding was determined in the presence of 
10 mM theophylline. Following incubation, bound and free radioligand were 
separated by sucking the suspension onto glass fibre filters (Whatman) pre-
soaked in 0.3% polyethyleneimine under vacuum using a Brandel Harvester. The 
filters were washed three times with 50 mM Tris HCl pH 7.4 before they were 
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counted using Ultim Gold™ XR scintillation fluid (Perkin Elmer). The counts in 
dpm were converted to fmol of [3H] ZM241385 bound using the specific activity 
of the radioligand. Specific binding was determined by subtracting the binding 
measured in the presence of theophylline (non-specific) away from those 
measured in buffer only (total). Binding data was analysed using the computer 
package GraphPad Prism. Curves of total, non-specific and specific binding 
against [radioligand] (nM) were plotted and fitted using a non-linear regression. 
The curve fit gave values for the maximum number of binding sites occupied by 
the ligand (Bmax) as well as the receptor’s equilibration dissociation constant (Kd) 
for [3H] ZM241385. The Kd is the concentration of radioligand required to occupy 
half of the available binding sites and, therefore, is a measure of the affinity of 
the ligand for the receptor. The Bmax is a reliable estimate of the receptor’s 
expression level.  
Single-point binding assays on membrane bound hA2aR had a final volume of 200 
µl, contained between 1-10 µg of protein and ca. 10 nM [3H] ZM241385. Non-
specific binding was determined in the presence of 10 mM theophylline. 
3.8.2 [3H] NECA binding 
Saturation binding using [3H] NECA was performed on membranes containing 
Rag23 in the same way as that described for [3H] ZM241385 with the following 
differences: i) the assay cocktail had a volume of 100 (instead of 500) µl, ii) [3H] 
NECA was used at considerably higher concentrations (20 – 500 nM), and iii) 
adenosine deaminase was omitted as it metabolises NECA rendering the 
radioligand unable to bind to the receptor.  
3.9 SDS-PAGE 
20 µl of each protein sample to be analysed by SDS-PAGE was mixed with 5 µl of 
NuPAGE® LDS Sample Buffer (Invitrogen) and heated for 10 min at 60°C. 
Denatured samples were loaded onto a 12-well 10% NuPAGE® Bis–Tris pre-cast 
gel (Invitrogen) along with an aliquot of SeeBlue Plus2 pre-stained marker. The 
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gel was run in MES buffer according to the manufacturer’s instructions (200V for 
40-50 min). Protein bands were visualised by staining with SimplyBlue™ SafeStain 
(Invitrogen). 
 
3.10 Detergent screening and fluorescence size-
exclusion chromatography (FSEC)  
2 ml of yeast membranes (at a concentration of 20 mg/ml) containing either HT-
Rag23-TLB or SI-CLBH were solubilised using the detergents DDM, DM, NM and 
βOG as well as the detergent-lipid mixture DDM/CHS. 0.6 ml of 10% detergent 
stock solutions were added to the membranes and the mixtures stirred for 1 h at 
4°C. Samples were then centrifuged at high speed (50,000g, 10 min) to pellet 
any unsolubilised material. The supernatant containing the iLOV-tagged MP was 
filtered before 500 µl of it was injected onto a Superose™ 6 FLPC gel filtration 
column equilibrated in buffer (either Tris, HEPES or sodium phosphate – all pH 
7.4) containing 5% glycerol and an appropriate concentration of the detergent 
being studied (0.05% DDM, 0.15% DM, 0.3% NM and 0.8% βOG). The column was 
run at a rate of 0.3 ml/min, and 0.6ml fractions were collected. 200 µl of each 
fraction was transfered to a black Corning 96-well plate and the intensity of 
iLOV fluorescence measured using a platereader. Following this, FSEC profiles 
were plotted. 
 
3.11 Expression and purification of accessory enzymes 
3.11.1 Tobacco Etch Virus (TEV) protease 
BL21(DE3) cells that had been previously transformed with pET15b-TEV protease 
(a gift from Dr. Alan Riboldi-Tunnicliffe, University of Glasgow) were grown 
overnight from a glycerol stock in 5 ml of LB media at 37°C. The next morning, 
the cells were added to 500 ml of fresh media and grown to an OD600 of 0.7. TEV 
protease expression was induced by adding 1 mM IPTG. The temperature was 
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reduced to 22°C, and the cells shaken for a further 16 h. Cells were harvested by 
centrifugation (4000g, 20 min) and then resuspended in lysis buffer (150 mM 
NaCl, 25 mM imidazole in 50mM Tris HCl pH 8.0). Cells were broken using a 
Constant Systems cell disruptor (3 passages at 20 kPsi). The broken cells were 
centrifuged at 10,000g and the supernatant containing TEV protease passed over 
a 5 ml Nickel column that had been equilibrated in lysis buffer. The column was 
washed extensively with lysis buffer to remove any contaminant proteins before 
the TEV protease was released from the column using an imidazole (0 – 800 mM) 
gradient in 150 mM NaCl, 50 mM Tris HCl pH 8.0. DTT and EDTA were added to 
the elution fractions (both to a final concentration of 1 mM) to prevent the TEV 
protease precipitating out of solution. Fractions containing TEV protease were 
pooled and desalted into 150 mM NaCl in 50 mM Tris HCl pH 7.4 using a PD10 
column. TEV protease was aliquoted (1 ml samples with a protein concentration 
of 5 mg/ml) before being snap-frozen with liquid nitrogen and stored at -20°C.  
3.11.2 Human Rhinovirus C3 protease 
BL21(DE3) cells that had been previously transformed with pET15b-C3 protease 
(a gift from Dr. Alan Riboldi-Tunnicliffe, University of Glasgow) were grown 
overnight from a glycerol stock in 5 ml of LB media at 37°C. Expression and Ni2+-
affinity purification of C3 protease was performed as described for TEV protease 
(Section 3.11.1). An additional gel filtration step (Sepharose C6 column 
equilibrated in 150 mM NaCl, 50 mM Tris HCl pH 7.4) was then performed to 
improve enzyme purity. 
3.11.3 Biotin ligase 
The biotin ligase (BirA) gene was amplified from E. coli strain 0157 genomic DNA 
using the primers TGACCACATATGATGAAGGATAACACCGTGCCACTG and 
CGTAGAGGATCCTTATTTTTCTGCACTACGCAGGGA. The PCR product was 
introduced into pGem T-Easy as described in Section 3.3.1 before it was sub-
cloned into NdeI/BamHI-digested pET15b vector. Correct recombinant plasmids 
were identified by restriction analysis and sequencing. The BirA expression 
plasmid was transformed into BL21 (DE3) cells and expressed and purified as 
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described in Section 3.11.1. The only exception being that no DTT and EDTA 
were added to the elution fractions. 
 
3.12 Purification of HT – trunc dG hA2aR – T(L)B  
The basic buffer (HT-TLB buffer) used to purify HT – trunc dG hA2aR – T(L)B was 
150 mM NaCl, 10% glycerol in 50 mM Tris HCl pH 8, 0.05% DDM, 0.01% CHS.  
3.12.1 Membrane solubilisation 
Membranes containing either HT – trunc dG hA2aR – TB or HT – trunc dG hA2aR – 
TLB at a concentration of 20 mg/ml were solubilised by adding a 10:2 DDM:CHS 
stock solution to the membranes so that the final DDM concentration was 2.5%. 
The mixture was stirred for 2 h at 4°C. Following this, the sample was 
centrifuged at 150,000g for 30 min. The supernatant containing the detergent-
solubilised receptor was added to an equal volume of HT-TLB buffer prior to the 
Ni2+-affinity chromatography step. 
3.12.2 Ni2+-affinity purification of HT– trunc dG hA2aR –T(L)B 
A 5ml Ni2+ column was equilibrated in HT-TLB buffer containing 75 mM 
imidazole. The supernatant containing receptor was then passed over the 
column three times. The Ni2+ column was washed with HT-TLB buffer containing 
500 mM (instead of 150) NaCl and 75 mM imidazole. Receptor was eluted from 
the column using 500 mM imidazole in HT-TLB buffer. Elution fractions were 
analysed by SDS-PAGE (Section 3.9)  
3.12.3 Biotinylation and purification using streptavidin  
In vitro biotinylation of Ni2+-affinity purified HT-trunc dG hA2aR – TLB was 
performed by adding 1 mg of pure BirA to the receptor along with 50 µM biotin, 
20 µM ATP and 10 mM Mg-o-acetate. The mixture was stirred continuously 
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overnight at 4°C. The next morning the receptor protein was doubly desalted 
into HT-TLB buffer using PD-10 columns (GE Healthcare) to remove free biotin. 
Streptavidin resin (Pierce) was equilibrated with HT-TLB buffer. Biotinylated 
receptor was added to the streptavidin slurry and mixed by rotating on a wheel 
at 22°C for 4 h. The sample was centrifuged (4500 g, 10 min) to pellet the resin. 
The supernatant containing contaminant proteins was discarded. The beads were 
washed extensively with HT-TLB buffer to ensure that any proteins that had 
weakly bound to the beads were removed.   
3.12.4 Tag removal using TEV protease 
Tag removal from biotinylated HT – trunc dG hA2aR – TLB bound to streptavidin 
beads was performed by adding 5 mg of TEV protease to the resin in HT-TLB 
buffer containing 0.5 mM EDTA, 3 mM reduced glutathione and 0.3 mM oxidised 
glutathione. The slurry was stirred slowly overnight at 4°C. The next morning, 
the sample was centrifuged (4500g, 10 min), and the supernatant reverse-
purified with Ni2+ beads to remove the HT tag and TEV protease. The cleaned-up 
sample was retained for SDS-PAGE analysis.  
3.12.5 Gel filtration of enriched HT – trunc dG hA2aR – TB 
Ni2+-affinity purified HT – trunc dG hA2aR – TB was concentrated to a volume of 
ca. 500 µl and injected onto a Superose™ 6 FLPC gel filtration column 
equilibrated in HT-TLB buffer. The column was run at 0.3 ml/min and 1 ml 
fractions collected. The elution profile (A280 v time) was recorded. Peak 
fractions were retained for analysis by SDS-PAGE.  
3.13 Purification of Rag23 in DDM 
Membranes containing Rag23-CLBH were resuspended in 100 mM NaCl, 10% 
glycerol in 10 mM HEPES pH 7.4 (Rag buffer) at a concentration of 20 mg/ml. 
Membranes were stirred with 100 µM NECA for 30 min at 4°C before DDM was 
added from a 10% (w/v) stock solution so that the final detergent concentration 
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was 2.5%. The solubilisation mixture was stirred for a further 2 h before it was 
centrifuged at 150,000g for 30 min. The supernatant containing Rag23-CLBH was 
diluted with an equal volume of Rag buffer containing 0.05% DDM. A 5 ml Ni2+ 
charged His-trap column was equilibrated in Rag buffer containing 75 mM 
imidazole and 0.05% DDM. The detergent-solubilised material was batch-loaded 
onto the column. This process was repeated three times. The column was 
washed with Rag buffer containing 75 mM imidazole and 0.05% DDM. Rag23-CLBH 
was eluted from the column using Rag buffer containing 500 mM imidazole and 
0.05% DDM. Aliquots of those fractions that were fluorescent (i.e contained 
iLOV-tagged receptor) were retained for analysis by SDS-PAGE. The remainder of 
the material was pooled and desalted into Rag buffer containing 0.05% DDM 
using PD-10 columns. 20 µl of C3 protease was added per ml of partially-purified 
Rag23-CLBH along with 1 mM DTT and 1 mM EDTA. The cleavage cocktail was 
mixed overnight using a rotating wheel at 4°C. The next morning, Ni2+ beads 
equilibrated in Rag buffer containing 0.05% DDM was added to the cleavage 
mixture. The sample was placed back on the wheel for 30 min before it was 
centrifuged at 3000g for 5 min. This process was repeated until the supernatant 
was non-fluorescent. At this point, Rag23 was expected to be largely pure. The 
supernatant was concentrated to a volume of ca. 500 µl and applied to a 
Superose 6 column on an AKTA prime plus system (GE Healthcare) that had been 
equilibrated in Rag buffer containing 0.05% DDM. The column was run with a 
flow rate of 0.3 ml/min and 1 ml fractions were collected (which were later 
analysed by SDS-PAGE).  
3.14 Purification of SI in DDM 
SI was purified in DDM as described for Rag23 with the following exceptions. The 
basic purification buffer contained 150 and not 100 mM NaCl. The membranes 
were not pre-incubated with NECA prior to detergent solubilisation. The wash 
buffer for the Ni2+ column contained 500 and not 100 mM NaCl. Following SDS-
PAGE analysis of pure SI, the major band on the gel was excised for protein 
identification by tandem mass spectroscopy (MS-MS). This work was performed 
at the Proteomics Facility at the University of Dundee. The protein 
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concentration of pure SI was determined by measuring the A280 of the sample 
and dividing this number by 2.8 (which is the theoretical extinction coeffiecient 
at 280 nm for SI as determined by its amino acid content). This value was 
obtained using the ProtParam tool on the ExPASy Proteomics Server 
(http://www.expasy.ch/tools/protparam.html). 
3.15 Purification of SI in DM 
The purification of SI in DM was the same as that described in Section 3.14 with 
the following exceptions. The basic purification buffer was 150 mM NaCl, 10% 
glycerol in 50 mM sodium phosphate pH 7.4. The membranes were solubilised in 
DM and not DDM. All of the purification buffers contained 0.15% DM instead of 
0.05% DDM. The gel-filtration column was equilibrated with and run in 150 mM 
NaCl, 10% glycerol in 50 mM sodium phosphate pH 6, 0.15% DM. 
3.16 Circular dichroism 
All CD measurements were made at the Biophysical Characterisation Unit, 
University of Glasgow by Dr. Sharon Kelly. 
3.16.1 CD characterisation of SI 
Far- (region 190 - 260 nm) and near-UV (250 – 320 nm) circular dichroism spectra 
of pure SI were recorded on a Jasco J-810 spectropolarimeter using quartz 
cuvettes with 0.02 and 0.5 cm pathlengths, respectively. The SI sample had a 
protein concentration of 0.6 mg/ml. The far-UV CD data was fitted using the 
CDSSTR alogorithm (Johnson, 1999) to give an estimate of the secondary 
structure content of SI. 
3.16.2 Thermostability analysis of SI by CD 
A series of far-UV CD spectra of pure SI were recorded between 5 and 80°C at 
5°C intervals. Measurements were made in a cuvette with a pathlength of 0.2 cm 
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using protein with a concentration of 0.2 mg/ml protein. The extent of SI 
unfolding with temperature was determined by plotting the the size of the CD 
signal at wavelengths 209 and 222 nm as a % of the original values prior to heat 
denaturation.  
3.17 CPM assay 
A stock solution of CPM reagent (7-Diethylamino-3-(4-maleimidophenyl)-4-
methylcoumarin) (Sigma-Aldrich) was made by first dissolving it in dimethyl 
sulfoxide (DMSO) to a concentration of 25 mg/ml and then further diluting it 
with H2O to a final concentration of 4 mg/ml. Care was taken to prevent 
photobleaching of the CPM dye by storing it in the dark. The CPM thermal 
denaturation assays were performed in black Corning 96-well plates. For each 
condition investigated, protein and buffer control measurements were made in 
triplicate. Each protein well contained 10 µl of pure SI (0.5 mg/ml), 20 µl of a 
10x buffer solution and 20 µl of either a 10x additive (such as a salt) or H2O. 
Plates were incubated at room temperature for 5 min before 140 µl of 10% SDS 
was added to each well followed by 10 µl of the stock CPM reagent. Control 
samples were set-up in a similar fashion except that the protein aliquot was 
replaced with 10 µl of buffer. The plate was immediately transferred to a 
fluorescence platereader set at a temperature of 45°C. Fluorescence intensity 
readings were taken at regular intervals over a period of 3 h. Baseline 
fluorescence recorded in the buffer controls were subtracted from the values 
recorded in the protein wells, before the three difference values for each 
condition were averaged. Curves showing SI denaturation were plotted as an 
increase in fluorescence over time. To allow comparison of the extent of SI 
unfolding in different conditions, the maximum amount of unfolding was defined 
as the fluorescence intensity at t = 8000 s.  
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3.18 Crystallisation trials with SI 
3.18.1 Crystallisation of SI from detergent solution 
Pure SI (in both DDM and DM) was concentrated to ca. 10 mg/ml. SI purified in 
HEPES buffer containing DDM was used with the MemStart, MemSys and PegIon 
crystallisation screens (Table 3.2). SI purified in sodium phosphate buffer 
containing DM was used with the MemGold screen (Table 3.2). A Cartesian 
HoneyBee nanoliter dispensing system (Genomic Solutions Ltd) was used to add 
500 nl of the protein solution to 500 nl of the reservoir in each of the wells in 
the 96 well plate. The plates were stored in a Rhombix Crystal Plate Imager 
(Thermo Scientific) at 20°C and trays monitored automatically over a 3 month 
period. Possible crystal hits were followed-up manually by microscope. Crystals 
obtained in the initial screens were tested for X-ray diffraction using the in-
house X-ray facility at Glasgow (consisting of a Rigaku MicroMax 007 rotating 
anode generator coupled with MarResearch 345 image plate detector). 
Screen Manufacturer 
MemGold Molecular Dimensions  
 
MemStart Molecular Dimensions 
 
MemSys Molecular Dimensions  
 
Peg/Ion 1 & 2 Hampton Research 
 
Table 3.2 Commercially-available screens used for crystallising SI in detergent solution 
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3.18.2 Lipidic-sponge phase preparation 
Cholesterol doped sponge phases were prepared by dissolving either 0.5 or 5% 
(w/w) of cholesterol directly into melted mono-olein (MO) (1-mono-oleyl-rac-
glycerol) (Nu-Chek Prep). The molten MO/cholesterol mixture was weighed into 
small glass vials along with the appropriate amounts of either PEG400 or 
PEG1500 with 100 mM of a buffer solution (with or without 100 mM of a salt). 
The compositions of all the sponges are listed in Table 6.1. The vials were sealed 
tight and incubated on a roller for one day at 37°C. In cases where the sample 
was not homogenous after this treatment, it was heated to 50°C for 2-3 h and 
then re-incubated at 37°C. Afterwards, the samples were centrifuged (20°C, 
5500g, 30 min) and left until a transparent phase was observed. 
3.18.3 Crystallisation of SI in the lipidic-sponge phase 
Pure SI in DM was concentrated to ca. 10 mg/ml and then dialysed for 2h against 
sodium phosphate buffer containing 0.15% DM using mini-dialysis cassettes 
(Pierce). Trays were set-up as a series of hanging drops using EasyXtal Tool 24-
well crystal trays (QIAGEN). 1 µl of each sponge was pipetted onto the screw-in 
crystallisation support before 1 µl of the protein solution was added on top. The 
crystallization supports were screwed into the reservoir chambers which all 
contained 500 µl of reservoir solution (0.1 g l-1 Na3PO4, 0.55 M sodium acetate 
and 0.75 M HEPES pH 6.3). Trays were stored in a 20°C incubator and checked 
regularly for crystals. 
 4  Creating a generic system for the over-
expression and purification of human 
membrane proteins 
 
4.1 Introduction 
Although there are a few exceptions (e.g. rhodopsin), most mammalian 
membrane proteins have a low natural abundance. Therefore, the first step 
towards solving the structure of any mammalian membrane protein usually 
involves devising a robust methodology for making milligram quantities of the 
target protein in a heterologous system. The functional over-expression of 
membrane proteins is a non-trivial issue, and is one of the key “bottlenecks” in 
determining the structure of a membrane protein.    
The methylotrophic yeast Pichia pastoris is commonly used for producing soluble 
proteins of mammalian origin. There are several reasons for this including the 
yeast’s capacity to perform a range of higher-eukaryotic post-translational 
modifications as well as its ability to grow to high cell densities (ca. 109 
cells/ml) on cheap media in fermenter culture. Recombinant protein production 
is driven from the strong, methanol-inducible AOX1 promoter (Macauley-Patrick 
et al. 2005; Hartner and Glieder 2006), and can result in the production of tens 
or even hundreds of milligrams of target protein per litre of culture (Cregg et al. 
2000; Cereghino et al. 2002). It has also been recently shown that a diverse 
range of mammalian membrane proteins, including G-protein coupled receptors, 
transporters and ion channels, can be successfully made in P. pastoris (Weiss et 
al. 1998; Weiss et al. 1998; Newton-Vinson et al. 2000; Andre et al. 2006; 
Horsefield et al. 2008; Aller et al. 2009; Ho et al. 2009; Tao et al. 2009; Alisio 
and Mueckler). However, a potential limitation of P. pastoris as a host for 
making mammalian MPs is its inability to make cholesterol. Instead P. pastoris 
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synthesises another type of sterol called ergosterol which, despite being highly 
similar to cholesterol, is unable to stabilise mammalian MPs in the ways that 
cholesterol does (Opekarova and Tanner 2003). 
Even when a heterologous host as powerful as P. pastoris is used, the expression 
conditions for each target membrane protein must be optimised so that the 
maximal yield of protein possible is obtained (Singh et al. 2008). The amount of 
functional GPCR obtained in P. pastoris can be increased by reducing the 
induction temperature from 30 to 22°C (Andre et al. 2006; Fraser 2006) as well 
as adding either DMSO (which stimulates membrane synthesis) (Andre et al. 
2006) or a ligand (e.g. an antagonist) that stabilises the target protein (Weiss et 
al. 1998; Andre et al. 2006; Fraser 2006). With P. pastoris, a dramatic increase 
in protein production level occurs when expression is performed in a fermenter 
as compared to shake flask-culture. Careful optimisation of the methanol feed 
rate is essential to ensure that there is sufficient methanol present in the 
fermenter to drive maximal protein production without accumulating excess 
levels of methanol (which is toxic to the yeast at high (>4%) concentrations) 
(Cereghino et al. 2002). 
Once the target MP has been successfully expressed in milligram quantities, it 
must be purified to homogeneity before crystallisation trials can be started. MPs 
can be readily purified by affinity chromatography using tags such as His10 
(which binds to Ni2+ resin) and biotin (which binds to (strept)avidin) (Terpe 
2003). Tags can be added to a recombinant protein at either its N- or C-terminus 
by manipulating the DNA sequence of the expression vector using PCR. When 
working with MPs, however, it is imperative to determine the expression level of 
the recombinant protein with and without tags to ensure that addition of the tag 
has not affected the amount or functionality of the protein produced by the host 
cell.  
Previous work in our laboratory focused on producing the human adenosine 2a 
receptor (hA2aR) in shake-flask cultures of P. pastoris (Fraser 2006). A full-
length cDNA encoding the human adenosine 2a receptor was cloned into a 
modified version of the P. pastoris vector pPICZαA. The basic expression plasmid 
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obtained from Invitrogen had been altered by inserting a His10 tag between the 
Kex2 protease cleavage site and the EcoRI cloning site (Fraser 2006) (Figure 4.1). 
hA2aR was made as a fusion with the α-factor leader sequence from S. 
cerevisiae (Figure 4.1). When fused to the N-terminus of GPCRs expressed in P. 
pastoris, the α-factor leader sequence has been shown to increase the yield of 
functional receptor made by the yeast (Grunewald et al. 2004). The α-factor 
leader sequence is removed from the receptor following cleavage by the yeast 
protease Kex2 (which resides in the golgi complex) (Julius et al. 1984; Julius et 
al. 1984; Redding et al. 1991). The modified expression plasmid described in 
(Fraser 2006) was the starting point of all the work described in this thesis.  
 
Figure 4.1 Schematic diagram of the initial hA2aR expression construct (αH – dG hA2aR) 
Previously, a deglycosylated version (dG) of a full-length hA2aR cDNA had been cloned into a 
modified version of the P. pastoris expression vector pPICZαA (Fraser, 2006). The hA2aR is made 
as a fusion protein with the α-factor leader sequence from S. cerevisiae. The leader sequence is 
later cleaved off endogenously by the protease Kex2 resulting in the yeast making dG hA2aR with 
a His10 tag at its N-terminus.  
4.2 Identifying and removing the disordered C-terminal 
tail of the hA2aR 
Signalling proteins, including receptors, are involved in molecular information 
transfer. For these proteins to be able to function, they must be able to adopt 
multiple distinct conformations (Kobilka and Deupi 2007). This is accomplished 
through the proteins having great inherent flexibility and it is not uncommon for 
signalling proteins to contain natively-disordered regions (Gsponer and Babu 
2009). To identify those regions of the hA2aR that are highly flexible its amino 
acid sequence was analysed using the disorder prediction program RONN 
(www.strubi.ox.ac.uk/RONN). The results suggest that the C-terminal region 
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(αα 347 – 412) of the receptor is largely disordered as well as part of the third 
intracellular loop (αα 206 – 228) (Figure 4.2).  
The disordered regions that were identified are likely to hinder the formation of 
lattice contacts necessary for crystal formation (Lundstrom 2005; Warne et al. 
2009). As the receptor’s third intracellular loop is involved in G-protein 
activation (and necessary for function), it was decided at this stage to retain this 
part of the protein. In contrast, others have shown that the last 100 ααs of the 
hA2aR can be removed without substantially altering the ability of the receptor 
to activate Gs (Piersen et al. 1994; Olah 1997; Klinger et al. 2002). Therefore, a 
truncated hA2aR mutant (αα 1 – 320) in which the C-terminal region had been 
largely removed was created by PCR amplification and sub-cloned into pGEM T-
Easy (Figure 4.3). The truncated version of the hA2aR (with the C-terminal 
disordered region removed) was thought more likely to crystallise than the wild-
type receptor. 
 
Figure 4.2 RONN disorder prediction plot for the human adenosine 2a receptor 
The prediction software analyses the primary sequence of the target protein to try to identify those 
regions with high flexibility. Residues with a “probability of disorder” value >0.5 (indicated by the 
solid black line) are predicted to be natively disordered. The plot suggests that the C-terminal 
region (αα 347 – 412) of the receptor is largely disordered as well as part of the third intracellular 
loop (αα 206 – 228). 
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Figure 4.3 Restriction analysis of pGEM T-Easy containing either full-length or truncated 
deglycosylated hA2aR  
Digestion of recombinant plasmid with EcoRI gave a vector band of 3.0 Kb and another band of 
either 1.2 or 0.9 Kb corresponding to full-length and truncated receptor, respectively.  
4.3 Fusion of a biotin acceptor domain to the C-terminus 
of the hA2aR increases its expression in P. pastoris 
4.3.1 Vector construction 
Previously, it has been shown that fusion of the biotin acceptor domain from 
Proprionibacterium shermanii to the C-terminus of selected GPCRs improves 
both the yield and stability of the protein when it is made in P. pastoris 
(Grunewald et al. 2004; Lundstrom et al. 2006). Here, we wanted to determine 
whether or not attachment of this domain to the C-terminus of the hA2aR would 
similarly increase its expression level in P. pastoris. Another reason for wanting 
to fuse this domain to our protein of interest was to create a second affinity tag 
for purification purposes. This domain can be specifically biotinylated in vitro 
using the enzyme biotin ligase. Following this, the target protein can be isolated 
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by affinity chromatography using (strept)avidin beads (Chapman-Smith and 
Cronan 1999). This approach has a high purification factor as the abundance of 
biotinylated proteins in nature is very rare (Cronan 1990). 
The 75αα biotinylation domain from P. shermanii was cloned into αH – trunc dG 
hA2aR (Figure 4.1) downstream of the NotI site according to Materials and 
Methods Section 3.3.3 (Figure 4.4). At the same time, two Tobacco Etch Virus 
(TEV) protease recognition sites were incorporated into the vector. The first one 
was introduced between the N-terminal His10 tag and the EcoRI site used for 
cloning the target proteins (Figure 4.4). The second is situated between the C-
terminal tail of the receptor and the biotin acceptor domain (Figure 4.4). The 
purpose of adding the TEV sites was 2-fold. Firstly, cleaving off the His tag with 
TEV opens up the possibility of performing a reverse purification step using Ni2+ 
resin allowing cleaved tag, His-tagged TEV protease as well as contaminant His-
rich proteins to be removed (Ford et al. 1991; Walker et al. 1994). Secondly, 
cleavage at both TEV sites will generate “tag-free” target protein that can be 
used in crystallisation experiments (Ford et al. 1991). Constructs were made 
that contained both full-length and truncated versions of the hA2aR (Sections 
3.3.3-4) (Figure 4.5). 
 
Figure 4.4 Schematic diagram showing the αHT-TB vectors containing either (A) full-length 
or (B) truncated hA2aR 
The original GU P. pastoris expression vector (Figure 4.1) was modified by the introduction of a 
biotin acceptor domain at the receptor’s C-terminus. Following biotinylation, this tag allows the 
protein to be purified by affinity chromatography using (strept)avidin beads. TEV protease 
recognition sites were inserted immediately up- and down-stream of the receptor coding sequence. 
Cleavage with TEV allows untagged hA2aR to be isolated. 
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Figure 4.5 Restriction analysis of αHT-TB recombinant plasmids containing either (A) full 
length or (B) C-terminal truncated hA2aR 
Digestion of the vectors with EcoRI/NotI resulted in release of the hA2aR cDNA (1.2 Kb full-length; 
0.9 Kb truncated) from the HT-TB vector (3.9 Kb). 
4.4 Yeast transformation and clonal selection 
There are several possible P. pastoris strains that can be used for making 
recombinant proteins. Two of the most common are the wild-type strain X33 and 
the protease-deficient strain SMD1163 (his4 pep4 prb1). Following synthesis, 
recombinant proteins are susceptible to attack by site-specific proteases 
(Milojevic et al. 2006). Heterologously expressed MPs can be cleaved by 
proteases located in the culture medium as well as those within the cell 
(Macauley-Patrick et al. 2005). Proteins with extensive natively disordered 
regions tend to show high protease-sensitivity. Proteolysis can be overcome 
either by removing the susceptible protease site(s) by mutagenesis or by making 
the protein in a host cell where several of the key proteaseσs have been 
genetically knocked-out. Previously, the Fraser group used the P. pastoris 
protease-deficient strain SMD1163 for making full-length hA2aR (Fraser 2006). 
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Here, however, the αHT - (trunc) dG hA2aR – TB constructs were introduced into 
X33 as this strain gives significantly higher biomass in fermenter culture 
compared to SMD1163 (Niall Fraser, personal communication).  
Both constructs were transformed into X33 according to Section 3.3 where the 
linearised DNA integrated into the yeast genome. Multi-copy integrants were 
isolated following selection with the antibiotic zeocin. Previously, it has been 
shown that the production level of recombinant proteins in P. pastoris is 
influenced by the number of expression cassettes that are incorporated into the 
genome following transformation (Grunewald et al. 2004; Macauley-Patrick et 
al. 2005). As different transformants make different amounts of the target 
protein it is essential to screen a range of colonies to identify the clone making 
the highest levels of recombinant protein. Small-scale (10 ml) expression trials 
were performed with eight transformants for both constructs according to 
Section 3.5.2. Membranes were isolated for each colony and receptor expression 
levels were determined by single-point radioligand binding assay as described in 
Section 3.8 using a tritiated version of the high-affinity hA2aR-specific 
antagonist ZM241385 (Palmer et al. 1995; Poucher et al. 1995) (Figure 4.6). For 
both constructs, an approximate 3-fold difference in receptor expression level 
was observed between clones that had been transformed with the same plasmid 
(Figure 4.6). The average expression levels for the full-length and truncated 
receptors across all the tested transformants were 18.0 +/- 2.5 and 16.4 +/- 2.5 
pmol/mg protein, respectively, showing that the yeast made the full-length 
receptor and truncated mutants to essentially the same level. The highest 
expressing colony for both constructs was retained for subsequent experiments.  
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Figure 4.6 Clonal analysis of Pichia pastoris X33 transformants making either full-length or 
truncated hA2aR  
Small-scale expression trials were performed with eight transformants for both αHT-TB expression 
constructs (Figure 4.4). Membranes were isolated for each colony and receptor expression levels 
determined by single-point radioligand binding assay using a saturating (ca. 12 nM) concentration 
of [3H] ZM241385. The highest expressing colony for both constructs was retained for subsequent 
experiments. 
4.5 Saturation binding analysis of full-length and 
truncated hA2aR made in shake flask cultures  
The highest expressing colonies isolated from section 4.4 were grown on a 
medium scale (500 ml) in shake flasks. Following induction, cells were harvested 
and membranes made according to Section 3.6.3. The pharmacological 
properties of the expressed receptors were determined by saturation radioligand 
binding. In this approach, the amount of radioactivity that specifically binds to 
membrane-bound hA2aR was measured at a series of concentrations of [3H] 
ZM241385. For both αHT-TB tagged full-length and truncated receptor constructs 
specific radioligand binding against radioligand concentration was plotted and 
the dissociation constant (Kd) as well as the total number of binding sites (Bmax) 
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determined. Representative saturation binding curves are shown in Figure 1.7 
with the Bmax and Kd values for each construct shown in Table 4.1.  
Construct Bmax (pmol) Kd (nM) 
αH – full length dG hA2aR 
 
 
 
8.2 +/- 0.9 
8.5 +/- 0.1 
9.6 +/- 2.2 
1.8 +/- 0.4 
0.4 +/- 0.1 
1.2 +/- 0.6 
αHT- full length dG hA2aR – TB 
 
 
 
15.8 +/- 6.8 
18.8 +/- 0.3 
24.3 +/- 3.9 
1.5 +/- 0.3 
0.7 +/- 0.1 
4.2 +/- 1.6 
αHT- truncated dG hA2aR – TB 
 
 
20.9 +/- 2.0 
30.1 +/- 1.2 
31.8 +/- 1.5 
2.9 +/- 0.7 
4.4 +/- 0.4 
3.8 +/- 0.8 
Table 4.1 Pharamcological data for three different hA2aR constructs grown in shake flask 
culture 
Each construct was subjected to three separate radioligand binding experiments as indicated by 
the three Bmax and Kd values.  
Comparison of the Bmax values for the different hA2aR constructs suggests that 
the fusion of the biotin acceptor domain to the C-terminus of hA2aR increases 
the receptor expression level by approximately 2-fold. However, the truncation 
of the receptor’s C-terminal tail does not significantly affect its expression level. 
In native tissues the hA2aR has a Kd for ZM241385 of ca. 1.0 nM. In shake flask 
cultures of P. pastoris, Kd values in the range 1-4 nM were observed, indicative 
of weaker drug-receptor binding than in the physiological background. The most 
likely explanation for this observation is that oxygen starvation during receptor 
production prevented complete formation of its disulphide bonds (which are 
known to be essential for high-affinity ligand binding (Jaakola et al. 2008)). It 
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was hoped that this problem could be overcome by making receptor in 
fermenter culture where the dissolved oxygen (DO) levels can be readily 
regulated (Cereghino et al. 2002; Jahic et al. 2006). 
 
Figure 4.7 Representative saturation binding curves for three different hA2aR constructs 
made in X33 shake flask cultures: (A) αH– dG hA2aR, (B) αHT– dG hA2aR –TB, and (C) αHT– 
trunc dG hA2aR –TB  
Saturation binding analysis was performed according to Section 3.8.1. The data was fitted using 
GraphPad Prism software.  
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4.6 hA2aR production in fermenter culture 
One of the main advantages of using P. pastoris for recombinant protein 
production is its ability to grow to high cell densities (ca. 109 cells/ml) in 
fermenter culture (Jahic et al. 2006). This can be achieved by maintaining the 
DO content of the culture greater than 20% as well as tightly regulating the 
methanol feed rate (Cregg et al. 2000). The transition from recombinant protein 
production in low cell-density shake flask cultures to that in high cell-density 
fermentations requires considerable optimisation to obtain maximal yields of the 
target protein (Cereghino et al. 2002; Singh et al. 2008). This is particularly true 
when the methanol induction (protein expression) phase is performed at low (22 
instead of 30°C) temperatures where care has to be taken not to overfeed the 
culture with methanol. In fermentations of P. pastoris the yeast are first grown 
on glycerol to increase the culture biomass before switching the carbon source 
to methanol for recombinant protein production.  
A series of fermentations were performed on a 5 litre scale using the X33 
transformant found to make the highest levels of αHT – trunc dG hA2aR – TB, in 
which a series of parameters including length of the glycerol feed phase as well 
as the methanol feed rates were optimised. Maximal cell biomass was obtained 
by growing the yeast for 18h on basal medium followed by feeding the culture 
with glycerol for a further 11 h (Figure 4.8). This resulted in a culture OD600 of 
over 300 which is equivalent to ca. 200g wet weight of cells per litre of culture. 
This phase was followed by a 1h starvation period during which time the culture 
was not fed any carbon source. This step was included to ensure that all of the 
added glycerol had been completely consumed by the yeast as glycerol represses 
protein expression from the AOX1 locus even in the presence of methanol 
(Cereghino et al. 2002).  
At the start of the methanol-feed phase, the hA2aR antagonist theophylline was 
added to the culture to enhance the levels of functional receptor made by the 
yeast (Fraser 2006). In addition, receptor production was carried out at 22°C as 
previously it has been shown that twice as much functional hA2aR can be 
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obtained in shake-flask cultures of P. pastoris by performing induction at 22 
instead of 30°C (Fraser 2006). The induction phase was started on a low 
methanol feed rate (4 h at 0.09 ml min-1) to allow time for the cells to adapt to 
growth on methanol as its sole carbon source preventing unnecessary cell death 
(Cereghino and Cregg 2000; Cereghino et al. 2002). 
 
Figure 4.8 A typical fermentation showing how yeast biomass and hA2aR production level 
varies with time 
The yeast were grown on basal media for 18h (A) followed by a glycerol-feed phase lasting a 
further 11h (B). A starvation period (C) ensured that all of the added glycerol had been completely 
consumed. A short methanol adaptation phase (D) allowed the cells to accommodate the change 
of carbon source reducing the possibility of cell death. Finally, receptor production occurred during 
the methanol-feed phase (E) with maximum expression levels obtained after ca. 30 h.  
The methanol feed-rate was increased in a step-wise fashion in order to identify 
the rate that gave the maximum hA2aR expression level without causing cell-
toxicity arising from the accumulation of excess methanol. The yeast were fed 
at a particular rate for 12 h and then sample removed from the culture to allow 
the receptor expression level to be determined by single-point radioligand 
binding analysis (results not shown). This allowed the development of an 
optimised feeding protocol which after the cells had acclimatised to the 
methanol carbon source consisted of 12 h at 0.13 ml/min followed by 36 h at 
0.33 ml/min. Under optimal conditions, the human adenosine 2a receptor could 
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be routinely made with expression levels greater than 100 pmol receptor per mg 
protein (eg Figure 4.9). 
The αHT-trunc dG hA2aR-TB made in fermenter culture had Kd values for [3H] 
ZM241385 of 0.7 +/- 0.1, 0.8 +/- 0.1 and 0.9 +/- 0.2 nM. These values are 
essentially the same as that observed for the hA2aR in native tissues (Uustare et 
al., 2005), and reflected tighter binding of the radioligand to the receptor when 
it was made in fermenter as compared to shake-flask culture (Section 4.5). The 
improvement in the quality of receptor made by the yeast in fermenter culture 
is most likely due to the consistently high levels of dissolved oxygen that will 
ensure all of the disulphide bonds in the recombinant protein are fully formed.  
 
Figure 4.9 A representative saturation binding curve of αHT- trunc dG hA2aR-TB produced 
in fermenter culture 
Saturation binding analysis was performed as described in Section 3.8.1. The data was fitted using 
Graph Pad Prism. Receptor production levels greater than 100 pmol/mg protein were routinely 
obtained. The Kd values obtained for hA2aR made in fermenter culture were essentially the same 
as that observed in native tissue (Uustare et al., 2005), suggesting that the receptor made was of 
high quality. 
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4.7 Purification of HT- trunc dG hA2aR - TB 
To solve the 3-dimensional structure of any mammalian membrane protein it is 
first necessary to obtain milligram quantities of pure, monodisperse and stable 
protein. Mild non-ionic detergents (e.g. DDM) are often used to remove proteins 
from biological membranes as they are not sufficiently harsh to strip away all of 
the native-lipids (some of which are often essential for protein function) 
(Johansson et al. 2009). Previously, it has been shown that the hA2aR can be 
released from yeast membranes in an active state using a combination of DDM 
with the cholesterol derivative cholesterol hemisuccinate (CHS) (Weiss and 
Grisshammer 2002; Fraser 2006). Here, αHT – trunc dG hA2aR – TB in X33 
membranes was similarly treated with DDM/CHS. Insoluble material was 
removed by centrifugation and the supernatant containing receptor passed over 
Ni2+ resin. After the receptor had bound to the column, it was washed with 
buffer containing 75 mM imidazole (to remove contaminant His-rich proteins) 
and 500 mM NaCl (to remove those proteins that had bound to the column by 
ionic interactions). Receptor was released from the column using a 0-1 M 
imidazole gradient and the elution fractions analysed by SDS-PAGE (Figure 4.10).  
 
Figure 4.10 SDS-PAGE analysis of partially purified HT – trunc dG hA2aR – TB 
Receptor containing membranes were solubilised using DDM/CHS. The recombinant protein was 
purified by Ni2+ affinity chromatography. 20 µl aliquots from each elution fraction were analysed by 
SDS-PAGE. Following treatment with Simply Blue Safe Stain (Invitrogen), a major band at ca. 49 
kDa corresponding to the tagged receptor was observed.  
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As the receptor was relatively pure following the Ni2+ column, the hA2aR 
fractions were pooled, concentrated and loaded onto a Sepharose C6 gel 
filtration column (which allows proteins to be separated according to their size). 
In addition to its purification capacity, size-exclusion chromatography (SEC) is 
also a good indicator of protein quality as the size and shape of the elution peak 
gives insights into the heterogeneity and aggregation status of the applied 
protein(s) (Gutmann et al. 2007). The ideal result denoting pure, monodisperse 
protein is a single large symmetrical elution peak while several peaks arising 
from the one protein suggests that it may be aggregated and as such is 
unsuitable for structural studies (Kawate and Gouaux 2006). When the highly-
enriched hA2aR sample was applied to the column several major peaks were 
observed in the SEC elution profile (Figure 4.11), suggesting that the receptor 
population contained aggregate complexes. However, it was not obvious at what 
stage receptor aggregation had occurred – whether it was during the detergent-
solubilisation step, Ni2+ purification and/or application to the gel filtration 
column. This result made it clear that substantially more work was going to be 
required to develop an optimal purification protocol for the hA2aR. 
Furthermore, it highlighted the need for an experimental tool that would allow 
the receptor’s dispersity/aggregation status to be followed throughout the 
purification procedure. 
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(A) 
 
(B) 
 
Figure 4.11 Analysis of a highly-enriched hA2aR sample 
(A) Elution profile following application to a Sepharose C6 gel filtration column. If the partially-
purified receptor was monodisperse, the elution profile would have contained essentially a single, 
large symmetric peak. However, several heterogeneous peaks were observed, demonstrating that 
the receptor was aggregated. However, it was not obvious at what stage during the purification 
process receptor aggregation had occurred. (B) SDS-PAGE analysis showing multiple bands 
therefore substantiating aggregation had formed. 
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4.8 Conclusion 
Pichia pastoris is an excellent host cell for the overproduction of recombinant 
proteins including membrane proteins of mammalian origin. However, as 
illustrated by the work described in this chapter, the commercially available 
vector is far from what is required to maximise the production levels as well as 
simplify the detergent extraction and subsequent purification procedures for 
human membrane proteins. 
The addition of the biotinylation domain from P. shermanii had previously been 
shown to increase protein expression (Grunewald et al. 2004; Lundstrom et al. 
2006) and through its addition to the C-termini of the hA2aR expression 
construct a minimum of a 2-fold expression level increase was seen. However, 
while the truncation of the hA2aR C-termini did not have signification effects on 
its expression it was retained to help improve its crystallizability. 
An optimised protocol was developed that gave maximal production of our target 
proteins in fermenter culture at an induction temperature of 22°C. Care was 
taken to find a methanol feed rate that gave the highest levels of protein 
production without causing the accumulation of excess methanol in the culture 
(which is known to be toxic to the yeast). The hA2aR produced in fermenter 
culture had more native-like pharmacology than when the yeast cells were 
grown in shake flasks. This is likely due to the incomplete formation of 
disulphide bonds (which are known to be necessary for high-affinity ligand 
binding) in the hA2aR when it is made in shake-flask cultures of yeast. This is not 
surprising as the DO levels in fermenter culture can be maintained >20% whereas 
the DO levels in shake flasks are essentially zero. This observation will be 
applicable to other proteins made in P. pastoris and suggests that following 
clonal selection the highest-expressing transformant should be put straight into 
fermenter culture to assess whether or not the yeast is going to be a suitable 
host for making milligram quantities of the target protein for structural studies. 
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In short, by investing time optimising both the expression construct and 
expression method it is possible to obtain yields of active protein suitable for 
structural studies.  
 5  iLOV: a novel fluorescent reporter for 
membrane protein applications  
 
5.1 Introduction 
The over-expression and purification of membrane proteins can be a labour-
intensive process. One of the many challenges of working with MPs concerns the 
detection of recombinant MPs in both expression and purification experiments. 
As most, though not all, MPs are colourless, target protein identification is 
usually performed by methods such as radioligand binding and/or Western 
blotting. However, these techniques can be time-consuming, use a lot of protein 
and do not give any information on the aggregation state of the protein in 
detergent solution.  
The process of identifying target membrane proteins can be accelerated by 
fusing a fluorescent reporter to the protein of interest (Sarramegna et al., 2002; 
Drew et al., 2006). This allows recombinant MPs to be monitored indirectly by 
measuring fluorescence from the tag (Drew et al., 2006). To be successfully 
employed as a reporter protein, the fusion partner must be stable in the host 
cell used for recombinant expression, easily quantifiable and give fluorescence 
levels that accurately correlate with the amount of recombinant protein present 
(Drew et al., 2008). 
Green fluorescent protein (GFP) from the jellyfish Aequorea victoria was the 
first, and remains the most commonly used, fluorescent reporter (Chalfie et al., 
1994). GFP is so-called due to its strong green fluorescence emission upon 
illumination with visible light. GFP consists of 238 amino acids, and has a 
molecular weight of ca. 25 kDa (Prasher et al., 1992). The GFP chromophore is 
situated in a central α-helix located within an 11-stranded β-barrel (Figure 5.1) 
(Ormo et al., 1996), and is formed by the autocatalytic cyclisation of the 
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tripeptide Ser65 – Tyr66 - Gly67 (Remington, 2006; Huang et al., 2007; Malo et 
al., 2007). Chromophore maturation consists of four distinct phases: folding of 
the β-barrel, peptide cyclisation, oxidation and dehydration (Huang et al., 
2007). The oxidation reaction is the rate-limiting step in chromophore 
formation, and requires molecular oxygen. Despite its usefulness as a 
fluorescence reporter, GFP has a couple of drawbacks: i) it has a tendency to 
oligomerise, and ii) it cannot be used in conditions that are anaerobic/have low 
oxygen content (Drepper et al., 2007).  
(A) 
 
(B) 
 
Figure 5.1 The three-dimensional structures of (A) GFP and (B) LOV2  
The structure of GFP (accession code 1EMA) was described in (Ormo et al., 1996) and that for 
LOV2 (accession code 1G28) in (Crosson and Moffat, 2001). 
Although GFP has been traditionally used to monitor biological events in vivo, it 
has recently been used as a tool to monitor protein folding in vitro. For 
example, it has been shown that the folding state of soluble recombinant 
proteins made in E. coli can be rapidly determined by fusing GFP to their C-
termini as the level of GFP fluorescence observed was found to correspond with 
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the amount of correctly folded target protein (Waldo et al., 1999). In contrast, 
fusion protein that had been misfolded ended up in inclusion bodies and was 
non-fluorescent (as the GFP chromophore did not form). Since this first 
observation, this methodology has been successfully adapted for use with 
membrane proteins where C-terminal GFP fusions have been used to identify 
those membrane proteins that express well in both E. coli (Drew et al., 2002; 
Hamman et al., 2002; Drew et al., 2005; Drew et al., 2006; Link et al., 2008) 
and S. cerevisiae (Newstead et al., 2007; Drew et al., 2008) and those that do 
not. The GFP tag has also been shown to be useful for identifying those 
detergents that give monodisperse protein immediately following solubilisation 
of the membrane via fluorescence size-exclusion chromatography (FSEC) 
(Kawate and Gouaux, 2006; Newstead et al., 2007; Drew et al., 2008). 
Although highly useful for organisms such as E. coli and S. cerevisiae, GFP is not 
ideal for use with P. pastoris as this yeast grows to high cell densities in culture 
largely consuming the dissolved oxygen in the media. This is particularly true in 
shake-flask cultures of P. pastoris. The strict requirement for molecular oxygen 
in the formation of the GFP chromophore suggested to us that a LOV-type of 
fluorescence reporter (derived from plant phototropins) may be better suited for 
use in P. pastoris than GFP as LOV fluorescence is not affected by oxygen 
availability (Drepper et al., 2007).  
Phototropins are blue-light (region 320-500 nm) receptors that regulate several 
different physiological processes in plants that serve to maximise the efficiency 
of photosynthesis. These include phototropism, light-induced stomatal opening, 
as well as chloroplast movements in response to changes in light intensity 
(Christie, 2007). Phototropins consist of two distinct regions: a N-terminal 
photosensory domain with a serine/threonine kinase domain at its C-terminus. 
Within the photosensory domain are two highly conserved regions that have 
sequence homology with a family of proteins that are activated by light, oxygen 
or voltage (LOV) called LOV1 and LOV2 (Christie et al., 1999; Jones and Christie, 
2008). Light-induced phototropin kinase activity requires LOV2 (but not LOV1) 
photoreactivity though the mechanism by which LOV2 regulates the kinase 
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domain is poorly understood (Christie et al., 2002; Matsuoka and Tokutomi, 
2005).  
Purification of milligram amounts of individual LOV domains expressed in 
bacteria has allowed their structure and photochemistry to be investigated in 
fine-detail. Individual, purified LOV domains are bright yellow and emit a strong 
green fluorescence when irradiated with UV/blue light. LOV domains non-
covalently bind flavin mononucleotide (FMN) in a central cavity through a 
combination of hydrogen bonds and van der Waals interactions (Figure 5.1) 
(Christie et al., 1998; Crosson and Moffat, 2001; Christie, 2007). Upon 
irradiation, a covalent adduct forms between the flavin chromophore and a 
conserved cysteine within the LOV domain (Salomon et al., 2000). This reaction 
is fully reversible, and in darkness the LOV domains return to their initial ground 
state (Salomon et al., 2000).  
Recently, Christie and co-workers have created a novel LOV-based fluorescence 
reporter called iLOV that can be used for both in vivo and in vitro applications 
(Chapman et al., 2008). iLOV was derived from the LOV2 domain of the 
Arabidopsis thaliana phototropin 2 by performing several rounds of DNA 
shuffling. The iLOV protein has increased fluorescence quantum yield and 
reduced photobleaching compared to wild-type (Chapman et al., 2008). iLOV has 
certain intrinsic properties that suggested that it may make a useful reporter of 
recombinant membrane protein production in all systems but particularly in P. 
pastoris. These include: i) iLOV is relatively small (10 as compared to 25 kDa for 
GFP), ii) fluorescence from the flavin co-factor occurs immediately from the 
time that the iLOV domain is assembled (in contrast to GFP where formation of 
the fluorophore takes ca. 4 h (Heim et al., 1994)) making it useful for accurate 
time-course studies, and iii) iLOV fluorescence is unaffected by oxygen 
availability (unlike GFP where chromophore maturation has an absolute 
requirement for molecular oxygen) (Drepper et al., 2007). This last property of 
iLOV is of particular relevance for studying recombinant (membrane) protein 
production in shake flask cultures of P. pastoris as their oxygen content is 
essentially zero. 
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Over the course of my Ph.D., I made several different P. pastoris expression 
constructs containing the iLOV fluorescent reporter which are describes in this 
chapter. In all of the vectors, an iLOV cDNA was inserted into the plasmid C-
terminal to the cloning sites for the recombinant protein, and was introduced to 
simplify the expression and purification of my target MPs. In addition this 
chapter describes the photochemical properties of iLOV, as well as how this tag 
can be used to monitor protein expression (clonal selection; time course of MP 
production in fermenter culture), perform detergent screening and facilitate 
protein purification.  
5.2 Fusion of a fluorescent reporter protein to the 
receptor’s C-terminus  
As the vast majority of mammalian membrane proteins are colourless they 
cannot be followed visually during the purification process. Rather those 
fractions containing the target protein have to be found either by visualisation 
techniques (e.g. Western blotting) or by performing a functional assay (e.g. 
radioligand binding). While these approaches are highly successful in identifying 
the desired fractions they have many drawbacks not least in the amount of time 
and protein required to do the assay. However, by fusing the protein of interest 
to a fluorescent marker it is possible to track the expression and purification of 
the recombinant protein by eye following excitation of the reporter at an 
appropriate wavelength (Drew et al., 2006). Although green fluorescent protein 
(GFP) from Aequorea victoria has been successfully used for tracking membrane 
protein production in E. coli and S. cerevisiae (Chalfie et al., 1994; Drew et al., 
2008), we decided to use a fluorescent protein derived from a plant phototropin 
Light-Oxygen-Voltage (LOV) domain (Briggs, 2007 a,b). This reporter protein 
fluoresces from the time it is synthesised (upon binding its co-factor flavin 
mononucleotide), and has oxygen-independent fluorescence intensity (both 
unlike GFP) (Christie, 2007). The native LOV domain has been modified by 
Christie and co-workers to give the iLOV reporter which has improved stability 
and fluorescence intensity compared to the WT protein (Chapman et al., 2008).  
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iLOV cDNA was incorporated into the HT-TB expression plasmid between the C-
terminal TEV recognition site and the biotinylation domain (Figure 5.2). This was 
accomplished by introducing two new restriction sites (SpeI and NdeI) between 
the TEV site and the biotinylation domain, and then sub-cloning the iLOV DNA 
between the new restriction sites (Figure 5.3). By positioning the iLOV domain 
downstream of the target protein, it was possible to measure recombinant 
protein expression level via iLOV fluorescence (Section 5.6).  Furthermore, the 
tag was useful for determining the dispersity of the receptor following detergent 
solubilisation as well as during the purification process by fluorescence SEC.  
 
Figure 5.2 Schematic diagram showing the αHT-TLB expression plasmid 
The fluorescent reporter protein iLOV was incorporated between the downstream TEV protease 
recognition site and the biotin acceptor domain. The iLOV tag was useful for determining 
recombinant membrane protein expression levels as well as their aggregation status following 
detergent solubilisation. 
 
Figure 5.3 Restriction analysis of HT – trunc dG hA2aR – TLB 
Digestion of the recombinant plasmid with (a) EcoRI/NotI, (b) SpeI/NdeI and (c) EcoRI/NdeI gave 
bands at 1.0, 0.3 and 1.2 kb corresponding to trunc hA2aR, iLOV and trunc hA2aR-iLOV fragments 
of DNA, respectively. (The 0.3kb band is indicated with an arrow due to poor contrast). 
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5.3 Using conformationally-fixed hA2aR mutants to 
improve receptor stability 
Many signalling proteins including GPCRs have intrinsic flexibility that allows 
them to adopt multiple conformations (Kobilka and Deupi 2007). While this 
flexibility is essential for receptor activity it is also an impediment to 
crystallisation (Warne et al. 2009). This problem can, however, be overcome by 
trapping GPCRs in particular conformations using appropriate ligands. Indeed, 
the ligand-activated GPCRs that have had their structures solved thus far have 
all been co-crystallised with either a high-affinity antagonist or inverse agonist 
bound (e.g. (Palczewski et al. 2000; Cherezov et al. 2007; Rasmussen et al. 
2007; Rosenbaum et al. 2007; Hanson et al. 2008; Jaakola et al. 2008; Warne et 
al. 2008). In these examples, the ligands were not just used to fix the receptor’s 
conformation but to increase the thermostability of the protein in detergent 
solution also.  
An alternative approach to solving the twin problem of conformational 
heterogeneity and poor stability of GPCRs in detergent solution has recently 
been described by Tate and co-workers who, after performing an extensive 
mutational analysis of the turkey β1-adrenergic receptor, created a modified 
version of the receptor called M23 that preferentially binds antagonists and was 
ca. 30°C more thermostable than the WT receptor (Warne et al. 2009). This 
mutant was even stable in C8 detergents including octylthioglucoside in which it 
was crystallised with the antagonist cyanopindolol bound and structure solved to 
atomic resolution (Warne et al. 2009). 
More recently, Tate and co-workers have described two conformationally-fixed 
thermostable hA2aR mutants called Rant21 (which preferentially binds 
antagonists) and Rag23 (agonists) (Magnani et al. 2008) (Figure 5.4). To 
determine whether or not these mutants aggregated in the same way that had 
been found for the truncated hA2aR construct (Section 4.7), Rant21 and Rag23 
cDNAs (a kind gift from Dr. Chris Tate) were cloned into the αHT-TLB vector. 
The Rant21 and Rag23 cDNAs that had been provided to us had been truncated 
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at αα316. We, therefore, made an equivalent truncation of the WT receptor 
construct denoted GU. The glycosylation site in all three constructs was removed 
by site-directed mutagenesis. Finally, to further improve their stability and 
potential crystallisability the flexible region in intracellular loop 3 (αα 210-227) 
that had been identified previously using RONN (Section 4.2) was removed from 
the GU, Rant21 and Rag23 constructs. The integrity of the desired constructs 
was explored first by restriction analysis (Figure 5.5) and then by sequencing. 
All three constructs were transformed into yeast strain X33. Following 
fermentation, membranes containing iLOV-tagged receptor were isolated and a 
series of trial solubilisation experiments performed. Using FSEC, it was possible 
to determine the extent of receptor aggregation immediately after treatment 
with detergent. These results are presented fully in Section ?. In short, the CHS 
was found to be the cause of receptor aggregation observed in Section 4.6. My 
work focussed on Rag23 which could be purified with monodispersity in DDM in 
the absence of CHS (Section 6.2).  
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Figure 5.4 Sequence alignment of GU, Rant21 and Rag23 DNA sequences against WT hA2aR 
All three modified forms of the hA2aR had their glycosylation sites as well as 18 residues from the 
third intracellular loop and the C-terminal 96 residues removed. The αα changes in the Rag23 and 
Rant21 mutants are highlighted in red boxes. 
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Figure 5.5 Restriction analysis of recombinant αHT-TLB vectors containing either Rag23 or 
GU hA2aR 
Due to the mutations forming the conformationally-fixed Rag23 mutant, the Rag23 cDNA does not 
have a PvuII restriction site while the GU sequence does. On digestion of the Rag23 construct with 
PvuII a single band was observed due to linearization of the vector. In contrast, two bands were 
seen for the GU plasmid due to a single cut each within the insert and vector.  
5.4 Optimised tag removal by digestion with C3 protease 
The expression construct containing iLOV was re-engineered to simplify the tag 
removal process. With the HT-TLB vector, complete tag removal required 
successful cleavage at both TEV sites. Even allowing for the problems 
encountered with TEV solubility (section 5.10), it was thought that requiring two 
cleavage events for tag removal was unnecessarily complicated. To simplify the 
proteolytic procedure, the His10 tag was moved from upstream of the receptor 
coding sequence to downstream of the biotin-acceptor domain (Figure 5.6), 
creating a iLOV-biotin-His10 (LBH) tag. The remaining TEV site was replaced with 
one for human rhinovirus C3 protease (C), creating an αCLBH vector. A version 
without the α-factor leader sequence was also made -CLBH (Figure 5.6). C3 
protease has considerably higher cleavage activity than TEV which means that it 
gives efficient removal of tags from recombinant proteins even at low (4°C) 
temperatures (Knott et al. 1989; Terpe 2003). Moreover, unlike TEV where 
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milligram amounts of protease are required for tag removal (Mohanty et al. 
2003), only microgram quantities of C3 need to be added to the recombinant 
protein. It was envisaged that the superior enzymatic properties of C3 would 
overcome the solubility problems that had been encountered with TEV.  
 
 
Figure 5.6 Schematic diagram of the CLBH expression constructs with and without α-factor 
To simplify the proteolytic processing of the recombinant protein, the His10 tag in the αHT-TLB 
vector was re-positioned downstream of the biotin acceptor domain. Furthermore, the TEV 
protease recognition site was replaced with one for human C3 rhinovirus protease. A version of the 
CLBH vector without α-factor leader sequence was made, and a cDNA for human sterol isomerase 
cloned into it.  
Vector modifications were performed as described in Section 3.3.7. GU, Rant21 
and Rag23 versions of hA2aR were cloned into the Aα-CLBH vector and hSI cloned 
into A-CLBH. To ensure that all of the constructs had been made correctly, they 
were analysed by restriction digestion (Figure 5.7) prior to sequencing.  The 
CLBH constructs  allowed  for  the  rapid  purification  of both Rag23 and SI on a 
milligram scale. This work is described in Sections 6.2, 6.3 and 6.7. 
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(A)  
 
(B) 
 
(C) 
 
(D) 
 
Figure 5.7 Restriction digest analysis of (A) αGU-, (B) αRant21-, (C) αRag23- and (D) SI-
CLBH constructs 
All of the recombinant plasmids could be linearised using either EcoRI or NotI. Treatment with both 
of these enzymes resulted in release of either the hA2aR (0.9 Kb) or SI (0.7 Kb) cDNA from the 
CLBH vector (α factor – 4.2 Kb; no α factor – 3.9 Kb). Treatment with EcoRI and NdeI or SalI 
instead of NotI resulted in the release of larger inserts containing either iLOV (0.3 Kb) or LB (0.6 
Kb), respectively, in addition to the target protein cDNA.  
5.5 The spectral properties of iLOV 
Before iLOV could be used as a fluorescence reporter, it was necessary to 
characterise its spectral properties so that optimal excitation and emission 
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wavelengths could be determined (Figure 5.8). As the flavin co-factor is itself 
fluorescent, it was necessary to measure (and compare) the excitation and 
emission profiles for the same concentration of flavin (with that for iLOV). 
Lastly, excitation and emission spectra were recorded for yeast membranes to 
assess the extent of background fluorescence from endogenous flavoproteins. 
The iLOV emission spectrum has a distinctive peak at 485 nm with a pronounced 
shoulder at 525 nm. This is appreciably different from flavin which has a single 
broad peak from 510 - 540 nm (Figure 5.8 (A)). The fluorescence emission 
spectrum of the iLOV tag was the same when it was fused to the hA2aR (results 
not shown). As the spectral properties of iLOV are unchanged when it is attached 
to another protein iLOV can be used as a fluorescence reporter. Negligible 
fluorescence from the yeast membranes was observed (Figure 5.8 (A)), 
indicating that any fluorescence subsequently observed in membranes containing 
recombinant protein had to come from the iLOV tag. The optimal wavelength for 
measuring emission from iLOV was 485 nm. However, the shape of the emission 
spectrum suggested that iLOV fluorescence could be effectively measured in the 
range 485 – 530 nm. 
iLOV has a strong, broad absorption in the region 320-460 nm which gives rise to 
peaks at 350, 370 and 450 nm in its excitation spectrum (Figure 5.8 (B)). The 
equivalent spectrum for flavin is subtly but significantly different with just peaks 
at 355 and 390 nm. These results show that it is possible to selectively excite 
iLOV over flavin by using light with wavelength around 450 nm. 
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Figure 5.8 The fluorescence properties of equal concentrations of iLOV and flavin compared 
to native yeast membranes 
(A) Emission spectra were recorded from 470 – 600 nm following chromophore excitation at 450 
nm. (B) Excitation spectra were recorded from 300 – 460 nm measuring fluorescence emission at 
485 nm.  The optimal wavelength for exciting iLOV is 450 nm, whereas emission can be effectively 
measured in the range 485 – 530 nm.  
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5.6 Clonal selection using iLOV 
Once a recombinant expression plasmid has been transformed into P. pastoris, it 
is essential to screen a range of colonies to identify the clone making the highest 
levels of recombinant protein (as different transformants make different levels 
of the target protein). Screening is usually done by radioligand binding (where 
one is available) or by Western blotting. In Chapter 4, X33 transformants 
expressing HT-trunc dG hA2aR-TB were screened using the radioligand [3H] 
ZM241385. To accomplish this, small-scale (10 ml) expression trials were 
performed with eight transformants, membranes isolated for each colony and 
receptor expression levels determined by single-point radioligand binding assay. 
Although this process allowed the highest expressing transformant to be 
identified, this approach is cumbersome and consumed valuable time and 
resources. Here, clonal selection was performed on X33 colonies that had been 
transformed with GU-, Rant21- and Rag23-CLBH by measuring iLOV fluorescence 
in whole cells following induction. 
Twelve transformants for each construct were grown up overnight at 30°C in 1 
ml cultures of BMGY in a 48-well plate. To induce receptor production, the BMGY 
was replaced with BMMY and the yeast incubated at 22°C for 24 h. The test 
expression experiments for each colony were performed in duplicate. The cells 
were harvested by centrifugation, washed twice and then resuspended in 1 ml of 
water. The cells were transferred (in duplicate) to a 96 well plate, where iLOV 
fluorescence was measured (λexcitation = 450, λemission = 520 nm). Expression levels 
are always in the form amount of target protein per total amount of protein. To 
convert iLOV fluorescence into an expression level, it was necessary to have an 
accurate measure of the number of cells that contributed to the measured 
fluorescence. Initially, the optical density (OD600) of each culture was 
determined in a 96-well plate. However, it proved difficult to obtain 
reproducible data largely caused by cell sinkage as well as high turbidity (results 
not shown). Instead, cell biomass was quantitated by chemically permeabilising 
the cells and then measuring the protein concentration of the lysate. The main 
benefit of this approach was the improved reproducibility of the cell biomass 
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data which allowed the expression levels of different constructs to be compared. 
The clonal selection results for GU-, Rant21- and Rag23-CLBH are presented in 
Figure 5.9. For all three constructs, the vast majority of the transformants 
differed in their expression level by a factor of 2-3, similar to that which had 
been observed in the clonal analysis of HT- trunc dG hA2aR – TB (where receptor 
amount had been determined by radioligand binding analysis).   
 
Figure 5.9 Clonal selection using iLOV fluorescence  
GU-, Rant21- and Rag23-CLBH transformants were grown up overnight at 30°C in 1 ml cultures of 
BMGY. Receptor production was induced by replacing the media with BMMY and then incubating 
the yeast at 22°C for 24 h. Receptor levels were determined by measuring iLOV fluorescence from 
whole cells. Cell biomass was quantitated by chemically permeabilising the cells and then 
measuring the protein concentration of the lysate. For all five constructs, the majority of the 
transformants differed in their expression level by a factor of 2-3. 
To address whether or not higher expressing clones could be isolated on plates 
with high levels of antibiotic, X33 cells that had been transformed with GU-CLBH 
were grown on YPD plates containing different (0.2, 0.5, 1 and 2 mg/ml) 
concentration of zeocin. Twelve colonies from each plate were grown in 1 ml 
cultures, and receptor production induced as described in Section 3.5.1. The 
expression level was determined by measuring iLOV fluorescence per amount of 
total cell protein (Figure 5.9).  
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Although colonies isolated from the plates with higher zeocin concentrations did 
show the highest expression levels, they did not vary significantly from colonies 
isolated on plates with lower levels of antibiotic (Figure 5.10). As the expression 
level profile was essentially the same for all four plates, it suggested that there 
was no significant benefit in performing clonal selection at high (2 mg/ml) 
concentrations of zeocin. Rather, the results suggested that the best way to 
identify a highly expressing transformant is to screen a large number of colonies.  
Figure 5.10 The expression level of GU-CLBH in different transformants selected on plates 
with increasing concentrations of the antibiotic Zeocin 
The X33 P. pastoris strain was transformed with an expression plasmid containing GU-CLBH. The 
cells were grown on YPD plates containing different (0.2, 0.5, 1 and 2 mg/ml) concentrations of 
zeocin. Twelve colonies from each plate were grown in 1 ml cultures, and receptor production 
induced as described in Section 3.5.1. The expression level was determined by measuring iLOV 
fluorescence per amount of total cell protein. The expression level profile was essentially the same 
for all four plates, suggesting that there was no significant benefit of performing clonal selection at 
high (2 mg/ml) concentrations of zeocin. 
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5.7 Using iLOV to optimise MP production in fermenter 
culture  
The main benefit of using P. pastoris for recombinant MP production is its ability 
to grow to high cell densities in fermenter culture (where dissolved oxygen 
content, pH, temperature and feed rates can all be tightly controlled (Cereghino 
et al., 2002; Jahic et al., 2006)). For each different MP, the basic fermentation 
protocol needs to be optimised to ensure that maximal levels of the target 
protein are obtained. If recombinant protein expression levels have to be 
determined by either radioligand binding or Western Blotting, the optimisation 
process can be unnecessarily long.  
Previously, HT- trunc dG hA2aR – TB production in fermenter culture was 
optimised by determining the levels of membrane bound receptor at various 
time points by radioligand binding (Section 4.3.2). Receptor levels were only 
determined once the fermentation had been completed as it was simplest to 
make membranes for all of the time-points together before performing 
radioligand binding. Here, Rag23- and Rant21-CLBH production in fermenter 
culture was followed by measuring iLOV fluorescence from intact cells at regular 
intervals (Figure 5.11). Culture biomass was determined by measuring the wet 
cell weight per ml of culture at each of the time-points. From these two 
measurements, the receptor expression level could be quantified promptly 
(generally within 30 minutes of taking the sample). This speed of analysis is 
beneficial as it allows time-courses of recombinant MP production to be followed 
in real-time, allowing decisions about when is the best time to stop the 
fermentation during each run. The iLOV marker is ideal for time-course 
applications as, unlike GFP, there is no delay period between iLOV assembly and 
fluorescence from the chromophore. For both constructs, growth on glycerol 
gave a maximal cell density of ca. 300 g wet weight of cells per litre of culture. 
Maximal receptor expression was achieved by feeding the yeast on methanol for 
ca. 40 h. 
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(A) 
 
(B) 
 
Figure 5.11 Time-course of (A) Rag- and (B) Rant-CLBH production in fermenter culture 
Samples were taken at regular intervals throughout the fermentation. For each time point, 1 ml of 
cells was centrifuged and the pellet weight measured. The cell pellet was washed twice with (to 
remove free flavin present in the media) and then resuspended in water. iLOV fluorescence was 
measured using a platereader. Rag23- and Rant21-CLBH production levels were expressed as 
amount of iLOV fluorescence per amount of wet weight of cells. For both constructs, growth on 
glycerol gave a maximal cell density of ca. 300 g wet weight of cells per litre of culture. Maximal 
receptor expression was achieved by feeding the yeast on methanol for ca. 40 h.  
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5.8 Monitoring MP aggregation status using iLOV 
Although it is relatively easy to assess a protein’s purity (e.g. by SDS-PAGE) it is 
rather more difficult to determine its aggregation status. Often, it is not realised 
that the target protein has aggregated until it has been purified to homogeneity, 
rendering it useless for structural biology purposes (Postis et al., 2008). 
Aggregation is a common problem encountered when working with membrane 
proteins, and is usually caused by protein instability in the detergent that has 
been chosen for membrane solubilisation and purification purposes. Recently, 
the approach of fluorescence size-exclusion chromatography (FSEC) has been 
developed as a method for monitoring the aggregation status of MPs throughout 
the purification process following membrane solubilisation. When a pure 
monodisperse protein is applied to a SEC column, it elutes as a single peak with 
Gaussian symmetry (Gutmann et al., 2007). By attaching a fluorescent tag to the 
MP of interest, it is possible to assess whether or not the target protein is 
monodisperse at any stage of the solubilisation/purification procedure by 
applying it to a SEC column and then measuring fluorescence (target-protein 
specific) rather than A280 (all proteins) in the elution fractions. The elegance of 
FSEC is that it allows the aggregation status of recombinant MPs to be monitored 
even in the presence of other proteins (Kawate and Gouaux, 2006). A single, 
symmetric fluorescent SEC peak throughout the purification indicates that the 
target protein is stable. If the SEC elution profile has multiple fluorescent peaks 
with one of them located in the void volume it suggests that the target protein 
has become aggregated, and is unsuitable for further purification and 
crystallisation trials. GFP is the tag most commonly used for FSEC experiments 
(Kawate and Gouaux, 2006). Here, the usefulness of iLOV to monitor the 
aggregation status of HT – trunc dG hA2aR – TLB as well as Rag23- and SI-CLBH 
following detergent solubilisation is described.  
Previously, it has been shown that functional solubilisation of the hA2aR can be 
accomplished using a combination of DDM and cholesterol hemisuccinate (CHS) 
(Weiss and Grisshammer, 2002; Fraser, 2006). However, CHS is bulky, 
hydrophobic and has a tendency to drive MP aggregation (Chris Tate, personal 
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communication). Here, I wanted to investigate whether or not i) HT – trunc dG 
hA2aR – TLB was monodisperse in detergent solution following solubilisation with 
DDM/CHS, and ii) the DDM:CHS ratio affected the hA2aR aggregation status. 
Membranes were solubilised with DDM (final concentration of 2.5%) containing 
different amounts of CHS (CHS:DDM ratios of 1:5, 1:10, 1:25, 1:50, no CHS). 
Following centrifugation, the supernatant was applied to a Sepharose C6 gel 
filtration column in buffer containing 0.05% DDM with CHS added in the 
appropriate ratio. iLOV fluorescence was measured in all of the elution 
fractions.  The FSEC profiles showed that only a DDM:CHS ratio of 50:1 gave 
monodisperse receptor following solubilisation (Figure 5.12). At both higher and 
lower DDM:CHS ratios, the receptor was found to aggregate (Figure 5.12). 
Receptor that had been solubilised with a 50:1 DDM:CHS ratio was able to bind 
[3H] ZM241385 in solution (results not shown). These results showed that if 
enough CHS was included in the solubilisation mixture monodisperse receptor 
that retained its activity in detergent solution could be obtained. If, however, 
too much CHS was added, the additive caused the receptor to aggregate. In all 
of the profiles, a small broad peak with an elution volume around 25 ml was 
observed. On measuring the fluorescence emission spectrum of this peak, it was 
found to be flavin. The other, higher MW peaks all had the characteristic LOV 
emission profile consistent with them being oligomers/aggregates of LOV-tagged 
receptor. The free flavin comes from denaturation of the iLOV domain on 
treatment with detergent. As this peak did not obscure monitoring of the 
receptor’s aggregation status, it was concluded that iLOV could be used as an 
alternative reporter to GFP for FSEC experiments. 
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Figure 5.12 The effect of different DDM:CHS ratios on the aggregation status of HT – trunc 
dG hA2aR - TLB 
Membranes containing HT – trunc dG hA2aR – TLB were solubilised with DDM (final concentration 
of 2.5%) containing different amounts of CHS. Following solubilisation, the samples were 
centrifuged and the resulting supernatants analysed by FSEC. iLOV fluorescence in each of the 
elution fractions was measured using a platereader.  
Having identified conditions that gave monodisperse receptor following 
solubilisation, a Ni2+ purification step was performed. (This is detailed in 
Section). An aliquot of the partially purified receptor was applied to the gel 
filtration column, and the fluorescence content of the elution fractions 
measured (Figure 5.13). Disappointingly, a single broad peak that eluted at ca. 
12 ml was observed (that was appreciably different from the sharp peak around 
20 ml that had been seen in the post-solubilisation sample), showing that 
purification with the Ni2+ column had caused the receptor to aggregate. This 
effect may have of been caused by one of the chemicals contained within the 
purification buffers used with the Ni2+ column. To explore this possibility, a 
series of test solubilisation experiments were performed in the presence of 
either NaCl, imidazole or histidine. The detergent-solubilised material was then 
applied to the gel-filtration column equilibrated in a buffer containing the 
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chemical under investigation. Fluorescent elution profiles are shown in Figure 
5.14. The results showed that none of the reagents tested, in and of themselves, 
caused the receptor to aggregate. Rather it looked like the receptor became 
aggregated during the time it was bound to the column perhaps through a local 
enrichment in the concentration of CHS. Despite considerable effort to 
overcome this problem of aggregation, none could be found. In all subsequent 
hA2aR solubilisation and purification experiments conformationally-fixed 
thermostable mutants were used (Magnani et al., 2008). 
 
Figure 5.13 Analysis of HT - trunc dG hA2aR - TLB before and after Ni2+-affinity purification 
by FSEC and SEC 
The hA2aR was solubilised from yeast membranes using a combination of DDM (final 
concentration 2.5%) and CHS (ratio 50:1). The receptor was purified by Ni2+ chromatography as 
described in Section 3.12. Aliquots containing the hA2aR before and after purification were applied 
to a Sepharose C6 gel-filtration column, and the fluorescence elution profile measured for both 
samples (before – green; after blue). A single sharp peak at ca. 20 ml was observed for the post-
solubilisation sample. However, after Ni2+ purification, the peak was shifted to an earlier elution 
time (12 ml) and was considerably broader suggesting that during the purification step the receptor 
had become aggregated. This was confirmed by the absorbance profile following purification.  
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Figure 5.14 The effects of a range of buffer components on the aggregation status of HT-
trunc dG hA2aR – TLB in detergent solution 
A series of test solubilisation experiments were performed using a combination of DDM (final 
concentration of 2.5%) and CHS (50:1) in the presence of either NaCl, imidazole or histidine. The 
detergent-solubilised material was then applied to the gel-filtration column equilibrated in a buffer 
containing the chemical under investigation. The elution profiles showed that none of the reagents 
tested, in and of themselves, caused the receptor to aggregate. 
The hA2aR thermostable mutants Rant21 and Rag23 can bind [3H] ZM241385 and 
[3H] NECA in short chain detergents, respectively (Magnani et al., 2008). Here, I 
wanted to explore whether or not these mutants were monodisperse in a range 
of different detergents following solubilisation. As the hA2aR has already had its 
structure solved with ZM241385 bound (Jaakola et al., 2008), I focussed on the 
hA2aR agonist mutant Rag23. Membranes containing HT-Rag23-TLB were 
incubated with a saturating (100 µM) concentration of NECA and then solubilised 
with either DDM (alkyl chain C=12), DM (C=10), NM (C=9) or βOG (C=8). After 
centrifugation, the supernatants were applied to the gel filtration column pre-
equilibrated in buffer containing NECA as well as the appropriate detergent. 
Rag23 was found to be monodisperse in all of the non-ionic detergents tested 
even in βOG (Figure 5.15). Furthermore, monodisperse peaks were also obtained 
(for all of the detergents tested) when the receptor containing supernatants 
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were applied to the column 48 h after solubilisation, demonstrating that Rag23 
has prolonged stability in detergent solution (results not shown). Unfortunately, 
due to time constraints, it was not possible to characterise the Rant21 mutant 
by FSEC. 
 
Figure 5.15 FSEC analysis of HT-Rag23-TLB  
Membranes containing HT-Rag23-TLB were incubated with a saturating concentration (100 µM) of 
NECA before they were solubilised using detergents with different alkyl chain lengths – DDM (C = 
12), DM (10), NM (9) and βOG (8). Even with the harshest detergent βOG, monodisperse receptor 
was obtained. This experiment suggested that Rag23 is an excellent candidate for structural 
studies as it is remarkably stable even in short chain detergents.  
In order to determine the stability of SI in detergent solution membranes 
containing SI-CLBH in sodium phosphate buffer were solubilised using either 
DDM, DM, NM or βOG. After centrifugation, the supernatants were applied to the 
gel filtration column pre-equilibrated in sodium phosphate buffer containing the 
appropriate detergent. SI was found to be monodisperse in both DDM and DM 
(Figure 5.15). In NM, although a single fluorescent peak was observed it was 
appreciably broader than that which had been observed in either DDM or DM 
suggesting that the enzyme was starting to lose its stability in NM (Figure 5.15). 
When SI was solubilised with βOG, the protein was completely aggregated 
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(Figure 5.15). Remarkably, for a wild-type protein, SI displays good stability in 
the short-chain detergent DM (and to a lesser extent NM) suggesting that this 
protein may be an excellent candidate for structural studies.  
 
Figure 5.16 FSEC analysis of SI-CLBH 
Membranes containing SI-CLBH in sodium phosphate buffer were solubilised with either DDM, DM, 
NM or βOG. Remarkably for a native protein, SI was monodisperse in both DDM and DM. By NM, 
however, the fluorescent peak was starting to broaden suggesting that the enzyme was starting to 
lose its stability in this detergent. When SI was solubilised with βOG, the protein was completely 
aggregated.  
 
5.9 iLOV as a purification aid 
All protein purification steps involve binding of the target protein to a resin, 
washing the column or beads and then selectively eluting the protein of interest. 
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When performing any purification step, it is necessary to know how much of the 
target protein has bound to the column as well as which elution fractions contain 
the protein of interest. Such basic information can be hard to obtain if there is 
not a simple assay to measure the activity/presence of the protein of interest. 
Here, I describe how the iLOV tag can be used to overcome these purification 
difficulties.  
Yeast membranes containing HT – trunc dG hA2aR – TLB were solubilised with 
2.5%:0.05% DDM:CHS according to Section 3.103.12.1. Following centrifugation, 
the soluble fraction containing receptor was passed over a Ni2+ column. Receptor 
binding was monitored by comparing the fluorescence of the supernatant before 
and after passage over the column. Receptor binding to the Ni2+ column was 
readily visualised by illuminating it with UV light (Figure 5.17 (A)). The resin was 
washed with buffer containing 500 mM NaCl and 75 mM imidazole according to 
Section 3.13. This was to remove any contaminant proteins that had non-
specifically-bound to the column. The receptor was released from the column by 
passing buffer over it containing 300 mM imidazole, and fractions collected. 
Those containing iLOV-tagged receptor were readily recognised, as they were 
yellow in the light and fluorescent on exposure to UV (Figure 5.17 (B-C)). The 
fractions containing receptor were pooled and analysed by FSEC which showed 
that the hA2aR had become aggregated during the Ni2+ purification step (Section 
?). 
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(A) 
 
(B) 
 
(C) 
 
 
Figure 5.17 Visualisation of iLOV-tagged hA2aR during Ni2+-affinity purification 
(A) iLOV-tagged hA2aR bound to a Ni2+ column has a fluorescent green colour under UV-light. The 
receptor was eluted from the column using 300 mM imidazole. Fractions containing HT-trunc dG 
hA2aR -TLB are (B) yellow in colour and (C) fluorescent green following UV-irradiation. 
5.10 Immobilisation of fluorescently-tagged hA2aR using 
streptavidin beads 
The biotinylation domain was primarily included in the in-house expression 
vector as a second affinity tag for protein purification purposes. Biotinylated 
proteins are rare in nature with only one known in E. coli (Fall 1979), five in S. 
cerevisiae (Lim et al. 1987) and four in mammalian cells (Robinson et al. 1983; 
Chandler and Ballard 1988). As the levels of endogenous biotinylated proteins in 
P. pastoris are very low, it was envisaged that purification using this tag would 
result in a substantial enrichment of the target protein. Although it has been 
previously shown that the biotin acceptor domain from the P. shermanii 
transcarboxylase can be biotinylated endogenously by S. cerevisiae (Cronan, 
1990) to ensure that all of the fusion domains were biotinylated Ni2+ enriched 
HT- GU hA2aR-TLB was incubated at 4°C overnight with recombinant E. coli 
 
iLOV : a novel fluorescent reporter  132 
   
biotin ligase in vitro (Figure 5.18 (A)). After biotinylation was complete, the 
fluorescently tagged receptor was desalted before application to streptavidin 
beads. All of the fluorescently-labelled receptor bound to the beads (Figure 5.18 
(B)), showing that all of the fusion domains had been biotinylated in vitro. As 
the interaction between biotin and streptavidin is incredibly tight it was not 
possible to elute bound receptor from the beads using free biotin. Although the 
biotin-streptavidin bond can be broken at low pH (<3) these conditions were far 
too harsh to expose the receptor to. Rather, it was thought that the best way to 
remove the receptor from the beads was through tag cleavage. Initial studies 
using TEV protease were unable to get satisfactory cleavage, at either end of the 
recombinant protein, as the TEV that I made in the lab had poor solubility 
(results not shown). However, the usefulness of this immobilization technique 
has been confirmed using constructs containing the C3 protease recognition site 
(data not shown). 
(A) 
 
(B) 
 
Figure 5.18 In vitro treatment of HT – GU hA2aR – TLB with biotin ligase allows the receptor 
to be immobilised on streptavidin beads 
(A) SDS-PAGE of purified recombinant E. coli biotin ligase, (B) Following in vitro biotinylation of 
Ni2+-enriched hA2aR the receptor could be readily immobilised on streptavidin beads. This was 
visualised by looking at fluorescence from the iLOV tag under a UV light source.  
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5.11 Conclusion 
Having made a series of related expression constructs, optimal (CLBH) vectors 
were created that gave high level production of two different human membrane 
proteins (one Nin – hSI; one Nout – hA2aR) that could be rapidly purified to 
homogeneity using a generic protocol. The biotin acceptor site could be fully 
biotinylated in vitro using recombinantly expressed BirA. Due to the high 
expression levels achieved with both the hA2aR and hSI in fermenter culture, 
this tag was not required for their successful purification. However, the ability 
to immobilise any target protein by its C-terminus is an incredibly useful feature 
of the expression vector and should be compatible with drug discovery 
approaches such as Biacore and target-immobilised NMR spectroscopy. The 
inclusion of a fluorescent reporter C-terminal to the protein of interest helped 
greatly to assess the expression, detergent-extraction and purification 
processes. Finally, C3 protease was found to be a considerably better enzyme for 
removing the expression/purification tags from the recombinant protein than 
TEV as the TEV made in our lab had poor solubility. For the sake of simplicity, 
the final optimised expression vector had the iLOV-biotin-His10 (LBH) tags fused 
to the C-terminus of the recombinant protein. This allowed removal of all the 
tags in a single cleavage event with C3. The major disadvantage of having all of 
the purification tags at one end of the recombinant protein as compared to tags 
at both ends is that there is no guarantee of purifying protein that is completely 
intact. When all of the purification tags are at one end of the protein, it is 
possible to purify a proteolytic fragment of the target protein. However, when 
there are tags at either end of the target protein, by performing a two-step 
purification procedure it is possible to isolate protein that has both its N- and C-
termini intact.  
The iLOV fluorescent reporter protein is a useful tool for optimising processes 
such as clonal selection, protein production in fermenter culture, detergent and 
construct screening as well as protein purification. The primary benefits of using 
iLOV are that it saves time, labour and cost as well as giving important insights 
into the stability of the target MP immediately after solubilisation as well as 
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during the purification process. This second advantage is considerable given the 
propensity of MPs to aggregate. An unexpected but incredibly useful property of 
the iLOV tag was discovered during the FSEC experiments where all of the 
elution profiles had a “late” peak consisting of flavin (that had been released on 
breakdown of the iLOV tag). The size of the flavin peak gave a direct measure of 
the amount of target protein denaturation that had occurred on treating the 
membranes with detergent. The presence of a large flavin peak in a FSEC 
experiment (following either detergent-solubilisation or -exchange) suggests that 
the target protein is unstable in the chosen detergent whereas the absence of a 
flavin peak in the elution profile suggests that the iLOV-tagged MP is stable. In 
short, by monitoring the free-flavin content of iLOV-tagged MPs in detergent 
solution it should be easy to identify those detergents in which the MP is 
unstable/has become denatured. 
One disadvantage of iLOV compared to GFP is that it is not compatible with in-
gel fluorescence experiments. As fluorescence from the iLOV chromophore 
comes from the flavin co-factor, when iLOV tagged receptor is treated with SDS, 
the iLOV domain denatures rendering it non-fluorescent. This means that iLOV-
tagged proteins on a SDS-PAGE cannot be visualised by placing it under a UV 
source. This is different from GFP-tagged proteins which retain their structure 
and fluorescence even after treatment with SDS (Drew et al., 2006). 
This Chapter also highlights the usefulness of conformationally-fixed 
thermostable mutants of GPCRs for structural biology purposes. Rag23 was stable 
in DDM without any CHS present. This is important as CHS has a tendency to 
drive MP aggregation. Furthermore, as Rag23 was monodisperse in a series of 
short-chain detergents it suggested that this mutant will make an excellent 
candidate for structural trials. Although time-consuming to make, thermostable 
mutants will likely allow structures of numerous proteins to be solved in the 
future that otherwise would likely to have proved to be intractable.  
 6 Structural studies on Rag23 and sterol 
isomerase  
 
6.1 Introduction 
Having created an optimal expression vector for making fluorescently-tagged 
mammalian membrane proteins in P. pastoris, I now wanted to use it to obtain 
milligram quantities of pure Rag23 and SI for structural studies. Although I could 
have worked on any of the three hA2aR constructs that I had made (Section 5.4) 
I chose to focus on Rag23 as it is the one that I considered most biologically 
interesting. Currently, the only structures of ligand-activated GPCRs in the PDB 
are in the inactive state. The next major challenge for structural biologists is to 
solve the structure of a receptor in an active conformation. Although Rag23 is a 
thermostable mutant, it is considerably less stable than its antagonist equivalent 
Rant21 (Magnani et al., 2008). I was, therefore, interested to know if Rag23 
could be purified to homogeneity in a mild-detergent (such as DDM) without the 
receptor becoming aggregated. As SI is an integral membrane enzyme, it was 
thought that this protein would be significantly more stable than the hA2aR. To 
test this hypothesis, I wanted to determine whether or not wild-type SI could be 
purified to homogeneity while retaining its monodispersity in short- (e.g. DM) as 
well as long-chain detergents (DDM). This Chapter describes my efforts to purify 
and biophysically characterise both Rag23 and SI. In addition, crystallisation 
trials (detergent and lipidic sponge phase) were performed with SI, and the 
results presented.   
6.2 Purification of Rag23 in DDM 
Aα-Rag23-CLBH was produced in fermenter cultures of P. pastoris as described in 
Section 3.5.4. Membranes were isolated according to Section 3.6.3, and 
saturation radioligand binding analysis performed using [3H] NECA (Figure 6.1). A 
 
Structural studies on Rag23 and SI   136 
Bmax value of ca. 26 pmol/mg protein was obtained with a Kd value of ca. 3 µM. 
Accurate Bmax or Kd values for [3H] NECA binding to my Rag23 construct could not 
be obtained as the experimental data suggested that complete receptor 
saturation would require the addition of between 10-50 µM radioligand – this was 
neither practical nor affordable. This result was both disappointing and 
unexpected. The Kd of the original Rag23 construct for [3H] NECA is ca. 21 nM 
(Magnani et al., 2008), displaying two-orders of magnitude higher-affinity for 
NECA than the version I had made. The most likely explanation for the 
difference in pharmacological properties between constructs is that my version 
of Rag23 has a substantial part of IL3 removed, trapping the receptor in a low-
affinity state for NECA. To test this hypothesis, the original Rag23 construct 
(which has its third intracellular loop intact) needs to be cloned into the Aα-
CLBH expression vector and, following transformation, the receptor’s 
pharmacological properties in yeast membranes determined. Unfortunately, due 
to the lack of time, it was not possible to do this.  
 
Figure 6.1 Saturation binding of [3H] NECA to Rag23-CLBH in P. pastoris membranes 
Saturation binding analysis was performed according to Section 3.8.2. The data was fitted using 
GraphPad Prism Software. A Bmax value of ca. 26 pmol/mg protein was obtained with a Kd value of 
ca. 3 µM.
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Even though the Rag23 construct I had made did not have the expected 
pharmacology, I still went onto to purify it. Prior to solubilisation, yeast 
membranes containing Rag23-CLBH were stirred with 100 µM NECA for 1h at 4°C. 
This was to ensure that all of the receptor binding sites were occupied with 
agonist prior to detergent treatment (as it has been previously shown that NECA 
confers an extra 16°C of thermostability on Rag23 in detergent solution (Magnani 
et al., 2008)). The receptor was released from the membranes by treatment 
with DDM. Following centrifugation, the supernatant containing receptor was 
applied to a Ni2+ column. The material that bound was washed with HEPES buffer 
containing 100 mM NaCl and 75 mM imidazole (to remove His rich proteins). It 
was not possible to wash the column with buffer containing a high (e.g. 500 mM) 
salt concentration as NaCl abrogates NECA binding to Rag23 (results not shown). 
Finally, the protein was eluted using 500 mM imidazole. Those fractions that 
were fluorescent (i.e. those containing iLOV tagged receptor) were analysed by 
SDS-PAGE (Figure 6.2). At this stage, Rag23 was only partially pure and it was 
not readily obvious which band corresponded to Rag23-CLBH. In contrast, after 
HT- trunc dG hA2aR - TB had been Ni2+-purified the receptor was largely pure 
with a single band clearly visible at ca. 49 kDa (Figure 4.10). The difference in 
purity of the Rag23 and trunc dG hA2aR constructs following Ni2+-affinity 
purification reflects their relative abundance in yeast membranes (compare 
Figure 6.1 with Figure 4.7). HT – trunc dG hA2aR- TB had an expression level 4-8 
times greater than that of Rag23-CLBH explaining why this receptor construct 
was significantly purer than Rag23 following a single Ni2+-affinity 
chromatography step. An aliquot of partially-purified Rag23-CLBH was analysed 
by FSEC, and a single sharp symmetric peak observed (Figure 6.3). This showed 
that my version of Rag23 was sufficiently stable in the presence of NECA to be 
purified using DDM as detergent.  
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Figure 6.2 SDS-PAGE of Ni2+-affinity purified Rag23-CLBH 
Elution fractions from the Ni2+ column that were fluorescent (i.e. those that contained iLOV-tagged 
Rag23) were analysed by SDS-PAGE. At this stage in the purification process, it was not readily 
obvious which band corresponed to Rag23-CLBH.  
 
Figure 6.3 FSEC elution profile following application of Ni2+-affinity purified Rag23-CLBH to 
a Sepharose C6 gel filtration column 
A single, symmetric fluorescent peak was observed demonstrating that monodisperse Rag23 could 
be purified in the presence of NECA using DDM as detergent. 
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Pooled Rag23-CLBH was desalted to remove the imidazole before it was cleaved 
overnight at 4°C with C3 protease. The following morning, a reverse Ni2+ 
purification step was performed. It was envisaged that when the cleavage 
mixture was applied to the Ni2+ beads the cleaved CLBH tag, the His-tagged C3 
protease as well as all of the contaminant proteins that bound to the original 
Ni2+ column would bind to the beads, leaving largely Rag23 in solution. The 
reverse-purified sample was concentrated and applied to a Sepharose C6 gel-
filtration column. The peak fraction from the gel filtration column was run on a 
gel and a single faint band at ca. 26 kDa was observed (Figure 6.4), consistent 
with the receptor’s MW (32.8 kDa). If time had allowed, the band thought to 
contain Rag23 would have been cut out from the gel and sent for analysis by 
tandem mass spectrometry (MS-MS) to unequivocally identify the purified 
protein. 
 
Figure 6.4 SDS-PAGE of pure Rag23 
Following treatment of partially-purified Rag23-CLBH (Figure 6.2) with C3 protease, the sample 
was reverse-purified using Ni2+ beads. The supernatant containing Rag23 was concentrated and 
applied to a Sepharose C6 gel-filtration column. The peak elution fraction was analysed by SDS-
PAGE and a single faint band at ca. 26 kDa corresponding to Rag23 was observed.  
Here, it has been shown that conformationally-fixed GPCR mutants that 
preferentially binds agonists (such as Rag23) can be purified to homogeneity 
with monodispersity as long as they are sufficiently thermostable to prevent 
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aggregation in detergent solution. If time had allowed, I would have liked to 
have repeated this purification using the shorter chain detergent DM. If 
monodisperse Rag23 could be purified in DM, it would significantly increase the 
exposed polar surface area of the receptor available for making lattice contacts, 
potentially allowing the formation of ordered protein crystals from detergent 
solution. However, the results in this Section also highlight the need to perform 
rigorous functional analysis of any mutants that are made for structural studies.  
6.3 Large-scale production of SI 
The A-SI-CLBH vector (Section ?) was introduced into the P. pastoris expression 
strain X33 by electroporation. Transformants were selected by growing the yeast 
on plates containing zeocin. Twelve colonies were grown up in 1 ml cultures of 
BMGY (basal media) overnight at 30°C. The following morning, the BMGY was 
replaced with 1ml of BMMY (induction media), and the cultures left for 24 h at 
22°C. The production level of SI for each clone was determined by measuring 
the amount of LOV fluorescence (FU) (emitted by whole cells) per milligram of 
protein (following chemical cell lysis) (Figure 6.5). Of the twelve colonies 
tested, one did not grow. In the eleven which did grow, a 2.5 fold difference in 
the SI production level was observed between transformants (Figure 6.5). As the 
expression levels seen for individual SI clones were considerably higher than 
those seen for native hA2aR (an increase in fluorescence of 1.2 to 8-fold for the 
same amount of protein measured) (compare Figure 6.5 to Figure 5.9), it 
suggested that wild-type SI was more stable than the receptor, and may make a 
good target for structural studies. The transformant making the highest levels of 
SI was retained for subsequent experiments. 
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Figure 6.5 Production of sterol isomerase in different P. pastoris transformants 
Twelve transformants were grown for 24h in BMGY at 30°C followed by another 24h in BMMY at 
22°C. SI expression levels for the eleven colonies that grew were determined by measuring the 
amount of LOV fluorescence (FU) (emitted by whole cells) per milligram of protein (following 
chemical cell lysis). A 2.5 fold difference in the SI production level was observed between 
transformants. 
Next, the SI clone that had been selected was grown in fermenter culture 
according to the protocol that had been optimised for the hA2aR. Samples were 
taken at selected time-points throughout the fermentation to determine both 
the culture’s biomass (by measuring wet cell weight) and the SI expression level 
(by measuring iLOV fluorescence from whole cells) (Figure 6.6). Biomass levels 
of ca. 300 g wet weight of cells per litre of culture were obtained, similar to 
that observed in hA2aR fermentations. Maximal SI expression levels were in the 
range 1 x 107 fluorescence units per milligram of cellular protein (Figure 6.6). 
This compares with 8 x 106 FU/mg observed for both Rant21 and Rag23 (Figure 
5.11).  
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Figure 6.6 Time-course of sterol isomerase expression in fermenter culture 
SI-CLBH was made in fermenter culture using the optimised protocol developed for hA2aR 
production. Wet cell weight and SI expression levels were determined at regular intervals. 
Typically, biomass levels of ca. 300g wet weight of cells per litre of culture were obtained with SI 
expression levels in the region of 1 x 107 fluorescence units per milligram of protein. 
 
6.4 Purification of SI in DDM using HEPES buffer 
Membranes containing SI-CLBH were prepared from yeast cells grown in 
fermenter culture (Section 3.6.3). The membranes were re-suspended in HEPES-
buffer pH 7.4 and then solubilised with DDM. Following centrifugation, the 
supernatant fraction (containing SI) was applied to a Ni2+ column where the SI 
bound to it via its His10 tag. Contaminant proteins were removed from the 
column by washing it with HEPES buffer containing 500 mM NaCl (to remove 
those contaminant proteins that bound to the Ni2+ resin via ionic interactions) 
and 75 mM imidazole. SI-CLBH was eluted from the column using an imidazole 
gradient (Figure 6.7). Those fractions containing SI-CLBH (as determined by 
measuring iLOV fluorescence) were analysed by SDS-PAGE to determine how 
pure the sample was after this purification step (Figure 6.8). The gel showed 
that the SI-CLBH was largely pure at this stage with a major band clearly visible 
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at ca. 44 kDa (SI-CLBH has a predicted MW of 45 kDa). The SI-CLBH expression 
level was so high that it essentially prevented any contaminant host proteins 
from binding to the Ni2+ column, explaining why it was largely pure following a 
single chromatographic step.  
 
Figure 6.7 Elution of SI-CLBH from a Ni2+ column using an imidazole gradient 
When detergent-solubilised membranes were passed over a Ni2+ column the recombinant SI-CLBH 
bound to the Ni2+ resin via its His10 tag. After the column had been washed, SI-CLBH was eluted 
from the column using a 0-1M imidazole gradient. A single, fluorescent peak corresponding to SI-
CLBH was released by ca. 500 mM imidazole. 
 
Figure 6.8 SDS-PAGE of partially purified SI-CLBH 
Peak fractions eluted from the Ni2+ column (Figure 6.7) were analysed by SDS-PAGE to determine 
the purity of the SI-CLBH. A major band at ca. 44 kDa (corresponding to SI-CLBH) can be clearly 
observed in all of the fractions. The gel showed that SI-CLBH was largely pure following application 
to the Ni2+ column.  
The enriched SI-CLBH sample was desalted before it was cleaved overnight with 
C3 protease. The sample was reverse purified the following day using Ni2+ beads, 
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concentrated to a volume of 0.5 ml and then applied to a Sepharose C6 gel 
filtration column. The elution profile only contained a single large symmetrical 
peak (Figure 6.9), demonstrating that SI was both pure and monodisperse in DDM 
making it useful for structural studies. Fractions across the elution peak were 
analysed by SDS-PAGE (Figure 6.10). The gel showed there was a single band 
with a molecular weight of ca. 22 kDa in all of the fractions tested. As SI has a 
predicted MW of 26.2 kDa, it was likely that the band contained SI. To confirm 
this possibility the protein band was excised and analysed by MS-MS. Peptide 
MTTNAGPLHPYWPQHLRL corresponding to αα 1-18 of SI was detected, 
confirming the identity of the purified protein. 
 
Figure 6.9 Elution profile of pure SI in DDM from a Sepharose C6 gel filtration column 
Following reverse-purification with Ni2+ beads, the SI-containing sample was concentrated and 
applied to the gel-filtration column. The buffer was 10 mM HEPES pH 7.4 containing 10% glycerol 
and 0.05% DDM. A single symmetric peak was observed showing that the purified SI was 
monodisperse. Fractions across the peak were analysed by SDS-PAGE (Figure 6.10)  
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Figure 6.10 SDS-PAGE analysis of SI-containing gel-filtration fractions 
Aliquots of the fractions from the gel-filtraton peak were analysed by SDS-PAGE. In all of the lanes, 
a strong band of ca. 22 kDa was observed suggesting that it was SI (actual MW 26.2 kDa). This 
band was cut-out and sent for MS-MS analysis. A peptide of MTTNAGPLHPYWPQHLRL was 
identified corresponding to αα 1 - 18  of SI confirming the identify of the purified protein. A further 
faint band could be seen at ca. 40 kDa which appears to be an SDS-induced dimer, as only one 
protein peak was observed by SEC. 
6.5 Secondary structure determination by circular 
dichroism 
Circular dichroism (CD) refers to the differential absorption of left- and right-
handed polarised light by chiral molecules (Kelly et al., 2005). CD signals only 
occur at those wavelengths where the asymmetric molecule absorbs. All proteins 
have several chromophores that absorb in the ultra-violet (UV) region of the 
electromagnetic spectrum including peptide bonds (which absorb between 180 
and 240 nm), aromatic amino acids (260 to 320 nm) and disulphide bonds (which 
have weak broad absorption bands around 260 nm).  
The different kinds of secondary structure (e.g. α-helix, β-sheet) that occur in 
proteins have characteristic CD spectra in the far UV (which arise from the chiral 
arrangement of the peptide bonds in each structure). A number of algorithms 
(e.g. SELCON (Sreerama and Woody, 1993), VARSLC (Manavalan and Johnson, 
1987), CDSSTR (Johnson, 1999) and CONTIN (Provencher and Glockner, 1981)) 
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have been developed that provide an estimation of a protein’s secondary 
structure composition from its far-UV CD spectra.  
Proteins also have measurable CD in the near-UV (260–320 nm) arising from its 
constituent aromatic amino acids (Trp, Tyr, Phe). The actual shape and 
magnitude of the near-UV CD spectrum for each protein depends on the number 
of each type of aromatic amino acid present, their mobility, their environment 
(H-bonding, polar groups and polarisability) as well as their position within the 
protein. The near UV-CD spectrum of a protein provides a valuable fingerprint of 
its tertiary structure, and can be used to compare, for example, the structural 
similarity of wild-type and mutant forms of the protein. 
Here, the far- and near-UV CD spectra of SI are presented. 
6.5.1 CD analysis of SI 
The near-UV CD spectrum (region 250-320 nm) of purified SI was recorded and 
found to consist of a series of peaks and troughs with maxima at 256, 265, 277 & 
291 nm and minima at 262, 270, 282 & 296, respectively (Figure 6.11 (A)). The 
secondary structure composition of SI was determined by recording a far-UV CD 
spectrum (region 190–260 nm) (Figure 6.11 (B)), and then fitting it using the 
CDSSTR alogorithm (Johnson, 1999). From this, the secondary structure content 
of SI was estimated to be 31 % α-helix, 26 % β-sheet, 23 % turn with 20 % of the 
protein disordered. This prediction suggests that SI is largely ordered (consistent 
with its catalytic function) and probably has transmembrane α-helices.  
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Figure 6.11 CD spectra of SI in the (A) near- and (B) far-UV 
The near-UV CD spectrum consists of a series of peaks and troughs with maxima at 256, 265, 277 
& 291 nm and minima at 262, 270, 282 & 296, respectively. On fitting the far-UV CD spectrum with 
the CDSSTR alogorithm (Johnson, 1999) the secondary structure content of SI was estimated to 
be 31 % α-helix, 26 % β-sheet, 23 % turn with 20 % of the protein disordered. 
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6.6 Assessing and maximising the thermostability of SI 
in detergent solution 
Removal of membrane proteins from their native lipid environment with 
detergent confers, to a greater or lesser extent, instability on them. 
Furthermore, as it can take weeks or even months for protein crystals to grow it 
is essential that the membrane protein has long-term stability in detergent 
solution. The stability of all membrane proteins in aqueous solution are affected 
by a range of factors including the buffer type as well as its pH, the ionic 
composition and strength of the buffer as well as the type of detergent used. 
Therefore, considerable effort needs to be invested for each protein of interest 
to find the conditions in which it is most stable. Through accomplishing this, it 
may be possible to purify the target protein in a short chain detergent increasing 
the probability of getting diffracting protein crystals. In Chapter 5, the effects of 
choice of detergent on hA2aR and hSI stability immediately following membrane 
solubilisation were investigated by FSEC. Although buffer and salt effects on MP 
stability can be assessed by FSEC too, this method is incredibly time consuming. 
An alternative approach involves purifying the target MP to homogeneity in a 
mild-detergent (such as DDM), and then measuring the thermostability of the 
protein in a range of buffer/salt conditions. The stability of any protein can be 
thought of in terms of its resistance to denaturation. Those proteins that are 
unstable denature easily whereas those that are stable require harsher 
conditions (e.g. high temperatures) before they start to unfold. Here, two 
methods (CD, CPM assay) for studying protein unfolding were explored with a 
view to finding those conditions that gave maximum SI thermostability in 
detergent solution. 
6.6.1 Investigating SI thermostability by circular dichroism 
CD can be used to study how a protein’s secondary structure changes with 
temperature giving insights into its thermostability. Here, a thermal 
denaturation of SI in 10 mM HEPES pH 7.5, 150 mM NaCl, 0.05% DDM was 
performed. The far-UV CD spectrum of SI was recorded at regular intervals 
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between 5 and 80°C (Figure 6.12 (A)). As the temperature increased, SI became 
partially denatured with a decrease in the minima peak intensities at both 209 
and 222 nm. This said, SI largely retained its near-UV CD profile even after 
heating to 80°C showing that even at this high temperature only ca. 30% of the 
total secondary structure had become lost (Figure 6.12 (B-C)). As it was not 
possible to remove all of the protein’s secondary structure by thermal 
denaturation, this assay was considered to be too insensitive for screening the 
effects of different buffers and salts on SI stability.  
(A) 
 
(B) 
 
(C) 
 
Figure 6.12 Thermal denaturation of SI assessed by circular dichroism  
(A) Change in the far-UV CD spectrum of SI over the temperature range 5 - 80°C. The extent of SI 
secondary structure remaining following heat denaturation was determined by measuring the size 
of the CD signal at (B) 209 and (C) 222 nm. 
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6.6.2 Using the CPM fluorophore to assess SI protein stability 
A sensitive fluorescence-based (CPM) thermal stability assay that can be used 
with MPs has recently been described by Ray Stevens and co-workers 
(Alexandrov et al., 2008). In this assay, reaction of a protein’s solvent-exposed 
cysteine residues with the thiol-specific fluorochrome N-[4-(7-diethylamino-4-
methyl-3-coumarinyl)phenyl]maleimide (CPM) results in the generation of a 
fluorescent signal. When a protein is thermally denatured in the presence of 
CPM as the cysteine residues located in the protein interior became solvent-
exposed an increase in CPM fluorescence intensity occurs over time. By altering 
the assay conditions (e.g. different buffers - types and pH; salts - types and 
concentrations; addition of specific ligands) in which the thermal denaturations 
are carried out it is possible to identify those reagents that confer 
thermostability on the target protein. This assay can be readily-adapted for use 
with 96-well plates allowing numerous conditions to be rapidly assessed. Another 
advantage of this assay is that it consumes relatively small amounts (1-10 µg) of 
protein as compared to CD measurements (which require several 100 µgs).  Here, 
the CPM assay was used to identify the optimal buffer and salt conditions that 
conferred maximal stability on SI. 
The approach of Alexandrov et al. (Alexandrov et al., 2008) was modified so that 
SI was denatured in the presence of SDS (to enhance the rate of unfolding) at a 
constant temperature of 45°C. Initial experiments were performed to determine 
the amount of SI that needed to be added to each assay to give measurable 
amounts of fluorescence (5 µg) as well as the length of time necessary for 
maximal unfolding to occur (2.5 h) (results not shown). Initial experiments were 
performed denaturing SI in the presence of different (50, 100, 150 and 200 mM) 
concentrations of NaCl (Figure 6.13). The amount of fluorescence due to the 
unfolding of SI was determined by subtracting the background fluorescence in a 
buffer control from that measured in the presence of protein. For each 
condition, the protein and buffer measurements were made in quadruplicate. 
For all four NaCl conditions, the amount of specific CPM fluorescence increased 
with time (Figure 6.13). The amount of fluorescence at t = 8000 s for each 
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condition was plotted in a bar chart (Figure 6.14A). This value is a measure of 
how much SI had become unfolded during the course of the assay. The higher 
the fluorescence, the more SI had become unfolded. The results showed that the 
amount of denatured SI progressively increased with the concentration of NaCl. 
From this, it was concluded that SI becomes less stable with increasing 
concentrations of NaCl. 
 
Figure 6.13 The unfolding of SI in the presence of different concentrations of NaCl  
The extent of SI denaturation was determined by reaction with the CPM reagent (which labeled 
solvent-exposed cysteine residues). As the protein unfolded, cysteines from the inner core became 
accessible to the fluorochrome resulting in an increase in fluorescence with time. 
This approach was used with a range of different salts and buffers (Figure 6.14-
16). To compare the effects of Na+, K+, Mg2+, Ca2+ and NH4+ ions on SI stability, 
CPM denaturation assays were performed in the presence of four different 
concentrations (50, 100, 150, 200 mM) of their chloride salt (Figure 6.14 A-C). 
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The trends obtained suggested that in terms of their effect on SI stability NH4+ > 
Na+ > K+ and that Mg2+ > Ca2+. The effects of anions on SI stability were 
investigated in a similar way (Figure 6.14 C-D). The results showed that Cl-, SO42- 
and NO3- have similar effects on SI stability. However, PO43- appeared to potently 
stabilise SI (Figure 6.14 D). NH4+ and PO43- are known to promote hydrophobic 
interactions within proteins, and it is likely that these ions stabilise SI by 
strengthening existing hydrophobic contacts (most likely in the transmembrane 
region of the protein) within SI.   
 
Figure 6.14 The effect of a range of salts on SI thermostability 
SI was denatured in the presence of the CPM reagent. The ability of different ions to stabilise SI 
was assessed by measuring the specific increase in CPM fluorescence at the end of the thermal 
unfold. Those ions that gave the smallest rises in fluorescence (e.g. NH4+ and PO43-) over the 
course of the assay had the greatest ability to stabilise SI in detergent solution.   
To determine whether phosphate itself was stabilising SI or was having an 
indirect pH effect, further SI thermostability assays were performed in a series 
of phosphate buffers that had different pH (range 4 – 9) (Figure 6.15).  A clear 
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trend was observed with greatest SI thermostability observed at pH 4. As the pH 
of the phosphate buffer increased more SI denaturation occurred. The effect of 
pH on SI stability was further investigated by performing a series of denaturation 
assays in four different buffers (MES, MOPS, HEPES, Tris) over the pH range 5.5 
to 8 (Figure 6.16 (A)). Similar to that observed in phosphate buffer, SI had 
greater thermostability at acidic than alkali pH. Lastly, the effect of selected 
transition metal ions on SI stability was investigated (Figure 6.16 (B)). Zn2+, Cu2+, 
Ni2+ and Co2+ were all found to stabilise SI.  
 
Figure 6.15 Effect of the pH of phosphate buffer on SI thermostability 
The thermostability of SI was pH-dependent. SI was most stable at pH 4. As the pH of the 
phosphate buffer increased more SI became denatured. 
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Figure 6.16 The effect of (A) pH and (B) the addition of transition metals on SI 
thermostability 
Similar to that observed in phosphate buffer (Figure 6.15), SI had greater thermostability at acidic 
than alkali pH. The transition metal ions Zn2+, Cu2+, Ni2+ and Co2+ were all found to stabilise SI. 
6.7 Purification of SI in DM using a phosphate-based 
buffer 
SI stability in detergent solution is clearly dependent on the choice of buffer 
used as well as its ionic content (Section 6.6). Using the information from the 
CPM denaturation assays, I set-out to develop a purification protocol that would 
give monodisperse SI in the short-chain detergent DM. SI is more stable at acidic 
than alkali pH. However, the efficiency of SI release from the membrane on 
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detergent solubilisation decreased dramatically at pH <7 (results not shown). 
Furthermore, His tag binding to a Ni2+ column is pH-dependent with the strength 
of interaction between the transition metal and the tag increasing as the buffer 
becomes more alkali. Using all of this information, a protocol based on a sodium 
phosphate buffer was devised in which the Ni2+ affinity, C3 cleavage and 
reverse-purification steps were performed at pH 7.5, and the gel-filtration step 
performed at pH 6. Under these conditions, pure, monodisperse SI in DM could 
be obtained (Figure 6.17). It was hoped that this protein would prove amenable 
to crystallisation.   
 
Figure 6.17 Elution of pure SI from the Sepharose C6 gel-filtration column equilibrated in 
sodium phosphate/DM buffer 
A protocol for purifying SI using a sodium phosphate buffer was devised in which the Ni2+ affinity, 
C3 cleavage and reverse-purification steps were performed at pH 7.5, and the gel-filtration step 
performed at pH 6. Under these conditions, pure, monodisperse SI in DM could be obtained. 
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6.8 Crystallisation of SI from detergent solution  
As SI could be purified to homogeneity with monodispersity (in both DDM and 
DM), it was thought that this enzyme would make a good candidate for 
crystallisation trials using conventional techniques. Initial screening with SI was 
performed using protein that had been purified in HEPES buffer pH 7.4 
containing DDM (Section 6.4). 500 nl of 20 mg/ml protein was pipetted into each 
of the drops in a 96 well plate using a Cartesian robot along with an equal 
volume of the reservoir solution from the Peg/Ion and MemSys/MemStart sparse 
matrix crystallisation screens. The plates were incubated in a Rhombix imager at 
20°C for 3 months with regular photographs taken (daily for the first week, 
weekly thereafter) to record crystal growth or precipitation formation. In 
several conditions, detergent crystals formed (Figure 6.18 (A)). Disappointingly, 
no protein crystals were observed. A possible explanation for this is that the 
DDM micelle is so big that not enough (and perhaps none) of the polar surface 
area of SI is exposed to form lattice contacts. To address this problem, I set-up a 
crystal tray (MemGold) with SI that had been purified in sodium phosphate 
buffer (pH 6) containing DM (Section 6.7). To reduce the number of detergent 
crystals that formed, a micro-dialysis step was introduced immediately prior to 
setting up trays in order to reduce the detergent’s concentration to just above 
its CMC. Although this helped to substantially reduce the number of detergent 
crystals formed (results not shown), no wells were found to contain diffracting 
protein crystals. Several conditions contained phosphate salt crystals (Figure 
6.18 (B)). Many wells contained light protein precipitate (Figure 6.18 (C)) which, 
given sufficient time and protein for optimisation, may in the future lead to the 
formation of small protein crystals.  
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(A) 
 
(B) 
  
(C) 
 
Figure 6.18 Efforts to crystallise SI in detergent solution 
(A) Initial attempts to crystallise SI in HEPES buffer containing DDM resulted in the formation of 
numerous detergent crystals. This problem was overcome by performing a micro-dialysis step 
immediately prior to setting up trays that ensured that the detergent concentration in the SI sample 
was just above its CMC. At a later stage, SI that had been purified in sodium phosphate buffer 
containing DM was used with the MemGold screen but no diffracting protein crystals were 
obtained. Several conditions did contain phosphate crystals (B). Many wells contained light protein 
precipitate (C) which, given sufficient time and protein for optimisation, may in the future lead to the 
formation of protein crystals. 
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6.9 Development of a cholesterol-doped sparse matrix 
lipidic-sponge phase crystallisation screen 
The recent structures of the human β2-adrenergic and adenosine 2a receptors 
were solved using crystals grown from cholesterol-containing lipidic cubic phases 
(Cherezov et al., 2007; Jaakola et al., 2008). However, due to difficulties in 
handling the cubic phase as well as restrictions on the range of MPs that can be 
used with the cubic phase (due to the relatively small water pores in the lipid 
matrix) the more fluid ‘sponge’ phase has become of interest to the membrane 
protein structural community. While work with lipidic sponge phases is still in its 
infancy they have already been used to obtain diffracting crystals of the purple 
bacterial photosynthetic reaction centre (Wohri et al., 2009). At the outset of 
my Ph.D. there was not a commercially-available lipidic sponge phase 
crystallisation screen.  Recently, however, the group of Richard Neutze 
(Chalmers University, Sweden) have devised such a screen (in which I played a 
small part in helping to develop) (Wohri et al., 2008). I have shown that up to 
10% cholesterol can be incorporated into lipidic sponge phases (results not 
shown). Here, I describe my own version of the the Neutze screen consisting of a 
series of cholesterol-doped sponges. 
The conditions used to make the cholesterol containing sponge phase screen 
were largely the same as that reported in (Wohri et al., 2008), and all contained 
the lipid mono-olein (MO) (Figure 6.19). Cholesterol-containing versions of the 
jeffamine sponges detailed in (Wohri et al., 2008) were not made. Similar to the 
Neutze sponge phase screen, three buffers (HEPES, MES and Tris) and three salts 
(NaCl, MgCl2, and Li2SO4) were used all at a concentration of 100 mM. The pH of 
the buffers ranged between 6.5 and 9. It was not possible to use buffers with 
strongly acidic pH as the MO ester bond is extrememly sensitive to hydrolysis 
(Engstrom et al., 2007). Cholesterol was mixed with the MO prior to sponge 
phase formation to ensure that the sterol was completely incorporated within 
the lipid matrix. Sponge phases were created as described in (Wohri et al., 2008) 
using cholesterol-doped MO for all conditions. Sponge phases were made that 
had two different concentrations of cholesterol (0.5 and 5 % (w/w)) to increase 
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the diversity of the screen. The complete cholesterol-doped sponge phase 
screen is listed in Table 6.1. PEG 400 and PEG 1500 were chosen to form the 
sponge-phases as they both have cryo-protectant properties which means that 
any protein crystals formed in any of the conditions can be directly transfered 
from the drop to the X-ray beam. Similar to that for detergent-based 
crystallisation screens, any crystals obtained using the sponge-phase screen will 
likely need optimised to improve their packing before crystals that diffract to 
high-resolution are obtained. 
 
Figure 6.19 Chemical structure of mono-olein 
 
6.10 Crystallisation of SI in the lipidic-sponge phase 
As the cholesterol-doped sponge phases described in Section 6.9 closely mimic 
mammalian membranes they should prove useful for crystallising a wide-range of 
human MPs. Here, I used the lipidic-sponge screen with SI to try to identify 
conditions that might yield diffracting crystals. 
SI that had been purified in sodium phosphate buffer containing DM was dialysed 
to remove excess detergent and then concentrated to 10 mg/ml. Hanging drop 
crystallisation trays were set-up in which 1 µl of the protein solution was 
directly added to 1 µl of one of the cholesterol-containing sponges. In addition, 
a buffer control was set-up for each sponge to give confidence that any crystals 
observed in the protein drops did indeed come from the protein and not from 
any of the chemicals present in either the buffer solution or sponge itself. The  
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Condition PEG % % MO % pH Buffer Salt 1 Salt 2 
    cholesterol  (100 mM) (100 mM) (100 mM) 
1 400 40 30 5 6.5 MES   
2 400 40 30 5 6.5 MES NaCl Li2SO4 
3 400 40 30 5 6.5 MES NaCl MgCl2 
4 400 40 30 5 7.5 HEPES NaCl Li2SO4 
5 400 40 30 5 7.5 HEPES   
6 400 40 30 5 7.5 HEPES NaCl MgCl2 
7 400 40 30 5 8.5 HEPES   
8 400 40 30 5 8.5 HEPES NaCl MgCl2 
9 400 40 30 5 8.5 HEPES NaCl Li2SO4 
10 400 40 30 5 9.0 TRIS   
11 400 40 30 5 9.0 TRIS NaCl MgCl2 
12 400 40 30 5 9.0 TRIS NaCl Li2SO4 
13 400 40 30 0.5 6.5 MES   
14 400 40 30 0.5 6.5 MES NaCl Li2SO4 
15 400 30 40 0.5 7.5 HEPES   
16 400 30 40 0.5 7.5 HEPES NaCl Li2SO4 
17 400 40 30 0.5 7.5 HEPES   
18 400 40 30 0.5 7.5 HEPES NaCl MgCl2 
19 400 40 30 0.5 8.5 HEPES   
20 400 40 30 0.5 8.5 HEPES NaCl MgCl2 
21 400 40 30 0.5 8.5 HEPES NaCl Li2SO4 
22 400 40 30 0.5 9.0 TRIS   
23 400 40 30 0.5 9.0 TRIS NaCl MgCl2 
24 400 40 30 0.5 9.0 TRIS NaCl Li2SO4 
25 1500 40 30 5 6.5 MES   
26 1500 40 30 5 6.5 MES NaCl Li2SO4 
27 1500 40 30 5 6.5 MES NaCl MgCl2 
28 1500 40 30 5 7.5 HEPES   
29 1500 40 30 5 7.5 HEPES NaCl Li2SO4 
30 1500 40 30 5 7.5 HEPES NaCl MgCl2 
31 1500 40 30 5 8.5 HEPES   
32 1500 40 30 5 8.5 HEPES NaCl MgCl2 
33 1500 40 30 5 7.0 TRIS   
34 1500 40 30 5 8.0 TRIS   
35 1500 40 30 5 7.5 TRIS   
36 1500 40 30 5 9.0 TRIS   
37 1500 40 30 0.5 6.5 MES   
38 1500 40 30 0.5 6.5 MES NaCl Li2SO4 
39 1500 30 30 0.5 6.5 MES NaCl MgCl2 
40 1500 30 30 0.5 7.5 HEPES   
41 1500 40 30 0.5 7.5 HEPES NaCl Li2SO4 
42 1500 40 30 0.5 7.5 HEPES NaCl MgCl2 
43 1500 40 30 0.5 8.5 HEPES   
44 1500 40 30 0.5 8.5 HEPES NaCl MgCl2 
45 1500 40 30 0.5 7.0 TRIS   
46 1500 40 30 0.5 8.0 TRIS   
47 1500 40 30 0.5 7.5 TRIS   
48 1500 40 30 0.5 9.0 TRIS   
Table 6.1 A cholesterol-containing sponge phase crystallisation screen for use with 
mammalian membrane proteins 
 
 
Structural studies on Rag23 and SI   161 
trays were sealed and stored at 20°C for one month. Due to the size of the 
crystallisation trays and the drops themselves, all visualisation events were 
performed manually using a microscope. Those conditions thought to be 
interesting were photographed. After one month most wells showed some 
protein precipitation over the sponge background (Figure 6.20 (A)). In certain 
conditions small crystalline material was observed (Figure 6.20 (B)). Due to time 
limitations, however, it was not possible to test the crystalline matter in our in-
house X-ray facility. The preliminary results presented here do suggest that the 
cholesterol-doped sponge-phase screen will prove to be a useful addition to the 
range of existing crystallisation screens currently used with mammalian 
membrane proteins.  
 
Figure 6.20 Efforts to crystallise SI using cholesterol-doped lipidic sponges 
(A) Image of sponge matrix containing protein. (B) Crystalline material in condition 5 (40% 
PEG400, 30% mono-olein, 5% cholesterol, HEPES pH 7.5) of the sponge-phase screen was 
observed along the perimeter of the sponge drop.  
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6.11 Conclusion 
This chapter shows that CLBH-tagged recombinant mammalian MPs (both Nin and 
Nout) can be purified to homogeneity in four simple steps (Ni2+-affinity 
purification; cleavage with C3 protease; desalt and reverse-purification with Ni2+ 
beads; gel-filtration). This vector system should be compatible for use with 
other mammalian MPs including type I GPCRs, membrane enzymes, transporters 
and ion channels. 
My work on Rag23 highlights the need to perform thorough functional assays on 
any mutants made for structural studies to ensure that the mutations which have 
been made do not affect the activity of the target protein. The IL3 deletion that 
I made in Rag23 was introduced to reduce the amount of disorder within the 
receptor. However, in making this deletion, I made a mutant that had low-
affinity for agonist most likely by trapping the modified receptor in a closed 
state. This was unfortunate, and prevented me from doing large-scale protein 
preparations for biophysical characterisation and structural studies.  
Sterol isomerase is an incredibly stable enzyme for a wild-type mammalian MP. 
Using information obtained from denaturation assays using the CPM reagent it 
was possible to devise a purification protocol in which monodisperse SI was 
obtained in the short-chain detergent DM using sodium phosphate as buffer. The 
power of the CPM assay is the detailed insights it is able to give on the buffer 
(both type and pH) and salt preferences of MPs in detergent solution. The 
approach I used to identify the conditions that gave maximum SI thermostability 
in detergent solution will be useful with other mammalian MPs. Whether or not 
it is possible to get diffracting crystals of SI in sodium phosphate/DM buffer 
remains to be seen.  
Finally, a cholesterol-doped lipidic-sponge phase sparse matrix crystallisation 
screen was created that was tested with SI. While some crystalline material was 
observed, time limitations prevented me from doing any X-ray analysis and 
crystal optimisation. However, the preliminary results obtained suggest that the 
screen may be useful for growing diffracting crystals of mammalian MPs.
 7 Discussion and future perspectives 
Solving the structure of a human membrane protein is a massive challenge as 
evidenced by the small (<20) number of structures that have been deposited in 
the PDB to date. Given the biological and pharmaceutical importance of many 
human MPs, there is currently a substantial effort within the structural biology 
community to find technologies that will overcome the existing bottlenecks in 
solving the structures of mammalian MPs. Unlike their bacterial equivalents (of 
which there are several hundred unique structures in the PDB), most human 
membrane proteins are intrinsically unstable in detergent solution. This means 
that there is an urgent need to develop new technologies: i) that allow the most 
stabilising detergent for each human MP to be readily identified, ii) for 
optimising buffer conditions to ensure maximal thermostability of each MP in 
detergent solution, iii) such as novel detergents and lipids that effectively 
stabilise mammalian MPs once they have been removed from the membrane, and 
iv) that allow mammalian MPs to be crystallised in a lipid environment. 
Furthermore, simple generic systems that allow the overproduction and 
purification of milligram amounts of a range of human MPs for crystallisation 
trials are required. Over the course of my Ph.D., I have developed a series of 
novel technologies that have sought to address some of these bottleneck issues.  
The CLBH vector system developed here allowed the successful over-expression 
and purification of both a conformationally-flexible (hA2aR) and a rigid-bodied 
(hSI) human membrane protein. Two versions of the CLBH expression vector 
were made – one with an upstream α-factor (that should be used for 
recombinant MPs with a Nout topology (such as the hA2aR)) and one without (that 
should be used with MPs that have a Nin orientation (such as hSI)). The CLBH 
vectors allowed both target proteins to be purified to homogeneity in four 
simple steps (Ni2+-affinity purification; cleavage with C3 protease; desalt and 
reverse purification with Ni2+ beads; gel-filtration). Any recombinant protein 
made using the CLBH system can be purified in the same way. In fact, the 
vectors have already been used in our laboratory to obtain milligram amounts of 
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the plant photoreceptor UVR8, adrenodoxin and the cytochrome p450 enzyme 
aldosterone synthase (Niall Fraser, personal communication).  
The iLOV fluorescent reporter protein was shown to be a useful tool for 
optimising laborious processes such as yeast clonal selection, protein production 
in fermenter culture, detergent and construct screening as well as for tracking 
protein purification, saving both time and energy. iLOV could also be used to 
assess the monodispersity of MPs in detergent solution by FSEC. Using this 
approach, it was shown that the cholesterol derivative CHS (which confers 
radioligand binding capacity on the hA2aR in detergent solution) promotes 
receptor aggregation during purification. Furthermore, iLOV was used to show 
that monodisperse Rag23 can be obtained in the short-chain detergent βOG 
immediately post-solubilisation. Such insights were only realised by measuring 
fluorescence from the iLOV tag. In contrast to GFP, when iLOV becomes 
denatured the co-factor flavin is released. This appears as a “late” peak on 
certain of the FSEC profiles. The size of the flavin peak gave a direct measure of 
the amount of target protein denaturation that had occurred on treating the 
membranes with detergent. The presence of a large flavin peak in a FSEC 
experiment (following either detergent-solubilisation or -exchange) shows that 
the target protein is unstable in the chosen detergent whereas the absence of a 
flavin peak suggests that the iLOV-tagged MP is stable. By monitoring the free-
flavin content of iLOV-tagged MPs in detergent solution by FSEC it is possible to 
readily identify those detergents in which the MP is unstable. One disadvantage 
of iLOV compared to GFP is that it is not compatible with in-gel fluorescence 
experiments. As fluorescence from the iLOV chromophore comes from the flavin 
co-factor, when iLOV tagged receptor is treated with SDS, the iLOV domain 
denatures rendering it non-fluorescent. This means that iLOV-tagged proteins on 
a SDS-PAGE cannot be visualised by placing it under a UV-source. This is 
different from GFP-tagged proteins which retain their structure and fluorescence 
even after treatment with SDS (Drew et al., 2006). 
Attachment of the biotin acceptor domain to the C-terminus of the hA2aR 
increased the receptor’s expression level by ca. 2-4 fold. Similar effects have 
been observed previously when this domain was fused to other type I GPCRs 
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made in P. pastoris (Grunewald et al., 2004; Lundström et al., 2006; Andre et 
al., 2006). It appears likely, therefore, that attachment of this domain to the C-
terminus of other MPs will increase their production levels in P. pastoris also. 
Increased expression helps to reduce the detergent costs associated with making 
large quantities of protein through reducing the volume of membranes required 
for solubilisation. Moreover, fusion of the biotin acceptor domain to MPs that 
express poorly by themselves in P. pastoris may help to make certain projects 
viable that otherwise would remain impossible. The biotin acceptor domain can 
also be biotinylated in vitro by treatment with recombinant biotin ligase. This 
then allows the target MP to be immobilised using (strept)avidin resin. This is an 
elegant feature of the expression vector, and is compatible not only with 
purifying low-abundance MPs but also with drug design techniques such as 
surface Plasmon resonance (SPR) or target immobilized NMR screening (TINS) 
(Vanwetswinkel et al., 2005) where the protein of interest has to be immobilised 
prior to use with molecular and/or fragment libraries. 
A considerable amount of time was spent developing an optimised P. pastoris 
fermentation protocol for make recombinant MPs at an induction temperature of 
22°C. The developed methodology allowed both the hA2aR and hSI to be made 
with a production level >10 mg protein per litre of culture (which is more than 
sufficient for structure-determination experiments by way of X-ray 
crystallography). However, the protein produced could equally be used in 
nuclear magnetic resonance (NMR) experiments. NMR is an excellent structural 
approach that gives information regarding protein motion at the molecular level 
complementary to that obtained from X-ray crystallography (which gives highly-
detailed information on the three-dimensional structures of proteins trapped in 
particular conformations). Several MPs have had their structures solved by NMR 
most of which have been of bacterial origin (e.g. Arora et al., 2001; Yu et al., 
2005; van Horn et al., 2009). Notably exceptions include archael sensory 
rhodopsin II (Gautier et al., 2010) and human VDAC-1 (Hiller et al., 2008; 
Bayrhuber et al., 2008). One of the major bottlenecks that has prevented the 
wide-spread use of NMR with mammalian MPs lies in the difficulties of obtaining 
labelled, functionally expressed protein for analysis. Traditionally, proteins for 
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NMR experiments are made in E. coli or yeast as these organisms both grow on 
minimal media into which heavy atom labels can be introduced. At present, 
however, most academic groups are unable to produce ‘active’ mammalian MPs 
in either bacteria or yeast. The main advantage of the optimised fermentation 
protocol described in this thesis is that it can be readily adapted for labelling 
mammalian MPs with heavy atoms including 15N, 13C and 2H. As the yeast are 
grown on a minimal media, 15N labelling can be achieved by using 15N ammonium 
hydroxide (as this is the sole nitrogen source used during fermentations), 13C 
labelling through feeding with 13C methanol and 2H labelling through making up 
the basal media in D2O (not H20). The quantities of hA2aR and hSI that can be 
made per fermentation are more than sufficient for NMR analysis, and this is an 
area of research that I would like to have pursued if there had been sufficient 
time.   
As demonstrated in this thesis, yeasts are powerful hosts for the overproduction 
of mammalian MPs. They are, however, far from being ideal cells for making 
human MPs as they differ from higher eukaryotes both in the type of 
glycosylation that they perform and sterol that they make. Although fungi and 
mammals share the initial steps of protein glycosylation (making the same core 
structure Man8-GlcNAc2), the final glycans attached to specific asparagine 
residues in glycoproteins are significantly different (Gemmill and Trimble, 1999). 
In mammals, regular, complex N-glycans of defined size are attached to the 
protein. In yeast, however, numerous mannose sugars are added to the core 
structure as the glycoprotein passes through the Golgi giving hypermannosylated 
N-glycans (with upto 100 mannose residues sometimes attached). As a result, 
glycoproteins made by yeast are highly-heterogenous in their composition and 
are incompatible with protein crystallisation. This problem can be overcome 
either by using glycosylation-deficient mutants (in which the asparagines that 
are glycosylated are mutated to glutamine) or by enzymatic treatment of 
purified glycoproteins with glycosidases in vitro. In recent years, however, 
strains of P. pastoris have been engineered in such a way that the yeast 
performs uniform complex N-glycosylation adding defined glycans that are 
terminally sialylated (Choi et al., 2003; Hamilton et al., 2003; Wildt and 
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Gerngross, 2005; Hamilton et al., 2006; Hamilton and Gerngross, 2007). Such 
strains have been used to make recombinant erythropoietin with biological 
activity (Hamilton et al., 2006). As yet, these genetically-modified versions of P. 
pastoris have not been used for the recombinant production of human MPs. They 
would, however, make excellent hosts for those human MPs where glycosylation 
is essential for the protein’s activity.  
A further drawback of using yeast for making mammalian MPs is that their 
membranes do not contain any cholesterol – instead they contain ergosterol. 
Although cholesterol and ergosterol have similar chemical structures, 
biologically they are non-equivalent (Opekarova and Tanner, 2003). Moreover, it 
is known that cholesterol is essential for maintaining the stability and function 
of many mammalian membrane proteins (e.g. Lagane et al., 2000; Tate, 2001; 
Opekarova and Tanner, 2003). It is likely, therefore, that a strain of yeast that 
synthesises cholesterol instead of ergosterol will be a superior host for making 
human MPs compared to wild-type. Currently, work is underway within the 
Fraser group to make cholesterol biosynthetic versions of both S. cerevisiae and 
P. pastoris with a view to determining their capacity to make mammalian MPs 
(personal communication, Dr. Niall Fraser).  
Although it is widely recognised that mammalian MPs are considerably less stable 
in detergent solution than ones of bacterial origin, it is poorly understood why. 
There is an emerging body of evidence that strongly suggests that cholesterol is 
a critical determinant of mammalian MP stability in the membrane, detergent 
solution as well as in lipidic crystallisation matrices. It is possible to ‘dope’ both 
cubic and sponge phases with cholesterol. Expression hosts can be chosen that 
have cholesterol-containing membranes. However, the issue of stabilising 
mammalian MPs in detergent solution remains. One possible approach is to 
create mutants such as Rag23 (Magnani et al., 2008) which have sufficient 
thermostability in detergent solution that they do not have any need for 
cholesterol. However, the most direct approach to solving the problem of 
protein instability in detergent solution is to devise novel reagents that mimic 
mammalian membranes more closely than existing commercially-available ones. 
Of note, three recently described detergents (the maltose-neopentyl glycol 
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(MNG) amphiphiles (Chae et al., 2010) and two cholesterol based detergents -   
facial amphiphiles (Zhang et al., 2007) and ChoBiMalt (Howell et al., 2010)) -
have been shown to be useful tools for stabilising and crystallising mammalian 
MPs in and from detergent solution (Chae et al. 2010; Annalora et al., 2010; Gay 
et al., 2010; He et al., 2010; Howell et al., 2010). I would be particularly 
interested to find out if the cholesterol-detergent ChoBiMalt (cholesterol – 
bimaltoside) could stabilise the hA2aR in the same way as CHS does without 
driving receptor aggregation during protein purification (as was observed in my 
work). 
The CPM assay was an excellent tool for understanding the buffer (type and pH) 
and salt preferences of SI in detergent solution. Using the information obtained 
from the denaturation assays, it was possible to purify SI in the short-chain 
detergent DM without it becoming aggregated using sodium phosphate as buffer. 
Since I finished in the lab, the Fraser group have since gone onto purify 
monodisperse SI in NM using ammonium phosphate buffer (Dr. Niall Fraser, 
personal communication). Such thermostability for a wild-type protein is rather 
unusual but suggests that hSI will make a good construct for structural studies 
(both by X-ray crystallography and NMR). When trying to crystallise any protein 
(membrane or otherwise), the first step usually involves using a range of 
commercially available sparse matrix crystallisation screens to try to identify 
conditions where the protein of interest comes out of solution to form regular 
crystals. Once “hits” have been identified, the crystallisation conditions are 
optimised in an attempt to obtain crystals that diffract to high-resolution. 
However, the results from the SI thermostability assays suggests that, at least 
for this enzyme, the probability of getting crystals from a sparse-matrix will be 
low as the protein is only stable in a limited range of conditions (ammonium or 
sodium phosphate, acidic pH). This suggestion was borne out from the limited 
number of crystallisation trays that I set-up. Rather, it seems sensible to try to 
find crystallisation conditions in which SI has known stability around the 
enzyme’s isoelectric point (pI) – pH 6.3. If time had allowed, I would have used 
the robotic systems in the lab to make a series of screens using either sodium or 
ammomium phosphate as buffer varing the pH between 5.5 and 7.5 in 
 
Discussion                                                                                                           169 
combination with different types and concentrations of PEG. Hopefully, this 
approach will yield some SI crystal hits.  
Although the CPM assay can be used to devise a purification scheme that yields 
monodisperse mammalian MPs in short-detergents, there are no guarantees that 
it will be possible to obtain protein crystals in the limited range of conditions in 
which the protein of interest is stable. Therefore, it is likely that the best way 
for getting crystals of mammalian MPs will be in either the lipidic cubic- or 
sponge-phase. It is no surprise then that all but one of the ligand-activated GPCR 
structures that have been solved to date (the human β2 adrenoceptor (Cherezov 
et al., 2007; Hanson et al., 2008); the human adenosine 2a receptor (Jaakola et 
al., 2008); the human CXCR4 chemokine receptor (Wu et al., 2010) and the 
dopamine D3 receptor (Chien et al., 2010)) used diffraction data collected from 
crystals grown in the lipidic cubic phase. Recognising the importance of cubic- 
and sponge-phases, I have established a cholesterol-doped version of a sparse-
matrix lipidic-sponge phase crystallisation screen. Although there was only 
limited usefullness for this screen with SI, it is likely that cholesterol-sponges 
will become increasing used within the Fraser lab as their attention turns from 
making to trying to crystallise human MPs.  
Lastly, although it was possible to purify a thermostable mutant of the hA2aR 
and hSI to homogeneity, the membrane-enzyme was considerably easier to work 
with. This is not surprising as SI is likely to have a rigid-structure where as the 
hA2aR is likely to have considerable conformational flexibility. This raises the 
issue of target-selection when setting out trying to solve the structure of a 
mammalian MP. Proteins that are similar to SI are likely to be considerably more 
tractable to work than GPCRs, and maybe amenable to a high-throughput 
structural pipeline approach. In contrast, GPCRs should only be worked on one at 
a time by any given person due to the extra difficulties involved in getting 
sufficient stable protein for structural studies.    
Over the next 5-10 years, I expect that there is going to be a rapid increase in 
the number of human membrane proteins that have had their structures solved. 
This will in no small part be due to the technologies that have recently been and 
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are currently being developed (such as the ones presented here) that allow 
milligram quantities of stable, functional and monodisperse membrane proteins 
to be produced. Furthermore, the use of lipidic crystallisation approaches 
(including both the cubic- and sponge-phase) for obtaining MP crystals that 
diffract to high-resolution are likely to become considerably more prevalent 
than they are today.  
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